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1 INTRODUCTION 
1.1. Single nucleotide polymorphisms: Biology and functional relevance 
The Human Genome Project and the many population-based scientific projects that followed 
have provided valuable resources for a better understanding of the evolutionary and 
biomedical importance of human genetic variation. For instance, chimpanzee and humans 
share 99% of their genomes (Chen et al., 2001; Ast, 2005) and there is only an 0.1% 
difference between two individual humans. Single nucleotide polymorphisms (SNPs), as the 
most abundant form of genetic variation, are mostly biallelic and therefore easy to assay once 
they are described. Given their abundance in the human genome (approximately one SNP 
every 100-300 bp (Sachidanandam et al., 2001; Ke et al., 2008)) and their ease of high-
throughput typing, SNPs progressively replace microsatellites as first-choice genetic markers 
in association and linkage studies (Hiller et al., 2006b; Reumers et al., 2008). Although the 
majority of these variations probably result in neutral phenotypic outcomes, i.e. functionally 
silent (Teufel et al., 2006), certain SNPs contribute significantly to phenotypic individuality, 
disease susceptibility, as well as to drug treatments (Wangkumhang et al., 2007). 
Nevertheless, the ‗neutral‘ SNPs can serve either as genetic markers or tagging SNPs. 
 
In the current release of dbSNP database, more than 12 million germline genetic variants have 
been recorded and the advent of next generation sequencing technologies will likely lead to a 
complete assessment of the inventory of human genetic polymorphisms in the foreseeable 
future. For this information to become fully useful, however, a functional annotation of the 
known DNA sequence variations will also be required. Although much interest focuses on 
coding SNPs (cSNP), since those SNPs impair the normal sequence and function of proteins 
and can be readily interpreted, SNPs can also influence pre-mRNA splicing (ElSharawy et al., 
2006), which usually have a more dramatic effect on the resulting protein than the alteration 
of a single codon. Splicing mutations have been suspected to be the most frequent cause of 
hereditary diseases (Lopez-Bigas et al., 2005). Although relatively hard to interpret, non-
coding promoter SNPs may also disrupt functional sites on the transcriptional level (Reumers 
et al., 2008). Thus, the identification of functional SNPs and their roles promises to provide 
important information not only for biochemical studies, but also for the study of other 
phenotypes of high relevance (Cavalli-Sforza, 2005; Teufel et al., 2006). 
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1.2. Pre-mRNA splicing: Mechanism and challenges 
Pre-mRNA splicing is an essential and a critical step in eukaryotic gene expression. Despite 
their relative large sizes, introns are co-transcriptionally removed by splicing with great 
accuracy and fidelity, although contrary to our expectations, currently known signals required 
for pre-mRNA processing are very degenerate and redundant (Soller, 2006). Therefore, the 
initial fundamental step in metazoan pre-mRNA splicing is the identification of exon-intron 
boundaries by direct interactions between the basal splicing machinery, the spliceosome, and 
pre-mRNA signature elements. In general, an acceptor splice site (ss) has a highly conserved 
AG dinucleotide, a preceding polypyrimidine tract and a branch point ‗A‘, whereas, the donor 
ss has a highly conserved GT and an extended intronic consensus sequence (Zhuang and 
Weiner, 1986; Wu et al., 1999). The basic biochemical mechanism of pre-mRNA splicing 
(Figure  1.1) mainly depends upon these canonical ss signals. 
 
 
Figure ‎1.1 The biochemical mechanism of pre-
mRNA splicing. 
Pre-mRNA splicing occurs via a two-step 
transesterification mechanism, which ends with the 
ligation of the flanking exons and releases the intron 
in the form of a lariat (Pagani and Baralle, 2004). 
The phosphodiester linkages are indicated by the 
letter p inside a circle or a diamond.  In the first step, 
the 2′-hydroxyl group of the A residue at the branch 
site attacks the phosphate at the GU 5′-ss. This leads 
to cleavage of the 5′ exon from the intron and the 
formation of a lariat intermediate. In the following 
transesterification reaction, which involves the 
phosphate (p) at the 3′ end of the intron and the 3′-
hydroxyl group of the detached exon, ligates the two 
exons. This reaction releases the intron, still in the 
form of a lariat (Pagani and Baralle, 2004). 
Illustration from (Mordes et al., 2006). 
 
 
In fact, the pre-mRNA splicing process is far more complicated as given in Figure  1.1. It is 
now clear that exon recognition is accomplished by the accumulated recognition of multiple 
weak signals, resulting in a network of interactions across exons as well as across introns 
(Faustino and Cooper, 2003). After initial ss recognition and pairing (Reed, 1996; Lim and 
Hertel, 2004), the catalytic components of the spliceosome are activated through extensive 
structural rearrangements, ultimately resulting in intron removal (Staley and Guthrie, 1998; 
Hertel, 2008). The building blocks of the spliceosome are uridine-rich small nuclear RNAs (U 
snRNAs) packaged as ribonucleoprotein particles (snRNPs) that function in conjunction with 
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over 300 distinct non-snRNP auxiliary proteins (Jurica and Moore, 2003; Chen et al., 2007). 
The major U2-type spliceosome, which consists of U1, U2, U4, U5, and U6 snRNPs, 
catalyzes the removal of introns with canonical (GT-AG) ss. The minor U12-type 
spliceosome that contains U11, U12, U4atac, U5, and U6atac snRNPs recognizes a small 
percentage of introns (<1% in Arabidopsis and humans) with noncanonical ss (Reddy, 2007). 
 
In fact, the core splicing signals lack sufficient information content for the splicing machinery 
to distinguish correct pairs of ss from cryptic ss, which are vastly more abundant than correct 
ss (Senapathy et al., 1990; Sun and Chasin, 2000). In this regard, additional cis-acting 
sequences are vitally required (Cartegni et al., 2002; Matlin et al., 2005). The final signal of 
the interactions between these various cis-acting layers results in guiding the spliceosome to 
the correct nucleotides (nt) for exon joining and intron removal. These elements make up 
what is now recognized as a ‗cellular splicing code‘, which appears to be particularly dense 
within and around exons (Wang and Cooper, 2007) (Figure  1.2). The first layer of the 
‗splicing code‘ consists of consensus ss sequences positioned at exon-intron boundaries that 
are essential for the splicing of all exons. It is this RNA-RNA base-pairing that specifies 
which nucleotides are involved in the precise cut-and-paste reactions that join exons. 
Consequently, mutations in the pre-mRNA that disrupt this base pairing decrease the 
efficiency of exon recognition. A second layer of information is an extensive and complex 
array of diverse intronic and exonic splicing enhancer (ISE and ESE) and suppressor (ESS 
and ISS) elements, which direct the spliceosome to the appropriate sites and inhibit use of 
potential cryptic ss (Wang and Cooper, 2007). ESEs promote splicing by binding to the SR 
protein family, whereas ESSs and ISSs repress splicing by binding to heterogeneous nuclear 
ribonucleoproteins (hnRNPs) (Cartegni et al., 2002). Enhancers and silencers tend to be short 
(~5-10 nt), degenerate consensus sequences (Matlin et al., 2005) and working in a context-
dependent manner (Pagani et al., 2003). Interestingly, the position of a splicing-factor binding 
site relative to the exon can determine whether they act positively or negatively (Kanopka et 
al., 1996; Ule et al., 2006). The role of ESE-bound SR proteins in ensuring the correct linear 
order of exons in mature mRNA has also been reported (Ibrahim el et al., 2005). To meet the 
physiological requirements of cells and tissues, most human genes are differentially spliced 
(Johnson et al., 2003) enabling proteomic diversity, which indeed adds another challenge to 
the spliceosome to appropriately regulate this more complex process in a comprehensive 
manner. Again, these challenges are met through several intercommunications between layers 
of cis-acting elements (Wang and Cooper, 2007) (details in next section  1.3). 
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Figure ‎1.2 The cellular splicing code. 
a) Pre-mRNA as it might appear to the spliceosome. Thick (or red) indicates consensus ss sequences at the 
intron-exon boundaries. Intronic thin (or blue) indicates additional intronic cis-acting elements that make up the 
splicing code. b) cis-elements within and around an alternative exon are required for its recognition and 
regulation. The 5′ ss and branch site serve as binding sites for the RNA components of U1 and U2 snRNPs, 
respectively. Exons and introns contain diverse sets of enhancer and suppressor elements that refine bone fide 
exon recognition. HnRNPs can inhibit exon definition by sterically blocking SR or U2AF interaction with the 
substrate (House and Lynch, 2008). HnRNPs also exert their actions on pre-mRNA differential splicing through 
either multimerization or looping-out mechanisms (Blencowe, 2006; Martinez-Contreras et al., 2006). 
Illustration from (Wang and Cooper, 2007). 
 
 
Even with the recent progress in identification of the precise consensus sequence of ss (Gao et 
al., 2008), the mechanism of ss recognition is not yet fully understood. The current two 
models depend on intron length and the initial steps of the spliceosome assembly. In the 
"intron definition" or traditional model, ss of introns <250 nt in length are recognized across 
the intron. The formulation of this model depends on the direct identification of the 5′ and 3′ 
ss of introns as the splicing unit, and spliceosomal components assembled around the intron 
that will be excised (Hertel, 2008). In the "exon definition" or new model, ss of long introns 
are usually recognized across the exon. Here, an interior exon is first recognized by the paired 
binding of Ul and U2 snRNPs and associated splicing factors to the 5 and 3 ss, followed by 
the juxtaposition of neighboring exons in the correct order (de Almeida and Carmo-Fonseca, 
2008; Hertel, 2008). It further assumes that processing of the last exon involves interaction 
between splicing components at the 3 ss and the polyadenylation complex, whereas 
recognition of the first exon is thought to be mediated by interactions of the nuclear cap-
binding complex with the spliceosome (de Almeida and Carmo-Fonseca, 2008). One 
mechanistic difference between the two models of ss selection may be the requirement of an 
additional exon juxtaposition step during exon definition (Hertel, 2008). Recent evidence also 
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indicates that intron excision from pre-mRNAs of higher eukaryotes requires a ‗transition‘ 
from ss recognition across short exons to organization of the spliceosome across long introns 
(Schellenberg et al., 2008). 
 
1.3. Alternative splicing and biological complexity: One gene, many proteins 
One of the most remarkable observations stemming from the sequencing of genomes of 
diverse species is that the number of protein-coding genes in an organism does not correlate 
with its overall cellular complexity. From where does complexity spring if not from the 
number of genes in an organism? Alternative pre-mRNA splicing is believed to be a major 
mechanism to bridge the gap between the gene and protein number (Graveley, 2001; Maniatis 
and Tasic, 2002), thereby allowing the expansion of the proteome and regulation of gene 
expression in higher eukaryotes. Alternative splicing is also known to play numerous critical 
roles in both normal and disease processes (Blencowe, 2006; Gabut et al., 2008). By 
definition, AS is the process by which pairs of ss are differentially selected to generate 
multiple mRNA variants from a single precursor (pre-) mRNA (Gabut et al., 2008). The 
greater frequency of AS events in mammals than in vertebrates again reflects the contribution 
of AS to this biological complexity (Kim et al., 2004). Furthermore, it has been estimated that 
40-60% of all human genes (Brett et al., 2002; Boue et al., 2003) and 74% of multi-exon 
human genes (Kapranov et al., 2002; Johnson et al., 2003) are alternatively spliced. In fact, 
large fraction of AS undergoes cell-specific regulation in which splicing pathways are 
modulated according to cell type, developmental stage, gender, or in response to external 
stimuli (Faustino and Cooper, 2003). Despite the growing list of mammalian protein factors 
known to regulate AS (Gabut et al., 2008), we still lack the information that allows us to 
predict cell- and tissue-specific AS or even which protein factors are most likely to target 
which exons (Blencowe, 2006). 
 
1.3.1. Patterns of alternative pre-mRNA splicing 
In a typical multi-exon mRNA, the splicing pattern can be altered in many ways (Figure  1.3). 
Most exons are constitutive; they are always spliced or included in the final mRNA. When a 
constitutive ss is put in a competitive context with other ss, often little is needed to switch a 
particular ss from a constitutive to an alternative one. Numerous examples of this scenario 
have been described leading to either alternative 5 or 3 ss usage, skipping of an exon 
(Cartegni et al., 2002; Black, 2003) or acquisition of new exons from repetitive Alu elements 
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(Lev-Maor et al., 2003; Sorek et al., 2004). A regulated exon that is sometimes included and 
sometimes excluded from the mRNA is called a cassette exon, which represents the most 
common type of AS, accounting for 33 to 53% (Thanaraj and Stamm, 2003; Blencowe, 2006). 
In certain cases, multiple cassette exons are mutually exclusive-producing mRNAs that 
always include one of several possible exon choices but no more; these type of exons are 
interchangeably used in the alternative transcripts (Malousi et al., 2007). The 5-terminal 
exons of an mRNA can be switched through the use of AS and alternative promoters, which 
are primarily an issue of transcriptional control. Similarly, the 3-terminal exons can be 
switched by combining AS with alternative polyadenylation sites. Control of polyadenylation 
appears mechanistically similar to control of splicing (Colgan and Manley, 1997). Finally, 
some important regulatory events are controlled by the failure to remove an intron from the 
transcript, a splicing pattern called intron retention (Black, 2003; Malousi et al., 2007). AS 
events are also classified into simple and complex depending on whether the exons flanking 
an alternatively spliced exon undergo a specific type of the aforementioned AS events 
(Thanaraj and Stamm, 2003; Malousi et al., 2007). Diverse silencer sequences, as well as 
some ESEs, play an important role in controlling the selection of alternative 5 and 3 ss and a 
specific class of silencers may also function to regulate intron retention events (Wang et al., 
2006). Moreover, the transcription factors acting at the level of initiation and elongation can 
impact ss selection. In particular, factors resulting in reduced rates of RNA polymerase II (Pol 
II) elongation can increase the inclusion of alternative exons (Kornblihtt, 2006). 
 
 
 
Figure ‎1.3 Modes of alternative splicing. 
Exons are shown as boxes and introns as lines. Gene regions with AS processing choices are illustrated in white 
and connected with dashed lines, while constitutive parts are depicted in black and connected with solid lines. 
For adenosine to inosine editing (A to I) an editing site complementary sequence (ECS) located in an intron pairs 
with the edited site in the exon. Design from (Soller, 2006). 
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1.3.2. Splicing regulatory mechanisms at genomic dimensions 
Splicing at short-distance tandem sites. Alternative splicing at donor or acceptor sites 
located just a few nucleotides apart is widespread in many species (Hiller and Platzer, 2008). 
For instance, NAGNAG tandem acceptors occur in ~30% and are functional in at least 5% of 
human genes, and 1.3% of the splice donors allow AS at both GY (underlined) of the unusual 
motifs GYNGYN (Hiller et al., 2004; 2006a; Hiller et al., 2006b). Both types of tandems 
enable subtle protein variations (Hiller et al., 2006b). Several of these tandem splice events 
contribute to the repertoire of functionally different proteins (advantageous), whereas many 
are neutral (being tolerated) or deleterious (may be causing disease). Remarkably, some of the 
functional events are differentially spliced in tissues or developmental stages, whereas others 
exhibit constant splicing ratios, indicating that function is not always associated with 
differential splicing (Hiller and Platzer, 2008). A large fraction may arise as a consequence of 
stochastic binding of the spliceosome at neighbouring ss (Chern et al., 2006). 
 
Splicing at long-distance. A common feature of genes in higher eukaryotes is the presence of 
very large introns, often extending over tens of kilobases. In the human neurexin 3 gene, 
which spans 1600 kb, the largest constitutively and alternatively spliced introns are 292 kb 
(between exon 16 and 17) and 347 kb (between exon 1 and 5), respectively (Tabuchi and 
Sudhof, 2002). Frequently hidden in such large introns are very short alternatively spliced 
exons (cassette exons), such as the 12 nt long exon 4 in the neurexin 3 gene. There are three 
major mechanisms to facilitate splicing of large introns: 1) looping out of intronic sequences 
to bring ss into proximity; 2) recursive splicing, which occurs when the 5 ss is regenerated 
after splicing of an intron and is used again; 3) intra-splicing, which occurs in nested genes 
that are transcribed in the same direction (details in (Soller, 2006)). Beyond cis-splicing at a 
single locus, there is evidence for specialized cis-splicing that results from read-through 
transcription of adjacent loci followed by splicing to generate transcription-induced chimeras 
from two genes, as in the TNSF12/TNSF13 chimera expressed in human T cells (Pradet-
Balade et al., 2002). In contrast to these cis-splicing events, trans-splicing joins exons from 
separate pre-mRNA transcripts. These transcripts can be encoded by different DNA strands at 
the same locus, as in trans-splicing of the mod(mdg4) gene in Drosophila, or by different 
alleles at the same locus, as for the lola gene, also in Drosophila (Horiuchi and Aigaki, 2006). 
 
Alternative donor ss selection. A widely accepted mechanism for alternative donor splicing 
is the differential binding of the U1 snRNA to one of the potential donor sites. According to 
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this ss competition model, AS happens when one donor is sufficiently able to compete with 
the other donor for U1 binding. Constitutive splicing at a tandem motif (exclusive selection of 
only one donor) occurs when either donor is much stronger and consequently outcompetes the 
other. Apart from the intrinsic strength of donor sites, SR proteins and hnRNPs affect ss 
selection. SF2/ASF and other SR proteins promote splicing at the intron- proximal donor site, 
whereas hnRNP A1 promotes the distal site. The relative concentration of SR proteins and 
hnRNPs affects donor selection, and tissue-specific variations in this ratio might lead to 
tissue-specific splicing patterns (Caceres et al., 1994) (reviewed in (Hiller and Platzer, 2008)). 
 
Alternative acceptor ss selection. In vitro experiments found evidence for different modes of 
acceptor AG selection that depend on the distance of the AG to the branch point. If the branch 
point is more than ~ 20-35 nt away from the AG, the AG selection occurs by a scanning 
mechanism that starts from the branch point and usually selects the intron-proximal AG 
(Smith et al., 1993; Chen et al., 2000). The proximal AG can be bypassed if it is too close to 
the branch point or if it is in competition with a more distal AG. This competition can lead to 
AS and depends on (1) the distance between the AGs (shorter distances lead to a higher 
competition), (2) the nucleotide upstream of the AGs (C and T are preferred over A and 
especially over G) and (3) the sequence between both AGs (Smith et al., 1993; Chen et al., 
2000; Chua and Reed, 2001; Dou et al., 2006). Scanning does not occur if the distance to the 
branch point is short (<20 nt) (Chen et al., 2000). In these cases, a distal AG can efficiently 
compete with a proximal AG given the distance between both AGs <6 nt (Chua and Reed, 
2001). Similar to donor selection, SR proteins were shown to promote proximal acceptor ss, 
whereas hnRNP A1 promotes distal sites (Bai et al., 1999). Thus, although AS is often 
regulated at the early splicing step, alternative acceptor selection can be regulated at the early 
and the late step (Lallena et al., 2002; Dou et al., 2006) (reviewed in (Hiller and Platzer, 
2008)). 
 
1.3.3. Global functions and communication of alternative splicing 
Protein isoforms, produced by AS, can differ in various aspects, including ligand binding 
affinity, signaling activity, protein domain composition, subcellular localization, and protein 
half-life (Stamm et al., 2005). In coordination with non-sense mediated decay (NMD), 
alternatively spliced transcripts can be degraded rapidly, providing a regulation and fine-
tuning mechanism of the adjustment of the protein level (Lewis et al., 2003). About 25% of 
transcripts will be switched off by pre-mature stop codons (PTCs) caused by AS and NMD. 
9 
This process that termed RUST, for regulated unproductive splicing and translation, currently 
represents the function of AS with the most obvious biological consequences (Stamm et al., 
2005). The coupling between transcription, mRNA processing and mRNA surveillance avoids 
the wasteful production of nonfunctional mRNAs with potentially deleterious effects for the 
cell. Current models suggest that RNA processing factors, such as U1 snRNP and SR 
proteins, are loaded onto the C-terminal domain of RNA Pol II and deposited on native 
transcripts as they are synthesized, thereby, promoting rapid cotranscriptional spliceosome 
assembly (de Almeida and Carmo-Fonseca, 2008). These models also imply that specific 
promoters might differentially affect AS processing by interaction with different factors 
(Soller, 2006). 
 
Although several observations suggest that splice variants may have a biological role, the 
mere presence of a splice variant in tissues does not mean that it has a biological function. In 
many cases AS occurs in genes that encode multidomain proteins where splice variants 
encode proteins that differ in their domain organization and hence are likely to differ in 
function. Thus, all splice variants deserve close scrutiny to determine if they have a regulatory 
role before they are ignored as artefacts. There is also a caveat in assuming that only 
conserved AS types are meaningful. AS events that are not evolutionarily conserved are not 
necessarily unimportant as they may be specific to one organism and reflect the biology of 
that organism and/or might have evolved more recently and contributed to the diversification 
of species (Reddy, 2007). Once again, variable splicing ratios do not always imply functional 
importance (Hiller and Platzer, 2008), and the tissue-specific expression of a gene does not 
always imply a tissue-specific function (Cajiao et al., 2004). 
 
1.3.4. Components influencing exon recognition and alternative splicing 
Given the complexity of higher eukaryotic genes and the relatively low level of ss 
conservation, the precision and flexibility of the spliceosome to identify and process exons 
within a given pre-mRNA is impressive. Indeed, multiple factors interact in these processes 
and include parameters such as, ss strength, the presence/absence of splicing regulators, RNA 
secondary structures, the exon/intron architecture, and the synthesis of pre-mRNA by RNA 
pol II itself (Figure  1.4). The relative contributions of each of these parameters control how 
efficiently ss are recognized and flanking introns are removed. Examples include: 1) greater 
complementarity with U1 snRNA and longer polypyrimidine tracts translate into higher 
affinity binding sites for these spliceosomal components and, thus, more efficient exon 
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recognition. 2) The interplay between activating and repressing cis-acting elements modulate 
the probability of exon inclusion. 3) Splice-site recognition is more efficient when introns or 
exons are small. 4) Exon skipping is also more likely to occur when exons are flanked by long 
introns in the human genome, most likely reflecting the influence RNA transcription exerts on 
pre-mRNA splicing. 5) Local RNA structures can either interfere with spliceosomal assembly, 
by either masking splicing repressor binding sites, looping out the exon, or preventing its 
recognition. 6) Like 5 capping and 3 polyadenylation, intron removal is physically and 
temporally linked to RNA transcription. That is, the ss of an exon can be identified by the 
spliceosome while downstream exons still await their synthesis by RNA Pol II (Hertel, 2008). 
 
 
 
 
Figure ‎1.4 Several 
components 
influencing exon 
definition. 
Illustration from 
(Hertel, 2008). 
 
 
 
 
 
 
 
 
Perturbations of post-translational modifications that are essential for optimal activity of many 
regulatory splicing factors, such as alterations in the phosphorylation state of specific SR 
proteins, also modulate AS. By influencing protein/protein and protein/RNA interactions, 
reversible protein phosphorylation modulates the assembly of regulatory proteins on pre-
mRNA and therefore contributes to the splicing code. Different kinases and protein 
phosphatase 1 are identified as the molecules that control reversible phosphorylation, which 
controls not only ss selection, but also the localization of SR proteins and mRNA export. 
Protein phosphatase 1 moves between cellular compartments, depending on the activity of the 
cell. This dynamic behavior links splicing to other activities of the cell and provides evidence 
as to how cellular signals modulate gene expression by influencing AS (Stamm, 2008). 
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1.4. Pre-mRNA (mis)splicing as a primary cause of disease 
The physiological importance of keeping mRNA biogenesis under tight quality control is 
well-illustrated by the growing number of human diseases known to be caused by errors in 
mRNA processing (de Almeida and Carmo-Fonseca, 2008). The AS processes are well 
regulated, but when mutations disrupt the ss or regulatory elements, disease can occur (Hiller 
et al., 2006a; Solis et al., 2008). Mutations can also cause disease through aberrant transcript 
production (Hiller et al., 2006a; Solis et al., 2008). Missplicing of cellular genes can either be 
a symptom of an underlying molecular defect, or the actual cause of the disease. It has 
recently been proposed that 60% of mutations that cause disease do so by disrupting splicing 
(Lopez-Bigas et al., 2005) and wrong ss usage has been observed in numerous diseases. 
Changes in AS are frequently observed in cancer, where they are probably the result of the 
cellular transformation. In several genetic diseases, such as FDTP-17 or spinal muscular 
atrophy (SMA), a change in splicing is caused by mutations and is the actual cause of the 
disease. Furthermore, regulated AS events control apoptosis and are necessary for the 
replication of many viruses, such as HIV. One way to treat such diseases would be to 
influence AS pathways and to send undesired cells into apoptosis or stop viral replication 
(Stamm, 2008). 
 
The distinction between cis- and trans-acting effects has important mechanistic implications. 
Effects in cis have a direct impact on the expression of only one gene, whereas effects in trans 
have the potential to affect the expression of multiple genes (Faustino and Cooper, 2003; 
Wang and Cooper, 2007). Cis-acting mutations can affect the use of constitutive or alternative 
ss. Disrupted constitutive splicing most often results in the loss of gene expression due to 
aberrant splicing. Alternatively, a cis-acting mutation that (in)activates one of two 
alternatively used ss will force expression of one of the AS patterns. Although a natural 
mRNA is expressed, its expression in an inappropriate tissue or developmental stage might 
result in disease. Then again, trans-acting splicing mutations can affect the function of the 
basal splicing machinery or factors that regulate AS. Mutations that affect the basal splicing 
machinery have the potential to affect splicing of all pre-mRNAs, whereas mutations that 
affect a regulator of AS will affect only the subset of pre-mRNAs that are targets of the 
regulator (Faustino and Cooper, 2003). 
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1.4.1. Cis-acting mutations: Possible dramatic effects upon the splicing code 
Transcript analyses from specific disease genes such as NF1, ATM, and others lead to the 
striking conclusion that as many as 50% of disease mutations in exons may impact on splicing 
(Cartegni et al., 2002; Blencowe, 2006; Pagenstecher et al., 2006). Of the mutations in the 
Human Gene Mutation Database (HGMD) (Stenson et al., 2003) that are not within ss, 78% 
are SNPs within exons (56.9%) or in microdeletions or microinsertions of up to six nt that 
occur primarily within exons (21.7%) (Wang and Cooper, 2007). Recently, the neural 
network efforts (Krawczak et al., 2007) have shown that within a splice site, SNPs and 
disease-associated (HGMD) mutations outside the obligate dinucleotides also differ from each 
other, both for acceptor and donor ss (Figure  1.5). 
 
 
 
 
Figure ‎1.5 Distribution of SNPs and splicing-relevant disease-associated mutations outside the obligate 
dinucleotide of splice-sites.  
Open bars represent SNPs, whereas solid bars represent splicing mutations. Charts from (Krawczak et al., 2007). 
 
 
Coding SNPs can disrupt (or eventually create) ESE and ESS; create new ss or strengthen 
cryptic ones; alter pre-mRNA secondary structures important for exon-definition; and, 
conceivably, modify the pausing architecture of a gene, provoking changes in RNA Pol II 
processivity, which might in turn affect ss choice. These defects are not exclusive of cSNPs: 
missense, nonsense and translationally silent mutations as well as exonic deletions or 
insertions can affect AS in similar ways. More than 50% of such mutations have been shown 
to disrupt at least one of the target motifs for the SR proteins (SF2/ASF, SRp40, SRp55 and 
SC35) found in ESEs (Liu et al., 2001). Even one-quarter of synonymous substitutions of 
exons 9 and 12 of the CFTR gene, which is mutated in cystic fibrosis, affected splicing 
(Pagani et al., 2005). Other examples of human disease genes, where (non)synonymous 
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mutations often affect exonic splicing control elements, include BRCA1 (breast cancer 1, early 
onset), HPRT1 (hypoxanthine phosphoribosyltransferase 1), and MAPT (microtubule-
associated protein tau) (Cartegni et al., 2002). 
 
Mutations located in noncoding regions, such as those affecting 5′ and 3′ ss, branch sites or 
polyadenylation signals, are frequently the cause of hereditary disease. Approximately 15% of 
mutations that cause genetic disease affect pre-mRNA splicing (Krawczak et al., 1992). In 
particular, 28% of the NAGNAG SNPs occur in known disease genes (Hiller et al., 2006a). 
Splice acceptors with the genomic NAGNAG motif may cause NAG insertion-deletions and 
can result in the gain/loss of a PTC in transcripts (Hiller et al., 2004; 2006a). Once more, 
many human diseases, including Fanconi anemia, hemophilia B, neurofibromatosis, and 
phenylketonuria, can be caused by 5 ss mutations that are not predicted to disrupt splicing. It 
is likely that such mutations disrupt the conserved pairwise dependencies between 5 ss 
nucleotides, as some human SNPs appear to alter splicing. The longer span and more plastic 
organization of 3 ss suggest that the pairwise associations at 3 ss will not reveal as many 
biases as the associations at 5ss (Roca et al., 2008). 
 
It is also clear that most SNPs and/or mutations exert their effect by changing splicing 
regulatory elements, and the rest can be explained on the basis of secondary structure 
rearrangements. Likewise, secondary structure can explain why mutations that change 
splicing motifs sometimes show no splicing effect. Most likely, the affected motifs are highly 
double-stranded in these cases (Hiller et al., 2007b). SNPs are capable of inducing in vivo 
different structural folds in mRNA structures and can ultimately affect biological function 
(Shen et al., 1999). For example, a silent mutation in human CFTR exon 12 that reduces exon 
inclusion from 80%–25% (Pagani et al., 2005) does not create or destroy splicing motifs, but 
leads to a higher single-strandedness of existing ESSs and a lower single-strandedness of an 
existing ESE (Hiller et al., 2007b). The mechanistic explanations may involve the 
occlusion/exposure of key cis-acting elements or the spatial modification of the distance 
between these elements (Buratti and Baralle, 2004). 
 
1.4.2. Trans-acting mutations: Disruption of the splicing machinery 
There are several genetic diseases in which a mutation disrupts the machinery of splicing, 
through either the constitutive components of the spliceosome or auxiliary factors that 
regulate AS (Faustino and Cooper, 2003). Two diseases, spinal muscular atrophy (SMA) 
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(Briese et al., 2005) and retinitis pigmentosa (Mordes et al., 2006), are caused by mutations in 
genes involved in snRNP assembly and function, respectively. SMA is an autosomal recessive 
disorder affecting motor neurons and is caused by loss of the survivor of motor neuron-1 
(SMN1) gene product, which is required for the assembly of core snRNPs in the cytoplasm 
before final maturation and nuclear import. Retinitis pigmentosa is one of the most common 
forms of blindness. Surprisingly, three dominant retinitis pigmentosa disease genes (pre-
mRNA-processing factor gene homologues PRPF31, PRPF8 and HPRP3) encode proteins 
required for proper assembly and function of the u4•u5•u6 tri-snRNP, a core and essential 
component of the spliceosome (McKie et al., 2001; Vithana et al., 2001; Chakarova et al., 
2002). The disease is probably due to disruption of spliceosome function, because it seems 
unlikely that all three genes or the u4•u5•u6 tri-snRNP have alternative functions. A third 
example is the Prader-Willi Syndrome (PWS), which is the first known example of a genetic 
disease in which pathogenesis might be due to mutation of a gene encoding a splicing 
regulatory factor. The PWS is a congenital disease that is caused by the loss of paternal gene 
expression from a maternally imprinted region on chromosome 15. Kishore et al. (Kishore 
and Stamm, 2006) provide evidence that HbII-52 snoRNA (small nucleolar RNA) exhibits 
sequence complementarity and regulates splicing of exon Vb of the serotonin receptor 5-
HC2CR. Loss of HbII-52 snoRNA expression in PWS results in aberrantly regulated splicing 
of 5-HC2CR. These results show that a snoRNA regulates the processing of a mRNA 
expressed from a gene located on a different chromosome and further indicate that a defect in 
pre-mRNA processing contributes to the PWS phenotype (Wang and Cooper, 2007). 
 
1.5. Study of allele-dependent splicing: Motivations and Perspectives 
Many facts are now becoming clearer to us. Alternative pre-mRNA splicing is a widespread 
phenomenon that affects approximately 75% of human genes (Moore and Silver, 2008). At 
the same time, many SNPs are known to be located in genomic regions of splicing relevance, 
including canonical ss, ESE, ISE, and other DNA sequence motifs (Fairbrother et al., 2004a; 
Pagani and Baralle, 2004; Kralovicova et al., 2005). These polymorphisms may lead to a 
disruption of the ‗splicing code‘, thereby causing the splicing apparatus to utilize cryptic ss 
nearby or to skip one or more exons. This means that common genetic variation can result in 
substantial, phenotypically relevant variation at the protein level (Wang and Cooper, 2007). 
Indeed, several examples of splicing-relevant SNPs underlying human diseases have been 
reported (Cartegni and Krainer, 2002; Colapietro et al., 2003). Variation in splicing patterns is 
known to be tissue specific, and for a small number of genes has been shown to vary among 
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individuals (Hull et al., 2007). Nevertheless, what is not clear is whether allele-dependent 
splicing phenomenon is an important mechanism by which common genetic variation affects 
gene expression and to what extent. Therefore, the screen of allele-dependent splicing 
occurrence in the context of the present study was motivated from many perspectives. 
 
1.5.1. Genomic and mechanistic perspectives 
After the sequencing of the human genome, one of the key questions in the field is the 
correlation of genetic and phenotypic variation. The population of mRNA splice products 
generated from a specific (DNA) haplotype can be regarded as an ‗intermediate phenotype‘, 
or ‗mRNA-phenotype‘, and the detailed characterization of this phenotype is clearly one of 
the prerequisites for being able to draw a link between variation at the DNA sequence and 
protein level (Graveley, 2008). As discussed from a disease perspective below, it is unlikely 
that the marked phenotypic diversity of complex organisms can be explained on the basis of 
single amino acid substitutions or frame shift mutations alone. It is hypothesized here that 
variation in splicing-relevant sequence motives may be an important factor for transcriptome 
variability. On the other hand, the sequence elements that control splicing are all relatively 
short and show little local (or evolutionary) conservation. Only the AG and GT dinucleotides 
present at virtually all splice acceptors and donors, respectively, and the branch site appears to 
be mandatory for correct and efficient splicing. The role of related control sequences like 
enhancers (ESE, ISE) or silencers (ESS, ISS) is less well understood. Owing to the scarceness 
of data, the splicing effects of individual genetic variants can still only be predicted with 
limited accuracy (Pagani and Baralle, 2004; Wang et al., 2004b), and most of the information 
on splicing motifs has been obtained from the alignment of such motifs to either ESTs or 
known structural gene models (Krawczak et al., 1992; Clark and Thanaraj, 2002). Overall, the 
available empirical data on allele-dependent splicing is limited and has mostly been generated 
in a non-systematic fashion. 
 
1.5.2. Disease relevance of allele-dependent splicing 
There is a growing realization that splicing efficiency is a significant contributor to 
phenotypic variability (Marden, 2008), and the contribution of splicing to phenotype has 
become particularly apparent through its impact on modifying the severity of human disease 
(Nissim-Rafinia and Kerem, 2002) and its contribution to disease susceptibility (Wang and 
Cooper, 2007). Indeed, a key factor in the motivation for the present study was the recent 
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positional cloning of the first sarcoidosis (a polygenic autoimmune disorder of the lungs 
(Valentonyte et al., 2005)) disease gene, namely BTNL2. Here, the main genetically 
associated SNP was predicted to cause an amino acid exchange. However, the functional 
impact exerted through that mutation could not explain the profound genetic effect observed. 
Indeed, the SNP-effect was strictly genotype-specific. This SNP, rs2076530, caused a 
substantial ―weakening‖ of ss and thus lead to use of a cryptic donor ss. This leads to a loss of 
4 bases in the transcript and a subsequent frame-shift and protein truncation (loss of 
transmembrane domain). Indeed, an estimated 20%–30% of disease-causing mutations is 
believed to affect pre-mRNA splicing (Faustino and Cooper, 2003), which is consistent with 
the recent suspicion that splicing mutations to be the most frequent cause of hereditary 
diseases (Lopez-Bigas et al., 2005). Consequently, an increasing number of SNPs have been 
described that cause diseases, both monogenic and polygenic, by a change or disruption of the 
normal splicing pattern (Cartegni et al., 2002; Garcia-Blanco et al., 2004). These splice-
relevant SNPs can alter important mRNA secondary structures affect donor and acceptor ss, 
branch points, exonic as well as intronic splicing enhancers and silencers (Hiller et al., 2006a; 
Hiller et al., 2007b). For example, the G allele of the silent coding SNP rs17612648 in the 
PTPRC gene that is associated with multiple sclerosis disrupts an ESS and abolishes the 
skipping of exon 4 (Lynch and Weiss, 2001). In fact, several splicing mutations of known 
disease relevance (Stenson et al., 2003) have also been studied in controlled in vitro 
experiments (Pagani et al., 2000; Wang et al., 2004a; Zuccato et al., 2004). 
 
Traditionally, researchers who want to track down the molecular basis of monogenic (―classic 
Mendelian‖) disorders have focused on frame-shifts or mutations that directly change the 
amino acid composition of proteins. Increasingly, mutations that influence the protein 
sequence or expression through effects on splicing are being recognized as causative factors 
in Mendelian disorders (Teraoka et al., 1999; Ars et al., 2000). On the other hand, the 
clarification of polygenic (―complex‖) disorders through systematic positional cloning is a 
rapidly evolving field. Within the last few years, positional cloning successes have been 
published for around ten genes in various disorders including rheumatoid arthritis, 
inflammatory bowel disease, Parkinson‘s disease, but to name a few. For instance, the 
common allelic variation, which  has been correlated with lower transcript levels of the 
soluble alternative splice form of CTLA4 gene, contributes to autoimmune tissue destruction 
(Ueda et al., 2003). The pace of discovery has significantly increased over the last few years, 
due to the availability of the annotated human genome sequence, the rapid development of 
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novel, more cost-efficient genotyping technologies, and the availability of large, well-
characterized patient cohorts. 
 
An important – and still very ―low-throughput‖ step in this process is the establishment of 
tangible links between genetic variation and transcript function. Obvious changes in gene 
function (e.g. amino acid exchanges at an active site, frame shift mutations) are present only 
in a fraction of cases. In-house expertise and reports in the literature show the difficulty of 
translating a clear genetic finding (i.e. a SNP with consistently positive association to disease 
in multiple populations) into a functional meaning. It is not clear what proportion of 
phenotypically relevant gene alterations is the result of mutation-driven splicing effects. 
Studies, which systematically addressed this issue in the monogenic disorders of ataxia 
telangiectasia and neurofibromatosis type I, have shown that splice mutations were involved 
in up to 50% of cases (Teraoka et al., 1999; Ars et al., 2000). On the other hand, the wide 
range for the predicted frequency of splicing mutations (15–60%) reflects our incomplete 
knowledge of the splicing code and the fact that mRNAs from mutant alleles are rarely 
assayed for splicing abnormalities. A long-term goal of deciphering the splicing code is to 
acquire the power to predict which disease-associated nucleotide alterations are likely to 
affect splicing (Wang and Cooper, 2007). Therefore, methodology and database resources that 
allow a rapid assessment of allele-dependent splicing for transcripts of interest (e.g. in an 
associated region) would greatly enhance the efficiency of gene finding experiments (Pagani 
and Baralle, 2004). In the meantime, systematic surveys of various disease-causing mutations 
for aberrant splicing would be enlightening, both for the individual mutations that are 
analyzed and for a broad-based analysis of the impact of splicing as a primary mechanism of 
disease. The main limitation will be obtaining RNA from the disease-relevant tissues (Wang 
and Cooper, 2007). 
 
1.5.3. Recent surveys approaching allele-dependent splicing 
While splicing defects have been well-studied in the context of rare diseases, the extent to 
which common SNPs influence mRNA processing is still relatively unknown. Recent large-
scale studies have suggested that a relatively high proportion of human genes show variation 
in expression due to allele-dependent splicing. In the few experiments approaching the last 
phenomenon from a transcript-based perspective, known SNPs identified as candidates for a 
splicing effect were tested with isoform-specific PCR (Hull et al., 2007), or chip-based 
methods were used to seek evidence for alternative splicing (Kwan et al., 2007; Kwan et al., 
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2008). Hull et al. (2007) analyzed the splicing patterns of 250 exons in 22 individuals who 
had been previously genotyped as part of the HapMap project. Consistent allele-dependent 
splicing was identified for six of these exons and the strongest effects were observed for SNPs 
close to an intron-exon boundary. In a genome-wide screening experiment using an exon 
tiling microarray, Kwan et al. were able to show co-segregation of isoforms and haplotypes 
(Kwan et al., 2007) and to correlate splicing patterns to genotypes at adjacent SNPs (Kwan et 
al., 2008). Another concurrent effort combined a genome-wide scan of publicly available EST 
and exon array data and showed evidence of allele-specific splicing events closely linked to 
SNPs (Nembaware et al., 2008). 
 
1.5.4. Biomedical perspective and drug design strategies 
Aside from its intrinsic biological concern, there is also a major biomedical interest in 
understanding the functional role of gene isoforms, as targeting the wrong isoform may result 
in unexpected damaging effects (Talavera et al., 2007). On the other hand, altered splicing 
patterns can serve as markers of the altered cellular state associated with disease even when 
they are not in the primary pathway of the disease mechanism and still have the potential to 
provide diagnostic and prognostic information (Faustino and Cooper, 2003). Since several 
drugs have been demonstrated to be significantly modulated by single nucleotide changes, the 
analysis of allele-dependent RNA splicing repertoires can help in this respect. The various 
therapeutic approaches that utilize splicing can either alter the splicing patterns of target genes 
or target specific splice variants at the RNA or protein level to achieve a therapeutic effect. 
For example, antisense RNA and DNA, small interference RNA (siRNA), and ribozymes are 
ectopic oligonucleotides that can be designed to recognise target aberrant mRNA molecules 
and elicit their cleavage (recently reviewed in (Pajares et al., 2007; Wang and Cooper, 2007)). 
 
1.5.5. Predicting effects of splice-relevant SNPs 
Soon after the discovery of exons and introns in adenovirus 2 genes in 1978 (Berget et al., 
1977; Chow et al., 1977) Walter Gilbert (Gilbert, 1978) postulated that: (1) different 
combinations of exons could be joined together to produce multiple mRNAs from a single 
gene; and (2) mutations at exon-intron junctions and at silent codon positions could influence 
pre-mRNA splicing modulation and lead to functionally different proteins. Although this 
hypothesis is in part proved in many recent genome-wide projects, it is still a challenging to 
deeply understand how single nucleotide change cause molecular alterations and expression 
19 
changes in gene products through pre-mRNA splicing process. The missing link between the 
generation of genomics data and their analysis by conventional biological approaches (Teufel 
et al., 2006) as well as the difficulty of the experimental approach (in particular, in its high-
throughput version), leaves ample room for the development of many bioinformatic tools that 
can provide a first picture of the problem (Talavera et al., 2007). Given that the impact of 
SNPs on splicing is also hard to predict in silico, silent or intronic SNPs that may cause a 
disease phenotype by changing splicing patterns are often not investigated (Pagani and 
Baralle, 2004). Furthermore, although modifications of the highly conserved AG/GT 
dinucleotides at the ends of introns are usually classified as deleterious, the impact of 
nucleotide variations at loosely defined positions and the creation of cryptic ss are more 
challenging. Unfortunately, testing all nucleotide modifications at the RNA level is a 
tremendous task that cannot be performed in a routine diagnostic setting. In this respect, 
assessment of the potential splicing effect of a specific mutation is important for decision-
making in molecular diagnostics (Houdayer et al., 2008). 
 
The use of algorithms allowing correct and reliable predictions of the impact of SNPs upon 
splicing process would therefore be of utmost importance. Several tools have been devised to 
undertake such assessment, including splice site prediction by a neural network (Reese et al., 
1997) (NNSplice 0.9: http://www.fruitfly.org/seq_tools/splice.html), Human Splicing Finder 
(Version 2.3: http://www.umd.be/HSF/), MaxEntScan (Yeo and Burge, 2004) 
(MES: http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html), automated splice 
site analysis (Nalla and Rogan, 2005) (ASSA:   http://splice.uwo.ca/ - service discontinued), 
the AST web application (http://ast.bioinfo.tau.ac.il/SpliceSiteFrame.htm), ESE Finder 
(Cartegni et al., 2003) (http://rulai.cshl.edu/tools/ESE/) and Relative Enhancer and Silencer 
Classification by Unanimous Enrichment (Fairbrother et al., 2002) (RESCUE-
ESE: http://genes.mit.edu/burgelab/rescue-ese/). 
 
The tools for the analysis of the canonical splice sites such as Alex‘s splice site score 
calculator, NNSplice, SSF and MES are based on the Shapiro and Senapathy matrices 
(Shapiro and Senapathy, 1987) but use different computational methods for splice site 
prediction. In principle, Shapiro and Senapathy carried out a systematic analysis of the RNA 
splice junction sequences of eukaryotic protein coding genes using the GENBANK databank. 
Thereby, they were able to identify splice junction consensus sequences from different classes 
of organisms. In turn, this led to the identification of potential ss in raw DNA sequences and 
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the finding of new ss and exons in known gene sequences, which may yield AS products in 
different in vivo situations. The recently reported neural network (NN) used in the present 
study (Krawczak et al., 2007) used all annotated RefSeq exon boundaries for training. It runs 
distinct algorithms that generate a score matrix for each ss (donor and acceptor). The 
RESCUE-ESE analysis tool searches for hexanucleotide sequences as potential ESE motifs 
that have been identified through a computational method that assessed the relative abundance 
of hexanucleotide sequence stretches in exons as compared to introns (Fairbrother et al., 
2002; Fairbrother et al., 2004b). ESEFinder uses systematic evolution of ligands by 
exponential enrichment (SELEX) and weight/position matrices to score ESEs responsive to 
the four most common human SR splicing factors proteins, namely SF2/ASF, SC35, SRp40 
and SRp55 ESEs (Cartegni et al., 2003). To ensure correct interpretation of the effects of 
disease-associated point mutations or polymorphisms, ESEfinder was freshly subjected to 
further refinement (Smith et al., 2006), which resulted in a score matrix with increased 
specificity for the prediction of SF2/ASF-specific ESEs. The recent interest in allele-
dependent splicing is also emphasized by a computational study (Lee and Shatkay, 2008) that 
yielded a list of potential splice SNPs through the combined use of 16 different bioinformatics 
tools and databases (http://compbio.cs.queensu.ca/F-SNP/). 
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1.6. Aims of the study 
The main aim of the present study was to systematically determine the extent to which 
common SNPs at splice sites influence pre-mRNA (alternative) splicing. 
 
To address this aim, the following specific sub-aims were addressed: 
 
 Establishment of a high-throughput methodology to assess the impact of 
naturally occurring SNPs on differential splicing. 
 
 Evaluation of the current prediction tools of allele-dependent splicing by 
investigating four specific classes of putative splice-SNPs: 
 the mutational imbalance at the authentic acceptor and donor consensus.  
 variation in tandem acceptors (NAGNAG). 
 the exonic-splicing enhancers (ESEs). 
 
 Assessment of the overall importance and efficiency of allele-dependent splicing. 
 
Establishment of a high-throughput methodology of allele-dependent splicing
Extraction of all public SNPs with allele frequency  ~ 10% (dbSNP, HAPMAP) 
In silico splice scoring analysis  
Potential candidate splice SNPs 
I- Web-based bioinformatics round 
II- Neural network round 
Experimental validation in cDNA-DNA panels    
Donor NAGNAG ESE
Donor acceptor
Screen of allele-dependent splicing  
Confirmed allele-dependent splicing events
Prediction rate and performance of prediction tools
A novel  dual-band splice reporter system
(A proof of concept)
in vitro
 
 
Figure ‎1.6 Flow diagram summarizes the experimental approach used in the present study. 
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2 METHODS 
2.1. Selection of putative splice SNPs 
In order to avoid unnecessary overlap, the methods used for the selection of putative splice 
SNPs are described in detail in the ‗Results‘ section. 
 
2.2. General methods 
2.2.1. DNA extraction and quality control 
DNA was isolated from different resources according to manufacturer‘s protocols. While 
‗MagAttract DNA Blood M48‘ (Qiagen, Hilden, Germany) was applied for lymphoblastoid 
cell lines, ‗QIAamp® DNA Micro Kit‘ (Qiagen, Hilden, Germany) was used for extraction of 
DNA from brain tissues. From EDTA whole peripheral blood samples, DNA was extracted 
using the ‗Invisorb® Blood Universal Kit‘ (Invitek, Berlin, Germany) with few modifications 
to the manufacturer‘s protocol in order to get the best DNA quality, as briefly described 
below. 
 
Fresh blood samples were stored at -80°C and thawed in a cold water bath before use. 
Erythrocyte lysis was achieved mainly by incubating 9 ml of blood for 10 min with 30 ml of 
Buffer EL at room temperature. Then the obtained suspension was centrifuged for 3 min at 
3,000 rpm and the supernatant was carefully discarded. This step was repeated with 20 ml 
buffer EL until the leucocyte-containing pellet was free of haem, which could cause problems 
in downstream experiments since haem can inhibit PCR reactions (Heath et al., 1999). The 
obtained pellet was resuspended in 3 ml of Lysis Buffer HL and 50 µl of Proteinase K and 
incubated for 2 hours at 65°C in a water bath under continuous shaking (95 rpm). The latter 
step leads to the lysis of the leukocytes and their nuclei to facilitate the release of DNA into 
the suspension, and agitation at 65°C improves lysis efficiency. To separate the DNA from 
cell and protein fragments, 1.8 ml of Precipitation Solution was added with vigorous mixing 
until white flakes of DNA precipitate became visible and then incubated on ice for 5 minutes. 
In case of unsuccessful DNA precipitation, the tube was incubated at -20°C for at least 2 
hours. Using 1 ml-pipette, DNA flakes were drawn out of the tube and transferred into a fresh 
Eppendorf containing 1 ml of 70% ethanol, and the tube was carefully inverted several times. 
The DNA was pelleted by centrifugation for 2 min at 13,000 rpm. If the DNA pellets were 
very loose, centrifugation was either prolonged or the speed was increased. The supernatant 
23 
was very carefully removed. The purified genomic DNA was then resuspended in 1200 µl 1x 
TE buffer for normal size pellet or in 600 µl in case of small pellet. DNA was completely 
dissolved by overnight incubation at 60°C. Continuous shaking or inverting of the tube from 
time to time during the incubation was recommended to increase the dissolving efficiency. 
Finally, the obtained DNA was stored either at +4°C for a short time (few days) or at -20°C 
for longer periods (over months). The quality of the extracted DNA samples was checked by 
agarose gel electrophoresis and quantified using PicoGreen
®
 assay (section  2.2.6.1). 
 
2.2.2. Total RNA extraction and quality control 
In order to obtain the suitable conditions for isolation of total RNA, all reagents, glassware 
and laboratory utensils were specially treated in order to avoid RNA degradation by RNAses. 
All plastic-ware was purchased as UV-sterilized consumables (50 ml conical tubes, pipet tips 
with aerosol filters) or RNAse-free consumables (microfuge tubes). All glassware, ceramic 
mortar and pestles, Teflon pestles and metal spatulas were cleaned with common laboratory 
washing detergent, rinsed thoroughly in distilled water and air-dried before wrapping in 
aluminum foil and baking at 180°C for 12-16 h before use, in order to inactivate any 
contaminating RNAses. In addition, solutions were prepared with 0.1% DEPC-treated 
distilled water and sterilized by autoclaving. 
 
Total RNA from peripheral blood and cell lines was isolated using the RNeasy (Qiagen) 
system. For RNA extraction from lymphoblastoid cell lines as well as from snap-frozen 
surgical specimens of brain tissue, the TRIZOL reagent (Invitrogen, Karlsruhe, Germany) was 
used according to the supplier‘s protocols. RNeasy technology simplifies total RNA isolation 
by combining the stringency of guanidine-isothiocyanate lysis with the speed and purity of 
silica-gel-membrane purification. On the other hand, the TRIZOL reagent, a mono-phasic 
solution of phenol and guanidinium isothiocyanate, is an improvement to the single-step RNA 
isolation method developed by Chomczynski and Sacchi (Chomczynski and Sacchi, 1987; 
2006). During sample homogenization or lysis, TRIZOL reagent maintains the integrity of the 
RNA, while disrupting cells and dissolving cell components. Addition of chloroform followed 
by centrifugation separates the solution into an aqueous phase and an organic phase. Total 
RNA remains exclusively in the upper aqueous phase, while most of DNA and proteins 
remain either in the interphase or in the lower organic phase. After transfer of the aqueous 
phase, the RNA is recovered by precipitation with isopropyl alcohol. After removal of the 
aqueous phase, the DNA and proteins in the sample can be recovered by sequential 
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precipitation. This technique performs well with small quantities of human tissue (50-100 mg) 
and cells (5 x 10
6
), and yields 5-15 µg of RNA from 1 x 10
6
 cultured cells. 
 
Before using isolated RNA in subsequent cDNA synthesis, the concentration was measured 
using NanoDrop (section  2.2.6.2) and the integrity was checked on gel electrophoresis 
(section  2.2.4). DNA contamination in isolated RNA was tested by amplification of a 
housekeeper gene, glyceraldehyde-3-phosphate dehydrogenase (G3PDH), as described in 
section (‎2.2.7). PCR product was then checked on 1.5% agarose-gel electrophoresis. The 
presence of a band at 983 bp in positive control, and its absence in both RNA samples and 
water control, indicated that isolated RNA was free from genomic contamination. Otherwise, 
if detected, RNA contaminated with DNA was treated with DNase enzyme (Qiagen, Hilden, 
Germany) according to supplier‘s recommendations, and checked again with G3PDH-PCR 
test until genomic contamination was no longer detected. 
 
2.2.3. First-strand cDNA synthesis and quality control 
Five hundred nanograms of isolated RNA was reverse-transcribed into complementary DNA 
(cDNA) using either random hexamers, oligo(dT) primers, or gene-specific primers using the 
RevertAid H Minus First Strand cDNA Synthesis Kit from Fermentas Life Sciences (St. 
Leon-Rot, Germany), or the Clontech‘s Advantage® RT-for PCR kit system, according to the 
supplier‘s instructions. The success of the first strand cDNA synthesis was checked using 2 μl 
(1:10) diluted cDNA reaction as a template for PCR amplification with G3PDH, as described 
in section (‎2.2.7). The amplification of an intensive intact band at 983 bp indicated successful 
first-stand cDNA synthesis. Because the quantification of the prepared cDNA was essential in 
our downstream nested RT-PCR assays, cDNA concentrations were also measured using 
NanoDrop technique as described in section ( 2.2.6.2). 
 
2.2.4. Gel electrophoresis 
The percentage of agarose in the gel varied depending on the expected size(s) of the 
fragment(s) to be applied. The smaller the size, the higher the concentration of agarose was 
used. In each case, ethidium bromide solution (10 mg/ml; 1µl/100 ml agarose gel) was 
included in the gel to enable fluorescent visualization of the DNA fragments under UV light. 
According to standard protocol, agarose gels were then submerged in TBE electrophoresis 
buffer in a horizontal gel apparatus. The DNA samples were mixed with 5µl (2x) loading 
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buffer and loaded into the sample wells. Depending on the desired separation and size of the 
gel chamber (BioRad, Munich, Germany), different electric parameters were as standard 
applied. Size markers were also co-electrophoresed with DNA samples, when appropriate for 
fragment size determination. In general, two size markers were used, namely the 100 bp DNA 
ladder (Invitrogen, Karlsruhe, Germany) and Smartladder (Eurogentec, Cologne, Germany). 
After electrophoresis, the DNA was viewed under UV-illumination and documented with the 
Gel Doc XR Gel Documentation System (BioRad, Munich, Germany). 
 
2.2.5. Elution of DNA fragments from agarose and PCR clean-up 
DNA fragments were excised and eluted from agarose gels using Wizard
®
 SV Gel and PCR 
clean-up system from Promega, according to the supplier‘s procedure. When desired, PCR 
products were also purified using the same kit system. The purified DNA was finally eluted in 
25 µl nuclease-free water. 
 
2.2.6. Measurement of DNA/RNA concentrations 
2.2.6.1. PicoGreen® assay 
For genotyping purposes, the concentrations of all DNA samples were quantified with 
PicoGreen
®
 assay (Ahn et al., 1996; Rengarajan et al., 2002). PicoGreen is a very sensitive 
fluorescent dye with very low own fluorescence used for quantitative assays of double-
stranded DNA (dsDNA) in solution. This dye enables the detection of as little as 25 pg/ml of 
dsDNA (Singer et al., 1997). Using a single dye concentration, the PicoGreen assay has a 
detection range extending from 25 pg/ml to 1 µg/ml dsDNA. While free dye is essentially 
nonfluorescent, it exhibits >1000-fold fluorescence enhancement upon binding to dsDNA 
(with excitation and emission maxima of ~500 nm and ~520 nm, respectively) (Singer et al., 
1997). The fluorescence enhancement of the PicoGreen is exceptionally high; little 
background occurs since the unbound fluorophore has virtually no fluorescence. Moreover, 
PicoGreen is very stable to photobleaching, allowing longer exposure times and assay 
flexibility (Ahn et al., 1996). 
 
Using a TECAN pipetting robot (Genesis RSP 150), full automation of pipetting, dilution, and 
normalization steps were established at ICMB (Kiel, Germany). The measurement of 96 DNA 
samples in parallel was formulated with the help of an in-house implemented software, 
namely SampleTool. Thirty-two DNA samples were arranged in duplicate in a 96-well optical 
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Sarstedt plate. Therefore, the worktable of the robot had capacity for three of such plates. An 
adjusted protocol was applied to measure DNA concentrations with PicoGreen
®
 dsDNA 
quantification reagent. The DNA samples and PicoGreen reagent were left to equilibrate to 
room temperature. The PicoGreen reagent was diluted with 1x TE buffer. The measurement 
plates were prepared to contain 4 different standard DNA solutions (1, 10, 100 and 500 
ng/ml), and 32 DNA samples in 1:40 dilution, in addition to negative controls and blank wells 
(1x TE buffer). One-hundred microliters from the diluted PicoGreen solution was then added 
to each well in the measurement plates, which contained 1:400 diluted DNA samples. 
Contents of all wells were well-mixed and incubated in a dark place for 5 min. Using a 
TECAN Spectrafluor Plus Fluorometer, DNA concentrations of the contents of each 
measurement plate were obtained with excitation wavelength 485 nm. The raw data files were 
exported for each plate separately. Concentrations and dilution factors were calculated using 
the average of the two measurements for each DNA and a standard curve. Normalized DNA 
concentrations were verified by a second measurement. If single tubes were measured without 
SampleTool, a special script was used. Depending on these data, required dilutions and 
volumes for subsequent whole-genome amplification were optimized and utilized. 
 
2.2.6.2. NanoDrop assay 
The concentrations of small volumes preparations, such as RNA, cDNA, plasmid DNA, and 
proteins, were measured in the present study by applying a ‗NanoDrop‘ technique using either 
NanoDrop
®
 ND-1000 Spectrophotmeter or IMPLEN Nanophotemeter. Two µl of diluted 
sample was pipetted directly onto the active measurement window of the device and directly 
measured against 2 µl nuclease-free water as blank. Optical density (OD) ratio (A260/A280 
and A260/A230) was also measured every time for purity estimation. Pure DNA and RNA 
were typically had A260/A280 ratios between 1.8 and 2.10. For pure RNA samples, i.e. free 
from genomic contamination, displayed ratio (A260/A230) values >2.0. 
 
2.2.7. Polymerase chain reaction 
Polymerase chain reaction (PCR), a method that rapidly produces numerous copies of a 
desired piece of DNA, was widely used for many purposes in the present study. For assays 
(SNPs) that did not fit to the design of high-throughput genotyping methods 
(SNPlex/TaqMan), direct genomic sequencing of PCR products were carried out using the 
mother protocol and thermal cycler settings outlined in Table  2.1 and Table  2.2, respectively. 
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Here, specificity was enhanced by using a touchdown thermoprofile as previously 
recommended (Don et al., 1991). To determine the optimal primer annealing temperature (the 
so-called, primer optimization step), a gradient (12°C across 12 positions) PCR was carried 
out using similar reaction mix (Table  2.1); the PCR products were then loaded an onto 1.5% 
agarose gel for electrophoresis, and the best annealing temperature of each tested primer pair 
was chosen and applied. 
 
 
Table ‎2.1 PCR protocol for direct genomic sequencing purposes 
 
Component Volume (l)/reaction Final Concentration 
GeneAmp
®
 10x PCR buffer II 2.50 1X 
MgCl2 [25 mM] 2.00 2 mM 
dNTPs [10 mM] 0.50 200 M 
Forward primer [10 M] 1.00 0.04 M 
Reverse primer [10 M] 1.00 0.04 M 
PCR-water 16.85 - 
Good mixing   
DNA [5 ng/μl]* 1.00 0.75 U 
AmpliTaq Gold
®
 [5 U/μl] 0.15 0.03 U/μl 
Gentle mixing   
Total volume 25.00  
- 
*
: DNA used here was obtained from 1:5 diluted whole genome amplification (WGA) product (see section ‎2.4.1). 
 
 
Table ‎2.2 Thermal cycling conditions of PCR for direct genomic sequencing 
 
Event Temperature (C) Time No. of Cycles 
Initial melting step/ Taq Polymerase activation 95 5 min 1 
Denaturation  95 30 sec td=-0.5°C/cycle 
 
Repeat 16 cycles 
Annealing of primers 65
*
 30 sec 
Extension (1kb/min) 72 1 min 
Denaturation  95 30 sec 
 
Repeat 20 cycles 
Annealing of primers 57
*
 30 sec 
Extension  72 1 min
**
 
Final extension: filling up the ends 
(recommended for TA cloning as well) 
              72 10 min 1 
Hold at                 4  1 
Storage -20 - - 
- 
*
: the optimal annealing temperature of each primer pair was obtained after performing primer optimization PCR.  
- 
**
: elongation time depends on length of amplicon: 1 kb/min. 
 
 
In order to test for genomic contamination in prepared RNA/cDNA, the so-called G3PDH-
PCR was carried out. As a standard, PCR amplification of a housekeeper gene 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) from 2 l of each prepared 
RNA/cDNA sample was performed with Human G3PDH Amplimers (10 mM) using the 
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GoTaq polymerase (Promega). The thermal cycler conditions were: initial melting at 96C for 
2 min, then 40 cycles at 96C for 2 min, 55C for 30 sec, and 72C for 1 min, followed by 5 
min final extension at 72C. On the other hand, to select white clones with correct insert size 
after TA-cloning procedure (section  2.2.9.1), PCR with M13 universal primers (M13-F: 
GTAAAACGACGGCCAGTG; M13-R: AACAGCTATGACCATG) was carried out using 
standard protocol of Taq DNA Polymerase (Qiagen; 5 U/µl). The thermal conditions were: 
initial melting at 95C for 5 min, then 30 cycles at 95C for 1 min, 53C for 1 min, and 72C 
for 2 min, followed by 10 min final extension at 72C. The DNA used here was extracted by 
heating 5 l from each grown white clone in a PCR machine at 95C for 10 min. Five µl from 
each M13-PCR product was then applied to a 1.8% agarose gel for electrophoresis. After 
cDNA preparation (section  2.2.3), reverse-transcription (RT)-PCR technique was carried out 
for transcript detection (Table  2.3 and Table  2.4). In each round of amplification, positive and 
negative controls were included to better monitor transcript expression and to verify the 
performance of reagents as well. 
 
 
Table ‎2.3 RT-PCR general protocol 
 
Component Volume (l)/reaction 
Nuclease-free water 15.80 
GoTaq green buffer [5X] 5.00 
dNTPs [10 mM] 1.00 
Forward primer [10 M] 1.00 
Reverse primer [10 M] 1.00 
Good mixing 
cDNA 1.00 
GoTaq polymerase [5 U/µl]  0.20 
Gentle mixing 
Total volume 25.00 
 
 
Table ‎2.4 Thermal cycling conditions for general RT-PCR protocol 
 
Event Temperature (C) Time No. of Cycles 
Initial melting step/ Taq Polymerase activation 96 2 min 1 
Denaturation  96 30 sec 
 
Repeat 26 cycles 
Annealing of primers 55
*
 30 sec 
Extension  72 1 min
**
 
Final extension               72 5 min 1 
Hold at                 4  1 
Storage -20 - - 
- 
*
:  annealing temperature differs from one primer pair to another.  
- 
**
:  elongation time depends on length of amplicon: 1 kb/min. 
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2.2.8. Digestion of DNA with restriction endonucleases 
It is well-known that restriction endonucleases recognize short DNA sequences and cleave 
double-stranded DNA at specific sites within or adjacent to their recognition sequences. The 
basic single- and double-digestions were carried out at 37C for 1-2 hours in an end volume 
of 10 (or 50) µl using appropriate buffer(s) conditions, as recommended from the supplier 
(New England Biolabs). 
 
2.2.9. Cloning 
2.2.9.1. TA Cloning for PCR products 
PCR products were cloned using the pCR 2.1 TOPO TA Cloning Kit (pCR
® 
II, pCR
® 
2.1) 
from Invitrogen according to standard procedure. This cloning system is based on the fact that 
Taq polymerase has a nontemplate-dependent terminal transferase activity that adds a single 
deoxyadenosine (A) to the 3´ ends of PCR products. The linearized vector supplied in this kit 
has single, overhanging 3´ deoxythymidine (T) residue. This allows PCR inserts to ligate 
efficiently with the vector (Zhou et al., 1995). In order to check for white clones with correct 
insert size, PCR with M13 universal primers was carried out as outlined in section ( 2.2.7). 
Corresponding M13-PCR products, which showed correct insert size from at least 30 clones, 
were sequenced according to standard procedure described below in section ( 2.2.12). The 
resulting sequence traces were aligned and analyzed using Sequencher (version 4.5) software, 
followed by manual verification of the alignments. 
 
2.2.9.2. Cloning using T4-DNA ligase 
The standard ligation reaction used 100 ng of vector. In order to calculate the best insert to 
vector ration, which is 3:1, the following formula was applied: [ng of insert= ((size of insert x 
100 ng of vector)/size of vector) x 3]. To control insert and vector concentrations after 
restriction digestion, they were applied to agarose gel electrophoresis parallel to smartladder. 
The DNA content was then eluted from gel with the Promega‘s kit system described above. 
Thereafter, the standard ligation reaction was done using 1 µl from each ligation buffer (10 x) 
and T4-DNA ligase, corresponding volumes of insert and vector to fit with the 3:1 ration, and 
the reaction was equilibrated to final volume of 10 µl with PCR-water. The ligation reaction 
was then incubated overnight at 14C. Quick ligation, when required, was also achieved by 
incubating the ligation reaction at room temperature for 2-3 hours. 
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2.2.9.3. Transformation 
Five µl of each ligation reaction was then gently pipetted into 25 µl of  Escherichia coli TOP 
10 competent cells and incubated on ice for 30 min. The reaction was then incubated, without 
mixing or shaking, for exactly 30 seconds in the 42°C water bath (heat shock step). The 
transformed mixture was immediately placed again on ice for at least 3 min. Next, 250 µl of 
pre-warmed S.O.C. medium was added to each reaction tube, and the mixture was incubated 
at 37C for 1-2 hours at 200 rpm in a shaking incubator. The content of each transformation 
vial was spreaded on separate, labelled LB agar plates containing appropriate antibiotics. The 
plates were inverted and incubated at 37C overnight. For each plate, 30 clones were picked 
and individually overnight cultured in 3 ml LB medium with the same antibiotics at 37C 
with shaking. Plasmid DNAs were then isolated (section  2.2.11). 
 
2.2.10. Site-directed mutagenesis 
Site-directed mutagenesis was performed using QuikChange
®
 Lightning Site-Directed 
Mutagenesis Kit (Stratagene), according to supplier‘s protocol. The mutagenic primer design 
was done using ‗Quickchange Primer Design Program‘ at Stratagene web site and primers 
were ordered as HPLC-purification grade from Microsynth Laboratory. The basic procedure 
utilizes a supercoiled dsDNA vector (10-100 ng/reaction) with an insert of interest and two 
synthetic oligonucleotide primers (125 ng/µl), both containing the desired mutation. 
Extension of the oligonucleotide primers generates a mutated plasmid containing staggered 
nicks. Following temperature cycling, each amplified product was treated with 2 µl Dpn I at 
37C for 10 min. The Dpn I endonuclease (target sequence: 5´-Gm6ATC-3´) is specific for 
methylated and hemimethylated DNA and is used to digest the parental DNA template and to 
select for the synthesized DNA containing the mutation. The nicked vector DNA containing 
the desired mutation is then transformed into XL10-Gold
®
 ultracompetent cells. The 
transformation and cloning procedure were carried out as described with E. Coli Top 10 
competent cells (see previous section:  2.2.9.3). 
 
2.2.11. Plasmid DNA purification 
Minipreps of DNA plasmids were isolated from 1.5 ml of overnight culture using Wizard
®
 
Plus SV Minipreps DNA Purification System from Promega, according to the manufacturer‘s 
protocol. For fast purification of large-scale transfection grade DNA, plasmid DNA was 
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purified from 200 ml of overnight culture with the help of the QIA Filter
TM
 Plasmid Maxi Kit 
from Qiagen, according to the supplier‘s procedure. The success of either application 
(Mini/Maxi) was checked by measuring the concentration of 2 µl of the isolated plasmid 
DNA using the IMPLEN Nanophotometer (see section  2.2.6.2). 
 
2.2.12. DNA Sequencing 
For DNA sequencing, the BigDye
® 
Terminator v1.1 Cycle Sequencing Kit from Applied 
Biosystems was used in the present study. Eight µl of PCR product were transferred to a 96-
well Costar plate and subjected to an enzymatic digestion (‗digest step‘), in order to remove 
primer-dimers, superfluous primers and free dNTPs. Highly concentrated PCR products, 
determined by agarose gel electrophoresis (section  2.2.4), were diluted 1:5 with PCR-water 
before the digestion reaction. Two µl of the digest mixture, which consisted of 0.30 µl SAP 
(Shrimp Alkaline Phosphatase; 1U/µl), 0.075 µl ExoI (Exonuclease I; 20U/µl) and 1.625 µl 
DDW, were then added. The digest reactions were then incubated at 37°C for 15 min. Here, 
ExoI digests single-stranded DNA molecules (Berthold and Geider, 1976) and remaining 
dNTPs were also destroyed, since a dephosphorylating SAP was used (Sauer et al., 2000). 
Thus, a potential dNTP/ddNTP imbalance, which could disturb the sequencing reaction, was 
avoided. The digestion reaction was then stopped by heating at 72°C for 15 min. The heating 
step inactivates SAP that could negatively affect the subsequent sequencing reaction. Next, in 
a separate 96-well plate, 2 µl of the digested product was mixed with 8 µl sequencing mixture 
(Table  2.5). Separate sequencing reactions were performed for forward and reverse primer, in 
order to confirm sequences as well as to monitor artefacts. The thermocycling settings, as 
outlined in Table  2.6, were applied for sequencing reaction. For isolated plasmid DNA as well 
as DNA purified from agarose gel, the ‗digest step‘ was skipped and sequencing reaction was 
directly carried out following the protocol outlined in Table  2.7, with the same thermocycler 
settings provided in Table  2.6. 
 
 
Table ‎2.5 Components for DNA sequencing reaction 
 
Component Volume (µl) 
Water (HPLC grade) 4.80 
Sample Buffer [5x] 1.50 
Sequencing forward or reverse primer [3.2 pmol/µl] 1.00 
Big Dye
™
 Terminator Ready Reaction Mix [v1.1]       0.70 
Total volume 8.00 
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Table ‎2.6 Sequencing Thermoprofile 
 
Event Temperature (C) Time No. of Cycles 
Initial melting step 96 1 min  
Denaturation  96 10 sec 
 
25 cycles 
Optimized annealing temperature of nested primer  55
*
 5 sec 
Chain termination reaction 60 4 min 
Pausing at                10  1 
Storage -20 - - 
- 
*
: The BigDye reaction  is optimized to a temperature range of 50 to 60 C, in order to avoid any premature termination stops above 60°C 
(Wen L., 2001). 
 
 
Table ‎2.7 Components for Plasmid DNA sequencing reaction 
 
Component Volume (µl) 
Water (HPLC grade) 3.50 
Plasmid (100 ng) 3.00 
Sequencing forward or reverse primer [4.8 pmol/µl] 1.00 
Sample Buffer [5x] 1.00 
Big Dye
™
 Terminator Ready Reaction Mix [v1.1]       1.50 
Total volume 10.00 
 
 
To generate high quality DNA sequence data, unincorporated dye terminators must be 
removed from sequencing product prior to capillary electrophoresis. MultiScreen Separation 
Plates, combined with easy column-loading and packing protocols, provide a very cost-
effective and high performance means for parallel processing of 96 sequencing reactions by 
gel filtration. In the present study, excess Fluorescent Dye Terminator, primers and 
unincorporated nucleotides were removed from the sequencing reactions based on gel 
filtration using modified cross-linked dextran, namely G-50 Sephadex Spin Columns. The 
Sephadex gel filtration matrix was prepared according to the standard protocol using a 96-
well Multiscreen Column loader (MAHVN 4550). The sequencing products were diluted with 
20 µl DDW and applied to the prepared Sephadex plate. The filtration plate was fitted on top 
of a MicroAmp
® 
Optical 96-well reaction plate and the sequencing products were eluted 
through the filtration column into the MicroAmp
® 
Optical 96-well by centrifuging at 2100 
rpm for 5 min. Finally this plate was sealed with an aluminum adhesive cover, to prevent 
contamination, and analyzed on a 3730xl DNA Analyzer. 
 
2.2.13. Transfection of cultured HeLa cells using FuGene 6 Reagent 
HeLa S3 cervical cancer cell line (ACC 161) from the German Collection of Microorganisms 
and Cell Cultures (DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH, Braunschweig, Germany) was cultured as monolayers and maintained in RPMI 1640 
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(PAA Laboratories GmbH, Pasching) containing 10% fetal bovine serum (PAA Laboratories 
GmbH, Pasching), 100 U/ml penicillin and 100 µg/ml streptomycin (PAA Laboratories 
GmbH, Pasching) in a humidified atmosphere with 5% CO2 at 37C. To prepare cells for 
transfection, adherent cells to be subcultured were first washed twice with 2 ml 1X PBS 
(Phosphate-Buffered Saline) and trypsinized (2 ml 1X sterile trypsin-EDTA solution; enough 
to cover the cell monolayer) to loosen adherent cells from the growth surface. Five minutes at 
37°C incubator was enough in most cases to detach all cells (microscopic examination). After 
detaching, 2 ml RPMI 1640 medium with 10% FCS was added to the cells to inactivate the 
trypsin. After centrifugation for 5 minutes at 1000 rpm, the supernatant was decanted and 
cells were resuspended again in 2-10 ml of the same medium depending on the size of the cell 
pellet. The cells were then diluted 1:25 (1 µl cell suspension: 24 µl Trypan blue/PBS) and 
counted using a hemocytometer (Brand, Germany), according to standard procedure. The cell 
count per ml was obtained from the following formula: (total number counted/4) x 50 x 
10,000. A total of 0.4- 0.8 x 10
6
 cells were plated per well in a 6-well plate for ~80% 
confluency the day of transfection. 
 
On the next day of plating, the transfection was performed using a cationic lipid-based 
transfection reagent (FuGENE 6; Roche) that complexes with DNA and transports it into the 
cell during transfection. For each well, transfection was done using 3 µl FuGENE 6 reagent in 
a total volume of 100 µl serum-free RPMI 1640 medium. One microgram vector DNA 
solution (0.5-50 µl) was then added to the pre-diluted FuGENE 6 reagent from the previous 
step. The tubes were very gently mixed by tapping. After 15 minutes incubation at room 
temperature, the content of each complex mixture (~100 µl) was dropwise pipetted to the 
corresponding well in the 6-well plate. The transfected cells were then returned to incubator at 
37C. All of these steps were performed under sterile conditions (in a laminar flow hood). 
Typically, 24-30 hours post-transfection, cells were rinsed and harvested in each time with 1 
ml cold 1X PBS. 
 
2.2.14. Protein lysate preparation and Western blotting 
Protein lysate preparation. Lysed protein extracts were prepared from transfected HeLa 
cells by boiling the tissue homogenates for 5 min in denaturing extraction buffer containing 
1% SDS, 10 mM Tris (pH 7.4), and 1% phosphatase inhibitor mixture II (Sigma-Aldrich 
Chemie, Germany). After sonicating twice (Bandelin Sonoplus GM 70) for 5 seconds, 
insoluble material was removed by centrifugation for 15 min at 16,000 X g at 4°C (Waetzig et 
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al., 2002). Protein extracts were snap-frozen in liquid nitrogen and stored at - 80°C. For all 
western blotting experiments, total protein was determined using ‗DC-Protein Assay‘ from 
BioRad. Thereafter, protein concentrations were directly measured at 750 nm (IMPLEN 
Nanophotemeter) from a calibrated standard curve using the Lowry method parameters. 
 
Western blot analysis. Western blotting experiments were mainly performed as described by 
Waetzig and co-workers (Waetzig et al., 2002) with minor changes. Protein extracts 
(standardized to 10 µg of total protein in 1X SDS-loading buffer/lane) were separated by 12% 
denaturing SDS-PAGE (Multigel Whatman Biometra; 30 min at 20 mA for stacking gel and 1 
hr at 50 mA for separating gel) and transferred to a polyvinylidene difluoride ‗PVDF‘ 
membrane (Hybond-P; Amersham Pharmacia Biotech) by semidry blotting (80 min at 40 mA: 
0.65 mA/cm
2
) using an electroblotter (PeqLab Biotechnologie). Following transfer, 
membranes were blocked at 4C overnight with 5% non-fat milk proteins suspended in 1X 
TBST on a Roller Mixer (Stuart). These inert milk proteins bind to the unoccupied membrane 
sites (without displacing the target protein from the membrane), thereby blocking non-specific 
binding of antibodies to PVDF membrane. After blocking step, the PVDF membrane was 
incubated for 2 hrs with primary antibody (DsRed monoclonal antibody (1:500) or Aequorea 
victoria (A.v.) GFP monoclonal antibody (JL-8) (1:1000), Clontech). After being washed in 
1X TBST (three times for 15 min), membrane was incubated for 30 min with a HRP-
conjugated secondary antibody (Rabbit polyclonal to Mouse IgG antibody - H&L (HRP) 
(ab6728) (1:2000), Abcam). Membranes were subsequently washed 3 times with TBST (three 
times for 15 min), incubated with ECL-Plus Detection Reagent (3,9 ml solution A plus 100 µl 
solution B; Amersham Biotech) for 3-5 min. Western blots were documented using Bio-Rad 
ChemiDoc XRS System, and pictures were taken using its CCD camera. As an internal 
control, PVDF membranes were stripped by a 4 min incubation at room temperature in 10 ml 
mixture of 0.1% SDS and 0.2% M NaOH, and then the blots were probed again with 1:1000 
mouse anti--actin monoclonal antibody (Clone AC-15, Sigma). 
 
2.2.15. Fluorescent Activated Cell Sorter (FACS)-Analysis 
In the present study, fluorescence-activated cell sorter (FACS) analysis was carried out using 
a FACSCalibur
TM
 cytometer (Becton-Dickinson, San Jose, CA) with filters suitable for both 
enhanced green and red fluorescent proteins (EGFP and RFP, respectively). Excitation of both 
proteins resulted from use of an air-cooled argon-ion laser (Excitation; 488 nm), detection 
parameters were set to the maximum emission wavelength for EGFP (Fluorescence channel 
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FL1, Emission: 53015nm) or RFP (Fluorescence channel FL2, Emission: 58515nm), 
respectively. For FACS analyses, HeLa cells were transfected as described (section ‎2.2.13) 
and after 24h cells were washed in ice-cold PBS and transferred into cytometer tubes in a 
final volume of 500 µl PBS. Untransfected HeLa (mock) cells were used at first to equilibrate 
the FACS system and to define cell-type specific instrument settings. Fluorescence was 
separately detected in channels FL1 (for EGFP) and FL2 (for RFP) in 20,000 cells/sample 
using a measurement speed of <1000 cells/sec. Fluorescence intensity for both individual 
parameters was quantified by applying the CellQuestPro
TM
 software package (Beckton 
Dickinson). 
 
2.3. Generation of matching DNA- cDNA pairs 
2.3.1. Recruitment 
The analysis of allelic splicing required a resource of cDNA from individuals with pre-
determined genotypes. Thus at the beginning of the present study, a total of 170 matching 
pairs of DNA and cDNA were extracted from either whole blood (N=25), lymphoblastoid cell 
lines (N=135) or brain tissue (N=10) obtained from surgical specimens. Proband recruitment 
protocols were approved by the institutional ethics committees at all participating institutions 
and written informed consent was obtained from all participants prior to the study. Samples 
were anonymized according to the local data protection regulations. 
 
Lymphoblastoid cell lines: A resource of 135 lymphoblastoid cell lines from normal 
individuals (N=58) and patients with inflammatory bowel disease (N=54) and sarcoidosis 
(N=23) was generated. Lymphoblastoid cell lines were obtained from B lymphocytes, which 
can be grown indefinitely in the laboratory after special treatment of the cells with Epstein-
Barr virus (EBV) (Cavalli-Sforza, 2005). Human B lymphocytes have a receptor for EBV and 
once infected, they can become immortalized with a high rate of success to produce a cell 
line. EBV remains episomal (nonintegrated) and therefore does not alter the endogenous 
genome (Strachan and Read, 2004). 
 
Corresponding resource of human leucocytes cDNA and DNA: As part of the regional 
POPGEN biobank project (Krawczak et al., 2006), 25 normal healthy controls were used to 
obtain corresponding samples of DNA and cDNA from peripheral blood. This resource served 
to minimize potential artefacts introduced through the viral transformation in the cell lines. 
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The area from which these normal control individuals came is thought to consist of a very 
homogenous Northern German population (Krawczak et al., 2006). 
 
Corresponding resource of human brain cDNA and DNA: In cooperation with the Department 
of Neuropathology, University of Bonn (Prof. Dr. Albert Becker), we obtained DNA and 
cDNA from 10 human brain samples derived from stereotactic surgery. Brain tissue biopsies 
were obtained from patients with chronic pharmacoresistant temporal lobe epilepsy in the 
Epilepsy Surgery Program at Bonn University. Surgical removal of epileptogenic tissue was 
necessary to achieve seizure control in all patients after standardized pre-surgical evaluation 
using a combination of non-invasive and invasive procedures (Kral et al., 2002). This 
resource was used to address potential tissue-specificity of the observed splicing effects. 
 
2.3.2. Plate layout 
For each sample, in addition to a label on the lid, each 2 ml tube received a barcode for 
tracking it in the laboratory information management system (LIMS), which is an in-house 
available database used to systematically store and retrieve information at ICMB. To be 
suitable for subsequent genotyping and RT-PCR analyses, these samples were arrayed in 
labelled 96-well microtiterplates (MTP). An overview of the corresponding DNA/cDNA pairs 
of control and patients samples recruited in this study is provided in Figure  2.1. Four wells 
were used for internal controls and quality control. These included three empty wells (no 
template controls [NTCs]), one positive control and the so-called CEPH cell-line control 
(Dausset et al., 1990). Negative controls were used to reveal potential contamination. 
 
 
Figure ‎2.1 Plate layout of 
matching DNA and cDNA 
controls and patients 
samples labelled with ICMB-
specific codes. 
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2.3.3. Quality control checkups 
After recruitment of samples, matching pairs of cDNA and genomic DNA (gDNA) were 
prepared from the respective tissue as described above (section  2.3.1). To ensure the quality 
of the prepared gDNA and cDNA, all the quality control checkups were carried out. The 
quality of all extracted DNA samples was checked on agarose gels (section  2.2.4), quantified 
using PicoGreen
®
 assay (section  2.2.6.1), and used for whole genome amplification. One 
intact band with high molecular weight was observed for qualified DNA, while a smear or 
weak bands indicated degraded DNA or low DNA concentration (i.e., failure of DNA 
extraction). This checkpoint was very important, since degraded DNA or a DNA 
concentration below 10 ng/l was not suitable for whole-genome amplification using multiple 
displacement reaction. The isolated RNA samples were also subjected to quality control 
checkups as well. These included quantification using NanoDrop technique and G3PDH-PCR 
test for genomic contamination (section  2.2.7). The isolated RNA was reverse-transcribed into 
complementary DNA (cDNA) using random hexamers (section ‎2.2.3) and the success of the 
first strand cDNA synthesis was also checked using PCR amplification with G3PDH. 
 
2.4. Whole-genome amplification and genotyping 
2.4.1. Whole-genome amplification 
To overcome the restrictions of poor DNA yield and limited amounts of available samples, 
which was not suitable for wide-scale genotyping experiments, a new whole genome 
amplification (WGA) method, namely GenomiPhi DNA amplification kit (Amersham 
Biosciences), was used in the present study. This method produced microgram quantities of 
high molecular weight DNA from as little as 1 ng of genomic DNA. The GenomiPhi assay 
utilizes bacteriophage Phi29 DNA polymerase from Bacillus subtilis - a unique, highly 
processive enzyme with excellent strand displacement activity- in combination with random-
sequence hexamer primers to amplify DNA in an isothermal (30C) process. Therefore, in 
standard displacement reaction, thermal cycling was not required (Lizardi et al., 1998; Dean 
et al., 2001). Because of the proofreading activity of Phi29 DNA polymerase (Esteban et al., 
1993; Nelson et al., 2002), DNA replication in this method is extremely accurate. 
 
The GenomiPhi method relies on the multiple displacement amplification (MDA) WGA 
reaction that was first described by (Dean et al., 2002), and has been recently considered 
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developed technique for high performance WGA (Lovmar and Syvanen, 2006). The basic 
idea of MDA is that, the random hexamers anneal to the single stranded target molecule and 
as the DNA polymerase elongates the primer, the upstream DNA strands are displaced. The 
displaced DNA strands can then serve as templates for new priming events, which results in 
primer elongation in the opposite direction. The MDA reaction continues, and new DNA 
strands are displaced to produce new templates and a hyperbranched structure, generating an 
abundance of copies of the original DNA molecule (Lovmar and Syvanen, 2006). Varying 
DNA concentrations in the initial sample will plateau during MDA, which is a potential 
benefit for MDA in large-scale genotyping applications because it unifies and increases the 
DNA concentrations of the samples (Lovmar and Syvanen, 2006). The performance of MDA 
is dependent upon the quality of the input DNA (Lage et al., 2003). In this regard, the quality 
of the DNA yield from degraded DNA templates is poor and often not suitable for genotype 
analyses. A degraded DNA template has fewer primer binding sites per DNA molecule for 
initiation of replication, and will thus undergo fewer hyperbranching events. In this case, the 
high processivity of the MDA reaction will not be fully utilized, which lowers the yield 
(Lovmar and Syvanen, 2006). For that reason, the extracted DNAs (section  2.2.1) were 
checked on agarose gel to insure their integrity. 
 
It was highly recommended to not use more than 1-2 l DNA volume in the Phi29 reaction. 
Therefore, DNA samples with higher concentration were diluted with 0.1x TE buffer to final 
concentrations of 10-30 ng/l. Two different versions of GenomiPhi kits, v1 and v2, were 
used for amplification of DNA. While version 1 is an overnight reaction, version 2 produces 
the same yield after two hours of reaction time. Moreover, there is no random amplification in 
empty wells thus no artefacts are generated. The procedure generated fragments between 10 
and 100 kb long. Briefly, 1 µl of a template DNA to be amplified was added to 9 µl of sample 
buffer on ice, and then heated to 95C for 3 min to denature the template DNA. Afterwards, 
the sample was immediately cooled, mixed with 9 µl of reaction buffer and 1 µl of enzyme 
mix, and incubated at 30C (16-18 hours for Kit-v1 or 2 hours for v2). After amplification, 
Phi29 DNA polymerase was heat-inactivated in a 10 min incubation at 65C. The quality of 
the amplified DNA was checked by agarose gel electrophoresis, to be sure that the WGA 
reaction had worked and resulted in one intact high molecular weight band (not a smear) for 
each reaction. The resultant wgaDNA was quantified using PicoGreen
®
 assay, in order to 
calculate the suitable volume from each sample to be used in downstream genotyping assays. 
Finally, the final 20 µl (~5 µg) reaction volume was diluted 1:5 with 1x TE-buffer (a final 
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volume of 100 µl; ~50 ng/µl). The 100 µl was split (2x 50 µl) into two fresh 96 well MT 
plates: one plate was used for SNPlex genotyping and the other for TaqMan plate production. 
 
2.4.2. Genotyping of amplified DNA samples 
As the experimental program was critically dependent on the availability of heterozygote 
transcript carriers, the DNA was used for cost-efficient genotyping and selection of 
individuals to reduce the number of cDNA-based experiments. The amplified DNA samples 
were genotyped in the present study using the high-throughput SNP genotyping platform at 
the ICMB, which was supported by an in-house LIMS and automation system (Hampe et al., 
2001; Teuber et al., 2005) and in-house expertise to develop project-specific software for data 
analysis (Hampe et al., 2001). Ten nanograms of amplified genomic DNA were dried in 96-
well plates and genotyped using either SNPlex technology or TaqMan (Applied Biosystems, 
Foster City, CA), depending upon technical feasibility (Appendix Table  8.1). For assays that 
failed, direct genomic sequencing with automated calling (Manaster et al., 2005a) was carried 
out. For the direct sequencing method, PCR was performed using 5 µl from each diluted 
wgaDNA (1ng/µl) (section  2.2.7). 
 
2.4.2.1. SNPlexTM Genotyping: An advanced high-throughput technology 
In the present study, the selected candidate splice SNPs were mostly genotyped using the 
recently developed SNPlex
TM
 genotyping system. This system represents an attractive 
alternative to existing genotyping methodologies, as it requires only three unlabeled probes 
per SNP, consumes very little genomic DNA, can be highly multiplexed, and uses widely 
available capillary electrophoresis (CE) instruments. The SNPlex
TM
 assay (Figure  2.2) 
involves eight main steps (De la Vega et al., 2005; Tobler et al., 2005), which were performed 
in three consecutive days, according to the established protocol at ICMB. The only SNP-
specific components of the assay were the ligation probes that participate in the 
oligonucleotide ligation (OLA), which was the key allele-discriminating step. Currently, up to 
48 SNPs can be addressed simultaneously in one OLA reaction over a 384 well MTPs. The 
SNPlex
TM
 system is based on an OLA-PCR assay with a universal ZipChute
TM
 probe 
detection for high-throughput SNP genotyping. In this method, fluorescently labeled 
ZipChute
TM
 probes are hybridized to complementary ZipChute
TM
 sequences that are part of 
genotype-specific amplicons. These ZipChute
TM
 probes are then eluted and detected by 
electrophoretic separation on Applied Biosystems 3730 or 3730xl DNA Analyzers. 
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In experiment, the wgaDNA was first fragmented for 5 min, diluted 1:2 with 1x TE-buffer to 
a final volume of 100 µl (~25 ng/µl), and then aliquots of 5 µl were dispensed using a 384-
channel Robbins Scientific Hydra microdispenser to fresh 384 MT PCR plates. After the 
plates were left to dry overnight in a closed cupboard, the plates were well-sealed and labelled  
with a unique barcode for database tracking. At this point, the plates were ready-to-use for 
SNPlex
™
 genotyping (preferably used within 6-12 months for optimal results). On the first 
day of genotyping, after an initial kinase step to phosphorylate linkers and ligation probes, the 
activated oligonucleotides were combined with fragmented wgaDNA (100–150 ng per well, 
i.e. 2–3 ng per assay) to perform genotyping in separate reactions. Since the design of the 
present study depended on the 96-well plate format to shape with the downstream cDNA-
arraying and RT-PCR experiments, a modified pipetting script was applied. By this means, 
DNA samples in 96-well plate format were four times pipetted into a 384-MTPs format, 
thereby allowing genotyping of four different 48-SNPlex pools in one run, which was cheaper 
and improved the robustness and throughput of the assay four-fold. The selected candidate 
SNPs were also frequent enough (≥ 10% heterozygosity) to be enriched in these 96 DNA 
samples. Next, the OLA reaction was prepared for each 48-SNPlex pool (Table  2.8), 
transferred to the pre-designed quarter of the 384-well SNPlex plate, and PCR (Table  2.9) was 
performed overnight. 
 
 
Table ‎2.8 Phosphorylating and Ligating Probes to gDNA (OLA reaction) 
 
Component Single reaction (l) 210 reactions (l) 
Nuclease-free water 2.30 483.00 
Oligonucleotide-Ligation-MasterMix 2.50 525.00 
Universal Linkers 48-plex 0.05 10.50 
dATP (100x) 0.05 10.50 
SNPlex System Ligation Probes 0.10 21.00 
Total 5.00 1050.00 
- Each SNPlex pool was prepared on a 210-reaction scale and dispensed, in the appropriate quarter of the 384 well plate. 
 
 
Table ‎2.9 Running the OLA reactions on the thermal cycler 
 
Step Step type Temperature (C) Time 
1 Hold 48 30 min 
2 Hold 90 20 min 
3 
 
25 cycles 
94 15 sec 
60 30 sec 
51 
3% ramp 
30 sec 
4 Hold 99 10 min 
5 Hold 4  
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Figure ‎2.2 SNPlexTM Genotyping system workflow. 
This involves eight main steps. (1) Activation of ligation 
probes and linkers by phosphorylation. (2) Ligation of 
linkers and probes on the genomic DNA target. During 
allele-specific OLA reaction, allele-specific oligonucleotide 
(ASO) probes and locus-specific oligonucleotide (LSO) 
probes hybridize to the genomic target sequence. These 
allele-specific and locus-specific probes ligate when they 
are hybridized to a perfectly matching sequence at the SNP 
site. Simultaneously, universal linkers are ligated to the 
distal termini of the ASO and LSO ligation probes. These 
linkers contain universal PCR primer–binding sequences as 
well as sequences complementary to ASO and LSO probes. 
A unique ZipCode sequence is attached at the 5′ end of the 
genomic equivalent sequence within each ASO. 
Consequently, by virtue of the ZipCode sequence, the OLA 
step encodes the genotype information of every SNP into 
unique ligation products. (3) Removal of unligated or 
incompletely ligated oligonucleotides and genomic DNA 
by exonucleases. (4) Simultaneous amplification of ligation 
products by PCR, using a set of universal primers. (5) 
Capture of biotinylated amplicons on streptavidin-coated 
plates, and removal of the unbound strand. (6) 
Hybridization of the universal set of ZipChute probes to the 
complementary ZipCode product sequence on the captured 
PCR strand. (7) Release of specifically hybridized 
ZipChute probes. (8) Detection of fluorescent ZipChute 
probes by CE; after elution, ZipChute probes are 
electrophoretically separated on an Applied Biosystems 
3730xl DNA Analyzer. The intensities of specific signals in 
each bin of a marker are automatically converted into 
cluster plots using GeneMapper
®
 Analysis Software. 
Illustration adapted  from (De la Vega et al., 2005). 
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On the second day, unligated and incompletely ligated oligonucleotides, as well as the 
genomic DNA templates, were removed by digestion with exonuclease I and λ-exonuclease. 
This so-called ―purification step‖ governs the reduction of signal background noise. Five l of 
purification master mix, Table  2.10 , was pipetted into each well of the OLA reaction plate. 
The plate was sealed, shortly vortexed, centrifuged, and transferred to the thermal cycler 
(Table  2.11). Then, 15 l of nuclease-free water was added to each well, mixed, spinned 
down, and subjected to PCR (Table  2.12 and Table  2.13) with two universal primers, one of 
which was biotinylated. The last PCR step was carried out in the thermal cyclers of the PCR 
laboratory, and not of the OLA laboratory, to avoid any chance of genomic contamination, as 
universal primers were used for amplification of ligated OLA reaction products. 
 
 
Table ‎2.10 Purifying Ligated OLA Reaction Products 
 
Component Single reaction (l) 
 
500 reactions (l) 
(For one 384 well plate) 
Nuclease-free water 4.20 2100.00 
SNPlex Exonuklease Buffer 0.50 250.00 
SNPlex Lambda Exonuklease 0.20 100.00 
SNPlex Exonuklease I 0.10 50.00 
Total 5.00 2500.00 
 
 
Table ‎2.11 Thermal cycle program for purification step 
 
Step Step type Temperature (C) Time 
1 Hold 37 90 min 
2 Hold 80 10 min 
5 Hold 4  
 
 
Table ‎2.12 Amplification protocol of ligated OLA reaction products by PCR 
 
Component Single reaction (l) 500 reactions (l) 
(For one 384 well plate) 
Nuclease-free water 2.42 1331.0 
SNPlex Amplification MasterMix (2X) 5 2750.0 
SNPlex Amplification Primers (20x) 0.5 275.0 
Total 7.92 4356.0 
 
 
Table ‎2.13 Thermal cycle profile for PCR amplification of ligated OLA products 
Step Step type Temperature (C) Time 
1 HOLD 95 10 min 
2 30 cycles 
95 15 sec 
70 60 sec 
5 Ho 4  
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After PCR, biotinylated amplicons were incubated with streptavidin-coated microtiter plates 
in the same PCR laboratory, using a special robot-program that mixed 17.5 l of the 
hybridization mixture (Table  2.14) with 3 l PCR-product. These mixtures were incubated for 
15 min at room temperature in a shaking incubator (TiMix Control) at 600 rpm. Using another 
program, the non-biotinylated amplicons were detached by mixing 50 l of 0.1 M NaOH in 
each well and direct incubation at room temperature for 5min in the shaking incubator at 800 
rpm. Upon removal of the non-biotinylated amplicon strands, 25 l of a mixture of 102 pre-
optimized, universal ZipChute
™
 probes (Table  2.15) was added to each well for hybridization 
and decoding of the genotypic information. Of these, 96 ZipChute
™
 probes corresponded to 
all 96 possible alleles of the 48 addressable SNPs in the multiplex. The six remaining 
ZipChute
™
 probes were needed for internal controls, such as the positive and the negative 
hybridization control (PHC/NHC). ZipChute
™
 probes are fluorescently labeled 
oligonucleotides, with each probe having a unique size (so-called mobility modifiers). The 
plates were then directly incubated at 37C in the shaking incubator at 600 rpm for 60 min. 
After stringent washing, the ZipChute
™ 
probes were eluted using 17.5 l sample loading 
master mix (Table  2.16), and incubation time of 10 min at 37C in the shaking incubator (at 
800 rpm). The universal ZipChute
™
 probes were finally detected by electrophoretic separation 
following to supplier‘s recommendations on Applied Biosystems 3730xl DNA Analyzers. An 
allelic ladder containing all available ZipChute™ probes was analyzed in parallel to correct 
run-to-run sizing variations. GeneMapper
® 
software was used for analyzing the raw CE data 
and calling SNP genotypes. Because one SNP is typically characterized by two possible 
alleles, two fluorescent peaks in a CE electropherogram represent the two alleles of a specific 
SNP (Figure  2.2). GeneMapper
® 
analysis software assigns individual genotypes, based on the 
intensity and location of peaks. Auto-calls of GeneMapper
® 
were manually checked for faulty 
genotype assignments before the data was exported from GeneMapper
® 
and imported into the 
in-house database ‘ibdbase‘. 
 
 
Table ‎2.14 Hybridization Buffer 
 
Component Single reaction (l) 1568 reactions (l) 
(For two 384 well plate)  
SNPlex Hybridization Buffer 17.491 27425.90 
Positive Hybridization Control 0.009 14.100 
Total 17.500 27440.00 
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Table ‎2.15 ZipChute™‎hybridization master mix 
 
Component Single reaction (l) 1528 reactions (l) 
(For two 384 well plate)  
ZipChute Mix 0.05 76.40 
Denaturant SNPlex System 11.25 17190.00 
SNPlex ZipChute Dilution Buffer 13.7 20933.60 
Total 25.00 38200.00 
 
 
Table ‎2.16 Sample loading master mix 
 
Component Single reaction  (l) 1682,285714 reactions  (l) 
(For two 384 well plate) 
SNPlex size standard 0.54 908.40 
SNPlex sample loading Reagent 16.96 28531.60 
Total 17.50 29440.00 
 
 
2.4.2.2. TaqMan® genotyping assay: A fluorogenic 5 nuclease assay 
Although SNPlex
TM
 technology is preferred as a high-throughput system, TaqMan
®
 is still 
very valuable and robust for genotyping a small number of SNPs that failed with SNPlex
TM
 
due to assay design failures. The TaqMan
®
 SNP Genotyping Assay is a single-tube PCR 
assay that exploits the 5 exonuclease activity of AmpliTaq Gold® DNA polymerase. The 
assay includes two locus-specific PCR primers that flank the SNP of interest, and two allele-
specific oligonucleotide TaqMan
®
 probes (Figure  2.3). These probes have a fluorescent 
reporter dye at the 5 end, and a non-fluorescent quencher (NFQ) with a minor groove binder 
(MGB) at the 3 end (De la Vega et al., 2005). An intact probe emits minimal fluorescent 
signal when excited, because the close physical proximity of the 5 fluorophore to the 3 
quencher causes the fluorescent resonance energy transfer (FRET) effect to quench the 
fluorescence emitted by the fluorophore. A fluorescent signal is generated when the intact 
probe, which is hybridized to the target allele, is cleaved by the 5 exonuclease activity of 
AmpliTaq Gold
®
 DNA polymerase during each cycle of the PCR reaction. The PCR primers 
amplify a specific locus on the genomic DNA template, and each fluorescent dye-labelled 
hybridization probe reports the presence of its associated allele in the DNA sample (Figure 
 2.3). In each PCR cycle, cleavage of one or both allele-specific probes produces an 
exponentially increasing fluorescent signal by freeing the 5 fluorophore from the 3 quencher. 
The use of two probes, one specific to each allele of the SNP and labelled with two 
fluorophores, allows detection of both alleles in a single tube (De la Vega et al., 2005). 
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TaqMan
®
 probes were labelled with the fluorescent dyes FAM
™
 (6-carboxyfluorescein) or 
VIC
®
 (proprietary dye from Applied Biosystems) and with the quencher TAMRA
™
 (6-
carboxytetramethylrhodamine, succinimidyl ester). The passive reference dye ROX (6-
carboxy-X-rhodamine, succinimidyl ester) was included in every well for normalization. 
Fluorogenic probes with an MGB produce enhanced allelic discrimination, because the MGB 
stabilizes the double-stranded probe template structure, thereby increasing the probe melting 
temperature (Tm) without increasing probe length (Kutyavin et al., 2000). This provides 
enhanced mismatch discrimination between these shorter probes, resulting in improved allele 
specificity. In the present study, most of the performed TaqMan
®
 genotyping assays were 
Assays-on-Demand, a pre-designed and validated assay format offered directly by the 
manufacturer. However, if pre-designed assays were not available, Assays-by-Design was 
ordered, i.e. assays were custom-ordered from ABI according to a user-defined sequence. 
Both types of assays required no further optimization. 
 
In experiment, 5 µl from wgaDNA was further diluted 1:80 to a final volume of 4 ml (~0.63 
ng/µl). Then, 5 µl was pipetted into the corresponding wells of the 96-well TaqMan plate and 
dried down at 60C for 2 hours, subsequently sealed, labelled with a unique barcode for 
database tracking. These dried TaqMan
®
 PCR plates could be kept for two years before use. 
The reaction components were mixed in a final volume of 5 l as demonstrated in Table  2.17. 
Typically, 5 µl of this reaction mix was added to the 96-well plates with the dried genomic 
DNA either manually or by a TECAN Genesis RSP 150 multipipetting robot. This process 
was carried out and tracked with the in-house software Pipettor, which was part of the 
integrated LIMS (Hampe et al., 2001; Teuber et al., 2005). The applied two-step PCR thermal 
cycling protocol is provided in Table  2.18. The endpoint read of fluorescence was performed 
with ABI Prism
®
 7700 Sequence Detection System and allele calling for each assay/plate was 
done manually to ensure data quality. A call rate of 95% was considered successful. Each 
successful assay produced three separated clusters/clouds representing the three genotypes, 
homoyzygotes for allele 1 were shown in red, heterozygotes (12) in green (both dyes are 
measured), and homozygotes for allele 2 in blue. The genotypes scattered between these 
specific clouds were considered as undefined genotypes and subsequently excluded from 
downstream analyses. Assays that did not show a cluster plot with these three recognizable 
clouds were deemed unsuccessful and genotyped by direct genomic sequencing. 
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Figure ‎2.3 Principle of TaqMan® assay. 
(A) Probe binding and primer extension in a TaqMan
®
 SNP Genotyping Assay. 
(B) Allelic discrimination is achieved by the selective annealing of matching probe and template sequences, 
which generates an allele-specific signal. Illustration modified from(De la Vega et al., 2005). 
 
 
Table ‎2.17 TaqMan® reaction mixture 
 
Component 
Assays-on-Demand Assays-by-design 
Volume (l)/reaction Volume (l) /reaction 
TaqMan
®
 master mix 2.500 2.500 
Read-to-use-assay mix 0.250 0.063 
Water 2.250 2.437 
Total volume 5.000 5.000 
 
 
Table ‎2.18 Thermal cycling conditions for TaqMan® genotyping 
 
Event Temperature (C) Time No. of Cycles 
Activation of Ampli TaqGold
®
 95 10 min 1 
Denaturation 95 15 sec 
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Annealing, elongation, nucleolytic cleavage of 
hybridized probes 
60 1 min 
Storage 4  1 
 
 
2.5. Arraying of corresponding cDNA 
In principle, the cDNAs were transferred using a TECAN-robot with cooled 96-well plate 
holders, in order to avoid degradation. In the present study, a customized software, namely 
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‗SpliceTool‘, was specifically developed to translate the genotypes into the plate position for 
cDNA-transfer (details in Results section  3.1.2). A schema of genotyping and cDNA-transfer 
is illustrated in (Figure  2.4). 
 
 
 
 
Figure ‎2.4 Schema of genotyping and cDNA selection. 
In step 1, two corresponding plates with DNA and cDNA were prepared with an identical position of each 
individual. In step 2, the cDNAs were selected on the basis of the genotypes and transferred to one column of 
the delivery plate (each delivery plate can thus hold the cDNA for 12 different subsequent sequencing assays). 
 
 
2.6. Transcript analysis using nested RT-PCR in genotyped cDNA samples 
2.6.1. Primer design criteria and semi-automation 
To verify the putative splicing effects and to avoid excessive PCR optimization, nested 
primers were designed (Farrell, 1999) according to the following criteria: 
 
i) Primers were preferably positioned in conserved exons flanking to the candidate 
SNP. 
ii) An additional exon was included on each side of the potentially affected exon if 
the amplicon length was short enough (600-800 nt long).  
iii) At least 50 nt of exonic sequence in the amplification direction was included in the 
amplification product to create sufficient overlap for subsequent sequence 
alignment (by SNPSplicer software; section  2.8). 
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iv) All nested primers were chosen to have similar annealing temperature (around 55- 
57 C) in order to be able to perform subsequent RT-PCR experiments in parallel 
for different candidate SNPs that were occupied the same 96-well plate. 
v) Because Repeatmasker, which is a tool for screening submitted DNA sequence 
against a broad library of repetitive elements, tends to be quite aggressive in its 
annotation of sequences (Phillips, 2007), when designing nested primers for RT-
PCR experiments, it was safer to include masked sequence and then check the 
resulting designs for specificity in BLAST and right spans of primers in BLAT 
search (searching if a given primer is unique in the genome). 
vi) As SNPs located within probes may affect their hybridization to target DNA 
sequence (Kwan et al., 2007), all probes containing SNPs were conservatively 
masked out to circumvent this problem (using SNP-BLAST search at NCBI). 
 
In order to fulfil the above-mentioned designing criteria and make this process fast and 
precise, another helping software tool, namely ―SkippedExonPrimer‖, was developed (details 
in Results section  3.1.3). Obtained primers were then manually double-checked using Primer 
Express software (Applied Biosystems). All primers (Appendix Table  8.1) were produced by 
Metabion (Martinsried, Germany). Primer stocks were diluted to a concentration of 100 µM 
with double-distilled water (DDW). These stocks were further diluted to 10 µM, aliquoted, 
and stored at –20˚C. 
 
2.6.2. Nested RT-PCR 
Nested RT-PCR reactions were performed using a chemical hot start enzyme, AmpliTaq 
Gold
®
 DNA Polymerase.  While one microliter of a 1:10 dilution of the reverse transcriptase 
reaction was used in the first round of amplification, 1 l of the first round amplification 
product was amplified in the second-round PCR using the same thermocycling protocol 
(Table  2.19 and Table  2.20). Here, the specificity of obtained products was enhanced by a 
touchdown thermoprofile (Don et al., 1991) in a nested PCR protocol (McPherson and 
Moller, 2000). All the primers used for nested RT-PCRs are provided in Appendix Table  8.1. 
PCR products from the second round were separated on 1.5% agarose gels and visualized 
under UV-illumination with the Bio-Rad Gel Doc XR gel documentation system according to 
the co-migrating DNA-size standards (100 bp DNA ladder). In case of more than one band, 
i.e. more than one splice variant, separate bands were excised from the gel, and extracted 
using the Minielute Gel Extraction kit (QIAGEN). Because genotypes were known, 16 
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different cDNA samples were initially considered for transcript analysis. However, in case of 
a signal for positive allele-splice effect, further independent cDNA samples were analyzed to 
confirm the effect. 
 
 
Table ‎2.19 Protocol of external and nested round RT-PCR 
 
Component Volume (l)/reaction 
PCR-water 18.05 
GeneAmp
®
 10x PCR Buffer II 2.50 
MgCl2 solution [25 mM] 2.50 
dNTPs [10 mM] 0.50 
External forward primer [10 M] 0.150 
External reverse Primer [10 M] 0.150 
cDNA 1:10 diluted (or first-round product
*
) 1.00 
AmpliTaq Gold
®
 DNA Polymerase [5 U/µl]  0.15 
Total volume 25.00 
 
 
Table ‎2.20 Thermal cycling conditions for external and nested round RT-PCR 
 
Event Temperature (C) Time No. of Cycles 
Initial melting step/AmpliTaq Gold
®
 activation 94 2 min 1 
Denaturation 94 15 sec  
(td =- 0.5°C/ cycle) 
For 12 cycles 
Annealing of primers 63 15 sec 
Extension  72 1 min
*
 
Denaturation  94 15 sec 
 
Repeat 25 cycles 
Annealing of primers 57 15 sec 
Extension  72 1 min
*
 
Final extension: filling up the ends
**
                72 10 min 1 
Hold at                  4  1 
Storage -20 - - 
- td: ‗touchdown‘ PCR; 
*
: elongation time depends on length of amplicon: 1 kb/min; 
**
:especially needed for TA-cloning 
 
 
2.7. Direct sequencing 
A major concern in the investigation of AS is the detection of potentially down-regulated 
splice variants. Nonsense-mediated mRNA decay (NMD) is a well-established mechanism 
that can lead to the down-regulation of transcripts carrying PTCs: If an intron is located > 50 
nt downstream of the stop codon, then termination codon is recognized as nonsense or 
premature (PTC) and the transcript will be down-regulated by NMD (Green et al., 2003; 
Lewis et al., 2003; Maquat, 2005). However, previous in-house experience in detection of AS 
at CARD15 locus indicated that direct sequence approach would work even in the presence of 
NMD. The presence of a second, alternatively spliced transcript was detected down to the 
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90:10% (Appendix Figure  8.1). Eight µl of PCR products from the second round were directly 
sequenced using the internal (nested) primers with the Big Dye™ Terminator chemistry 
(Applied Biosystems) according to the customized protocol described in section ( 2.2.12), and 
analyzed on an automated, high-throughput 96-capillary fluorescence detection system, the 
3730xl DNA Analyzer from Applied Biosystems. Sequencing was performed for both 
orientations (forward and reverse), to circumvent sequencing artefacts. The resulting sequence 
traces were assessed for evidence for allele-dependent splicing with a newly developed 
specialized tool- the SNPSplicer software (ElSharawy et al., 2006). 
 
2.8. Analysis Software: SNPSplicer 
As previously mentioned, direct sequencing of PCR products from cDNAs with sources of 
known genotype was used as an analysis tool within the experimental framework. 
Consequently, in order to make this an efficient process, the analysis needed to be supported 
by appropriate software. Therefore, a public-domain software solution, namely SNPSplicer 
(ElSharawy et al., 2006), was developed. SNPSPlicer aids in the rapid interpretation of allele-
dependent splicing of such screening experiments and, in turn, helps in the functional 
annotation of SNPs in a more high-throughput fashion than existing on-line tools. 
 
In order to use SNPsplicer software, a folder containing the following files for each SNP must 
be prepared: 
 a GenBank file of the sequence for a reference cDNA. 
 a text file containing the sequences of the two primers (forward and reverse). 
 several ABI or SCF trace files. 
 
The trace file names must end in ―.ab1‖ or ―.scf‖.  Each name must also include a 
classification string to indicate that file‘s genotype and read direction (i.e., _11_F; _12_F; 
_22_F; _11_R; _12_R; _22_R). Allele-dependent splicing was concluded to be present if a 
consistent pattern of alternative splicing was observed in all samples (including hetrozygotes 
and homozygotes). Interpreting the display of SNPSplicer is described in Results section 
(‎3.1.4) to avoid redundancy. For more details of the software package see (ElSharawy et al., 
2006) or visit the homepage: www.ikmb.uni-kiel.de/snpsplicer/. The software comes with a 
complete user manual and is open-source software licensed under the GNU Lesser General 
Public License. 
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2.9. Validation of allele-dependent splicing by cloning 
All allele-dependent splicing effects were verified by cloning. To this end, PCR products from 
the second round of amplification were separated on agarose gels, excised and extracted using 
the Minielute Gel Extraction kit from QIAGEN (Hilden, Germany). Extracts were cloned 
using Invitrogen (Carlsbad, CA, USA) TOPO TA Cloning Kit (pCR
®
II, pCR
®
2.1). For each 
genotype, 30 clones were picked and sequenced. The resulting sequence traces were aligned 
using Sequencher (www.genecodes.com), followed by manual verification of the alignments. 
 
 
2.10. Development of an in vitro splice reporter system 
To develop a novel in vitro splice reporter assay for alternative splicing, a test genomic 
region, comprising exons 7, 8 and 9 and the intronic regions, was chosen from PGM2L1 gene 
(chr 11; NM_173582). This genomic region was PCR-amplified using platinum Taq 
polymerase with primers (PGM_SacII_F at exon 7; PGM_R_BamH at exon 9) with 5 
restriction site of SacII and 3 restriction site of BamHI, respectively. The purified PCR 
product (1884 bp) was cloned with TA- cloning kit (Invitrogen) (section  2.2.9). As a standard, 
the retrieved genomic region of PGM2L1 was cloned at the SacII/BamHI restriction sites, at 
the MCS of the pEGFP-N1 vector (Clontech). The insertion of the genomic region was 
confirmed by double digestion with SacII/BamHI and verified by sequencing. To avoid an 
internal translation initiation site, the start codon of GFP of ‗PGM2L1-pEGFP-N1‘ construct 
was eliminated using QuikChange
®
 Lightning Site-Directed Mutagenesis Kit (Stratagene) 
(section  2.2.10) with the mutagenic primers ‗GFP_rem_ATG_F‘ and ‗GFP_rem_ATG_R‘. 
The ATG-removal was verified by sequencing the purified plasmid DNAs (Maxi) using the 
primer ‗NM173582_PCR_f‘. The produced vector, namely PGM2L1-pEGFP-N1 (Figure  2.5), 
was then subjected to FACS analysis (section  2.2.15). 
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Figure ‎2.5 Insertion of the test genomic region into the MCS of pEGFP-N1 vector. 
The genomic region that comprises exon7-exon9 (1864 bp) of PGM2L1 gene was inserted at the MCS of 
pEGFP-N1 vector using the SacII/BamHI restriction sites. To avoid internal translation initiation, the ATG-start 
codon of the resulting hybrid vector (at positions 2538-2540 bp) was eliminated using site directed mutagenesis. 
 
 
Next, the coding region of RFP (672 bp) was PCR-amplified using a high fidelity PWO Taq 
polymerase (Roche) from pDsRed2-N1 vector (Clontech) with primers (dsRed_Xho_f; 
dsRed_XhoI_r) that ended with recognition site of XhoI endonuclease. Here, the forward 
primer (dsRed_Xho_f) was designed to begin at the start codon of RFP and the reverse primer 
(dsRed_XhoI_r) to delete the TAG-stop codon of RFP to have a read-through when inserted 
into at XhoI in the PGM2L1-pEGFP-N1 vector in next steps. The purified PCR product and 
PGM2L1-pEGFP-N1 vector (Clontech) were separately digested with XhoI enzyme using 
standard protocol (section  2.2.8). PGM2L1-PEGFP-N1 was dephosphorylated using 1 µl 
alkaline phosphatase (New England Biolabs) in the digestion reaction. The purified DNA 
products were ligated using T4-ligase enzyme, transformed into E.coli Top 10 competent cells 
as described in section ( 2.2.9.3). The insertion of the cds of RFP was confirmed using 
digestion with XhoI enzyme. The insertion of both regions, cds of RFP and the test genomic 
region of PGM2L1, were validated by sequencing using three primers at different locations 
(dsRed2-578-f: located at RFP and read through PGM2L1; NM173582_PCR_f: started 
53 
reading at 430 bp of in PGM2L1; PGM_GFP_F_Seq: located at intron 8 of PGM2L1 and read 
through GFP of the parent vector). The resulting construct, namely ‗RFP-PGM2L1-pEGFP-
N1‘ vector, was then subjected to FACS analysis as described in section ( 2.2.15). 
 
To test the utility of the splice construct (RFP-PGM2L1-pEGFP-N1) in detecting ss variation, 
both acceptor and donor ss of test exon 8 (of the inserted genomic region of PGM2L1) were 
separately mutated using QuikChange® Lightning Site-Directed Mutagenesis Kit (Stratagene) 
(section  2.2.10). While the mutagenic primers (‗PGM_int8_CA_F‘ and ‗PGM_int8_CA_R‘) 
were used to mutate the obligatory GT-donor consensus to CA dinucleotides, the primers 
(‗PGM_int7_TC_F‘ and ‗PGM_int7_TC_R‘) were used to mutate the obligatory AG-
dinucleotides at acceptor ss (at the end of intron 7) to TC-dinucleotides. After standard 
transformation into XL10-Gold
®
 Ultracompetent cells and cloning procedure (described in 
section ‎2.2.9.3), plasmid DNA of the mutant clones were purified to transfection grade with 
the help of the QIA Filter
TM
 Plasmid Maxi Kit from Qiagen (section ‎2.2.11). To verify the 
success of the mutagenesis, 2 µl of each isolated plasmid DNA was separately sequenced 
using two different primers (NM173582_PCR_f and dsRed2-578-f). To monitor any 
alteration in the functional mode of the produced construct, FACS analysis and protein 
evaluation by SDS-PAGE/western blotting were carried out in duplicate for both wild type 
and mutant constructs. Briefly, for each type of analysis, 1 µg of each plasmid DNA (from 
maxi preparations) was transfected in duplicate to HeLa cells (section  2.2.13) in the presence 
of separate positive (pEGFP-N1 and pDsRed2-N1 vectors) and negative controls 
(untransfected mock cells). After one day of incubation at 37C, the transfected HeLa cells 
were washed and harvested in 1 ml PBS buffer. FACS analysis was carried out as described in 
(section ‎2.2.15). On the other hand, protein lysates were prepared from harvested HeLa cells 
using denaturing lysis buffer as described previously (section  2.2.14), assayed using BioRad 
DC-Protein Assay, and concentrations were measured at 75 nm using IMPLEN 
Nanophotemeter. Ten μg of total protein extract were then separated by SDS polyacrylamide 
gel electrophoresis, with subsequent electrotransfer to a suitable PVDF membrane, and 
subjected to Western blot analysis as described by (Waetzig et al., 2002) and in  section 
( 2.2.14). GFP was detected using a murine A.V. GFP monoclonal antibody (JL-8) (1:1000; 
Clontech), and an anti-mouse antibody conjugated to HRP (horseradish peroxidase; ab6728; 
1:2000) from Abcam was used as a secondary antibody. The blot was then stripped and 
reported for -actin, as an internal control, using mouse anti--actin monoclonal antibody 
(1:1000; Clone AC-15, Sigma) (see section  2.2.14). 
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3 RESULTS 
3.1. A high-throughput assay for the investigation of allele- dependent splicing 
In the present study, a high-throughput method was optimized and established to facilitate the 
screening of allele-dependent splicing (ElSharawy et al., 2006); Figure  3.1. In addition to the 
available high-throughput genotyping facilities at ICMB (Kiel, Germany), the method 
integrated a package of four new software tools that has been created and implemented in the 
in-house database infrastructure (described below). 
 
 
• cloning verification 
• nested RT-PCR and direct sequencing
• align sequence traces*
• screen for potential SNPs*
• matched DNA /cDNA resources
• SNPlex /TaqMan/direct  genotyping
• select different genotypes 
• array corresponding cDNA
11 11 11
12 12 12
22 22 22 -ve
• In silico splice SNPs filtration 
• In silico splice sites scoring analyses
• Selection of candidate splice SNPs
SNPSplicer Software*
Alex‘s ss score calculator
Neural Network
ESEfinder Alex‘s ss score calculator
Neural Network
 
 
Figure ‎3.1 Established workflow of the streamlined methodology used in the present study to screen for 
allele-dependent splicing instances. 
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3.1.1. MotifSNPs Tool: Extraction of splice SNPs from public database 
In order to carry out a genome-wide screen for candidate genes with potential splice SNPs, an 
online SNP evaluation tool, namely ‗Motif SNPs Input Page‘ (available at www.ikmb.uni-
kiel.de/motifsnps), was created in the framework of the present study. MotifSNPs tool is a 
standalone application that rapidly displays how a splice motif score changes in a biallelic 
SNP of interest. The results are displayed in a user-friendly html format. Figure  3.2 provides 
an illustrative sketch of the basic flow that has been used to extract biallelic SNPs that mainly 
reside in specific splice motifs, such as ESEs, donor and acceptor sites. This application 
rebuilt annotated genes in silico and analyzed the sequences (Figure  3.2 I): the tool obtained 
the annotation data of a specific cDNA using the cDNA annotation table ―RefSeqAli‖ from the 
UCSC Genome Browser homepage, extracted the sequences from the chromosome file, and 
rebuilt the gene in silico. The database build used in the present study was hg17 with 24292 
annotated sequences. Annotation mistakes, such as two exons without intronic sequences in-
between or intronic sequences shorter than 16 bp, were also corrected at this stage. In such 
cases, all sequence parts were merged to yield one correct exon annotation sequence. 
 
Next, every SNP in each sequence part (intron/exon) was filtered (Figure  3.2: II) and for each 
part, the application built two sequences (Figure  3.2: III). The first sequence contained the 
allele from the chromosome files and the second sequence with the second allele of every 
SNP inside this part. Finally the program collected the ―ChromFA”‎ (human genomic 
sequence in FASTA format) files from the UCSC Genome Browser homepage and scored 
ESE motifs matrices using the ESEfinder homepage (Cartegni et al., 2003). By combining 
these resources the program could easily find SNP(s) inside ESE motifs and ss (Figure  3.2: 
IV). Then, the application searched for motifs in both sequences and stored the results in two 
different lists. Also, ss sequences from the intron-exon and exon-intron changeover were 
extracted. The results containing the highest motif scores of each type in both sequences were 
then stored (Figure  3.2: V). The tool described here can be easily updated and adapted to 
populate additional splice motifs, because it uses configuration files that define the motifs. 
One can add a splice motif by opening the configuration file with a text editor and inserting 
the new scoring matrix. The file format is described in the file, readme.txt, which is included 
in the downloadable zip files. Splicing variants that are not annotated in the public database 
can be edited as new entries in this application. This is valid for de novo detected SNPs as 
well. Instead of using the cDNA annotation data, the application can also be operated with the 
table ―all_est‖ (Expressed Sequence Tags annotation). 
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Figure ‎3.2 A Workflow of extraction of splice SNPs from public database using MotifSNPs tool. 
 
 
3.1.2. SpliceTool software: Arraying of cDNA 
As transcripts with defined genotypes at potential splice SNPs were required and the selected 
candidate SNPs were frequent enough with about 10% heterozygosity, genotyping of an 
initial sample set of 92 gDNAs was performed in the present study. Because the principal 
existence of the SNPs after genotyping has been verified (section  2.4), only 16 different 
cDNAs needed to be analyzed in the subsequent steps to investigate allele-dependent splicing 
effects. Individuals representing the three possible SNP genotypes, 4 homozygotes for each 
allele and 8 heterozygotes, were chosen and the corresponding cDNA samples were picked by 
a robot and arrayed into 96-well plates for subsequent RT-PCR experiments. If possible, each 
genotype was represented by different tissue resources. For rare SNPs, where no samples 
homozygous for the minor allele were present, at least four heterozygotes had to be available 
in order a SNP to be included in the subsequent analyses. If evidence for allele-dependent 
splicing was obtained, additional independent cDNA samples were analyzed to confirm the 
effect (ElSharawy et al., 2008). 
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To facilitate automated arraying of cDNA samples of corresponding genotypes of each SNP, 
a SpliceTool software was created in the present study. Screenshots of the SpliceTool 
interface and utilization are shown in Figure  3.3. Technically, SpliceTool was developed as a 
user-friendly client program to work with data, which was stored in a Microsoft SQL Server 7 
database. The tool was written in Visual Basic 6 and implemented on a Microsoft Windows 
2000 system. It connects to the database via TCP/IP using the OleDb provider. For pipetting, 
SpliceTool remote controls the Gemini software (Tecan) via its named pipe interface. Using 
SpliceTool, individuals representing the three possible genotypes (denoted 11, 12, and 22) 
were identified and corresponding cDNA samples were robotically picked and arrayed into 
96-well plates for subsequent transcript RT-PCR analysis (ElSharawy et al., 2006). 
 
 
Figure ‎3.3 SpliceTool interfaces and 
arraying of cDNA samples. 
The upper screenshot shows the common 
interface window of the SpliceTool 
software that used for designing cDNA-
plate layouts. This screenshot illustrates 
the ease of using SpliceTool to facilitate 
choosing and arraying cDNA according 
to the corresponding genotypes of desired 
candidate splice SNPs in specified 96- 
well plate format. One can annotate tissue 
resources, required pipetting volume, 
warning volume to alert about consumed 
volume of cDNA samples, number and 
ID of SNPs to be arrayed, and other 
different database details. The lower 
screenshot of the program shows another 
window of the SpliceTool interface that 
helped for recalling genotyping data. 
Another useful option here, as shown at 
the bottom of the second screenshot, is to 
provide with a short report about allele 
frequency and heterozygosity of each 
genotyped splice SNP, which in turn, 
helped in designing downstream RT-PCR 
experiments. 
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3.1.3. SkippedExonPrimer Tool: Semi-automation of designing nested primers 
In order to facilitate design of nested primers, an assisting software tool, namely 
―SkippedExonPrimer‖, was created in the present study. As indicated from its name, 
designing nested primers on skipped exons flanking the candidate SNP of interest was not 
preferred, but rather on common or conserved ones. In principle, this tool was connected to a 
MySQL Server to get the annotation data of the UCSC table RefSeqAli. The annotation was 
then used to collect the relevant exon sequences from the UCSC ―ChromFA‖ files. 
Technically, this software was written in Visual Basic 6.0 to run on Microsoft platforms, e.g. 
Windows NT. The only prerequisite to start this software was a tab-delimited text file 
containing three columns: SNP ID, refseq annotation accession number and genomic position 
of each SNP. Using this (tab-deliminted text) input file, SkippedExonPrimer enabled 
accession to different required web interfaces: (1) ‗Primer3‘ (Rozen and Skaletsky, 2000) for 
picking desired primers with annotated criteria; (2) ‗SPIDEY‘ at NCBI, which is an mRNA to 
genomic alignment tool; (3) ‗UCSC Genome Browser‘ to check whether the obtained primers 
spanned conserved exons flanking the potential splice SNP‘s region and ensure specificity. A 
list of the primers used in the present study is provided in Appendix Table  8.1. 
 
3.1.4. SNPSplicer: A screening tool for allele-dependent splicing signals 
In the present study, a key software solution, SNPSplicer, was developed in order to support 
experiments that used corresponding pairs of gDNA and cDNA. This specialized new piece of 
software allowed a rapid interpretation to determine if a potential site-specific splice effect 
was present (ElSharawy et al., 2006). The basic display of SNPSPlicer (Figure  3.4) is 
described next, followed by three different practical examples (Figure  3.5- Figure  3.7) of the 
investigation of allele-dependent splicing. 
 
In its alignments, SNPSplicer relies on the fact that at least the initial 20-30 bases are located 
in a nondifferentially spliced exon and thus is able to anchor the sequences. Technically, 
SNPSplicer builds on a software library previously used for mutation detection and SNP 
genotyping software (Manaster et al., 2005a; Manaster et al., 2005b). SNPSplicer reads 
several files from one folder. These files consist of a GenBank file of the sequence for a 
reference cDNA, a text file containing the sequences of the two primers, and ABI or SCF 
trace files named to indicate their genotype and read direction. To show splicing differences 
between cDNA of individuals representing different genotypes, SNPSplicer groups the cDNA 
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sequences by genotype and read direction (Figure  3.4). The sequences are represented as 
horizontal strips in six sequence charts aligned underneath a strip representing the cDNA 
reference sequence; bases in the sequences are pale where they match the reference and dark 
where they differ. This makes systematic differences between groups easy to identify. Each 
base in the sequence occupies just a single pixel of width. Above the sequence charts is a 
horizontal line that represents the entire length of the cDNA reference sequence, with arrows 
identifying the primer locations. Below the sequence charts are trace groups for each 
genotype and read direction. In the trace group, traces from all sequences of the group are 
overlaid together. Clicking a trace group shows its individual traces in a panel on the right. 
Clicking a sequence chart refocuses the traces around the clicked base. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.4 A screenshot of the SNPSplicer interface and utilization. 
The interface of the program shows a schematic drawing of the reference sequence and the primer positions (1). 
The aligned traces of the forward and reverse sequences of the second round RT-PCR products for all three 
genotypes denoted 1-1, 1-2 and 2-2 at rs17581728, are displayed in the stacked sequence chart (2). This is a 
simple representation of sequences in a vertical stack; each sequence is one pixel high and each base is one pixel 
1 
3 
2 
4 
5 
6 
5 
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wide. The colour of each pixel indicates the base it represents and whether it agrees with the reference sequence. 
Bright colours indicate agreement and dark pixels show deviation from the reference sequence. A trace view of 
sequences from one genotype plotted in the same chart is provided (3) together with the individual traces for a 
particular genotype group (4). Clicking a base on window (4) gives a short report (5) about the base position and 
quantifies the areas under the peak (curve); this helped to quantify the relative amounts of more than one splice 
variants, if present, in the heterozygotes. ‗Mouse-over‘ across traces in window (4) also reports the name of the 
individual sequence at the bottom toolbar (6) together with the bp position. The ‗Pick Folder‘ button on the 
lower right-hand corner was added to the SNPSplicer results‘ window in order to move smoothly and pick 
quickly another SNP-folder for analysis without restarting the program. 
 
 
SNPSplicer does not do its own base calling; it relies on the calls in the trace files. Alignment 
to the reference sequence is done through a simple word match using a window of 20 bases, 
starting from each primer site. From that point on, it advances through the entire sequence, 
inserting and deleting bases as needed to preserve a fivebase sequence matching the reference. 
The utility of the approach is exemplified in next subsections. 
 
3.1.4.1. Example of the use of SNPSplicer showing a splicing-nonrelevant SNP 
The primary feature of SNPSplicer is the collection of six sequence charts in the upper half of 
the display screen. These show the groups of sequences with bases that differ from the 
reference sequence emphasized by darker shading. If the investigated SNP has no effect upon 
splicing, all the groups will look approximately the same; a few dark pixels indicate the 
presence of simple variation at these positions. Indeed, this represented the most frequent 
outcome in the present larger scale experiments and, in turn, served to focus resources on 
more promising splice SNPs for future functional and/or mechanistic analyses. 
 
A practical example of a SNP that showed no impact on pre-mRNA splicing process is 
illustrated in the output shown in Figure  3.5. Panel A of this figure shows the underlying 
genomic sequence surrounding exon 8 of caspase 5 (CASP5) and the position of the putative 
splice SNP rs540819:T>A in the intronic donor sequence of exon 8. Panel B shows the 
analysis results in SNPSplicer after the sequencing of PCR products of cell-lines with all three 
genotypes at rs540819:T>A (ElSharawy et al., 2006). From Panel B, it is evident that all 
genotypes display the same cDNA sequence, i.e., there is no evidence for an allele-dependent 
splice effect. As shown in panel C, the junction between exon 8 and 9 spliced without any 
impact from the tested SNP in all tested genotyped cDNA samples. 
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Figure ‎3.5 The use of SNPSplicer: a negative example involving a splicing-nonrelevant SNP. 
Panel A shows the annotation of the SNP (rs540819:T>A) in the intronic donor sequence of exon 8 of caspase 5 
(CASP5) gene. In panel B, the primers used in RT-PCR to experimentally validate the SNP effect on splicing are 
annotated on cDNA reference sequence (1). The stacked sequence chart shows the aligned traces of the RT-PCR 
products for all three genotypes at rs540819:T>A, denoted  1-1 (AA), 1-2 (AT), and 2-2 (TT) in both forward ‗F‘ 
and reverse ‗R‘ sequence read. It is clear in panel B that there is no evidence of allele-dependent splicing effect 
(no genotype-specific splicing effect is visible). This is because all genotyped groups at rs540819:T>A display 
the same cDNA sequence and look the same (ElSharawy et al., 2006). Dark pixels at both margins show 
deviation of the experimentally generated sequences from the reference sequence, which is a typical output at the 
start of sequencing reads from both direction (F and R). A trace view of sequences from one genotype plotted in 
the same chart is provided (3) together with the individual traces for a particular genotype group (4). On the top 
of the individual traces, the reference sequence is shown (4). Panel (C) shows the exon annotation of the 
observed cDNA sequence in area (4) of Panel (B). 
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3.1.4.2. Simple positive example of the use of SNPSplicer 
If the SNP affects splicing in a simple manner, then sequence beyond the splice site (to the 
right in forward traces and to the left in reverse traces of SNPSplicer display window) will 
show dark bands in one of the homozygous groups and possibly to some extent in the 
heterozygous groups. 
 
Figure  3.6 shows a practical example where a ‗‗simple‘‘ splice effect is detected: a genotype-
specific deviation from the consensus sequence is detected at one site in both the forward and 
reverse sequences. Panel A shows the underlying genomic sequence of surrounding exon 5 of 
the butyrophillin-like protein 2 (BTNL2) gene and the position of the putative splice SNP 
rs2076530:A>G in the exonic donor sequence of exon 5. Panel B shows the analysis results in 
SNPSplicer after the sequencing of PCR products of cell-lines with all three genotypes at 
rs2076530:A>G. The aligned traces of the forward and reverse sequences of the RT-PCR 
products for all three denoted genotypes, 1-1 (AA), 1-2 (AG), and 2-2 (GG), are displayed in 
the stacked sequence chart (2). 
 
It is evident from Figure  3.6 that at a specific site (indicated by the blue arrow), the 
homozygous trace stacks and some of the heterozygous trace stacks start to differ from the 
reference sequence in the respective read directions. This region is selected in the group trace 
view (3). The individual traces show the splice pattern of allele A (4). The blue shading in 
area (4) was added in the figure to indicate the junction of exon 5 to exon 6. Outside the blue 
box, the traces no longer correspond to the reference sequence, due to the deletion of four 
bases. The blue shading in panel C corresponds to area (4) in Panel (B). The putative splice 
effect was confirmed by cloning and sequencing of PCR products from the respective 
genotypes (ElSharawy et al., 2006). Panel C shows the genotype-specific splice pattern: the 
A-allele leads to a loss of 4 bases on exon 5 and subsequent frame shift of the underlying 
protein later in exon 6, as previously described in by Valentonyte and co-workers 
(Valentonyte et al., 2005). 
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Figure ‎3.6 "Simple positive example" of the use of SNPSplicer: allele-dependent splicing at BTNL2 locus. 
Panel A shows the sequence surrounding the splice SNP in BTNL2. In panel B, it is evident that the homozygous 
trace stacks and some of the heterozygous trace stacks start to differ from the cDNA reference sequence in the 
respective read directions (blue arrow). After cloning and sequencing of PCR products from the respective 
genotypes (ElSharawy et al., 2006), the genotype-specific splice pattern is confirmed: allele A at 
rs2076530:A>G, is associated with 4 bases (GTAG) deletion (panel C) and using of an alternative ss upstream of 
donor ss of exon5 (Valentonyte et al., 2005). 
 
 
3.1.4.3. Complicated example of the use of SNPSplicer 
If SNPSplicer yields a more complex result, this may indicate the interplay of more than one 
SNP on splicing process at the region under investigation. Figure  3.7 exemplifies the case. 
Panel A in this figure shows the genomic structure of FLJ40873 (or TCTEX1D1; Tctex1 
domain containing 1 gene). The primer positions of the RT-PCR are indicated with small red 
arrows in the genomic structure. The SNP rs3816989:G>A in the donor sequence of exon D 
was selected as a putative splice SNP. The SNP sequence is provided in Panel A. Panel B 
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shows the analysis results in SNPSplicer after the sequencing of PCR products of cell-lines 
with all three genotypes at rs3816989:G>A. The aligned traces of the forward and reverse 
sequences of the RT-PCR products for all three genotypes denoted 1-1 (AA), 1-2 (AG) and 2-
2 (GG) are displayed in the stacked sequence chart (2). Here, apparent genotype- specific 
differences are observed at two sites, which are highlighted with blue bold arrows. One of the 
regions is selected in the group trace view (3). The individual traces show the splice pattern of 
the allele A/G heterozygotes (4). The blue shading in area (4) was added in the figure to 
indicate the junction of exon C to exon D, outside of the blue box. The upper two traces no 
longer correspond to the reference sequence, while the bottom trace matches the reference. 
The underlying pattern only became clear after the underlying RT-PCR products were cloned 
and sequenced. Here, two different splicing effects were observed. The first splicing effect 
was the association of the A-allele at rs3816989:G>A with skipping of exon D, because it 
disrupts the GT consensus sequence at its donor ss (ElSharawy et al., 2006). From the cloned 
sequences, an additional exon (X), which is not present in the RefSeq annotation, was 
observed. This was associated with the presence of an additional SNP (rs2274987:T>C) that 
generates an ESE sequence in the intron between exons B and C. The C-allele created a novel 
ESE motif for SF2/ASF with an ESEfinder score of 4.01. However, the T-allele at 
rs2274987:T>C was no longer recognized by ESEfinder using the default cutoffs in 
ESEfinder (Table  3.1). The haplotypes of rs2274987:T>C and rs3816989:G>A together with 
the corresponding cDNA composition as observed in the cloned RT-PCR products are shown 
in Panel C. The [C-A] haplotype, i.e., the C-allele at rs2274987:T>C and A-allele at 
rs3816989, was associated with the insertion of new exon (X) and skipping of exon D, 
respectively. In the same order, the [T-A] haplotype was correlated with the absence of both 
exons X and D from the transcript. The [C-G] haplotype was not observed as a result of 
linkage disequilibrium (ElSharawy et al., 2006). The respective sequences have been 
submitted to GenBank (DQ411321). 
 
 
Table ‎3.1 ESEfinder analysis of rs2274987:T>C at FLJ40873/ TCTEX1D1 
 
(SF2/ASF: Threshold as given by ESEfinder = 1.956) 
Position
*
 Motif Score Splicing events (see Figure  3.7) 
23 (-72) CACACAA 4.01135 Exon X insertion 
23 (-72) CATACAA  No insertion 
-
*
: The position refers to the motif location within the inserted exon (94 bases), as given by ESEFinder. 
-    The two alleles of the SNP are underlined and presented in bold print. 
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Figure ‎3.7 "Complicated example" of the use of SNPSplicer: two different concurrent allele-dependent 
splicing events. 
As shown in panel B, the deviation from cDNA reference sequence of FLJ40873 (TCTEX1) gene was observed 
at two different positions indicated by the blue bold arrows (compare to Figure ‎3.5 and Figure ‎3.6: panel B). 
These results cannot be solely attributed to the originally targeted putative splice SNP rs3816989:G>A. The 
compound splice effect was revealed after cloning and sequencing of PCR products from the respective 
genotypes (Panel C). While the A-allele at rs3816989:G>A disrupts the obligatory GT consensus sequence at the 
donor of exon D and leads to its exclusion from transcript, the C-allele at a second SNP (rs2274987:T>C) creates 
a novel ESE motif for SF2/ASF splicing factor as revealed by ESEfinder (Cartegni et al., 2003) and leads to 
insertion of a new exon X (ElSharawy et al., 2006). 
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3.1.5. Direct sequencing approach 
The results from the present study showed that direct sequencing is a robust and sensitive 
screening tool even in the presence of nonsense- mediated mRNA decay. This is concluded 
from the results presented in the previous section ( 3.1.4), and supported from the previous in-
house experience of AS analysis of CARD15 locus (Appendix  Figure  8.1); see also (Hiller et 
al., 2006b)). Thus, the sensitivity for a qualitative detection of alternatively spliced transcript 
was detected down to the 80:20% range. Such transcript ratios were readily detectible in 
heterozygous state (ElSharawy et al., 2006). The analysis of homozygote cell lines, one for 
each allele, also allowed unambiguous detection of allele-dependent splicing (ElSharawy et 
al., 2008). 
 
3.2. First screening-round of allele-dependent splicing: Web-based tools 
In the first screening-round of allele-dependent splicing, freely available web-based in silico 
tools, which are designed to predict the impact of nucleotide variations on splicing, were 
utilized. While Alex‘s splice site score calculator (Shapiro and Senapathy, 1987; Senapathy et 
al., 1990), available online at http://violin.genet.sickkids.on.ca/~ali/splicesitescore.html, was 
used to select candidate splice SNPs at canonical donor and acceptor ss, ESEfinder tool 
(Cartegni et al., 2003), available at (http://rulai.cshl.edu/cgi-bin/tools/ ESE3/ esefinder. cgi? 
process=home), was used for SNPs at ESE sites. In parallel, candidate splice SNPs at 
NAGNAG tandem acceptor ss were selected from the study of Hiller and co-workers (Hiller 
et al., 2004), owing to the difficulty to predicting their functional consequences by available 
in silico tools without experimental settings (Hiller et al., 2006a). 
 
3.2.1. Candidate SNPs for canonical and NAGNAG splice sites 
Release 125 of dbSNP was screened for variants located within 3 nt of exonic or 6 nt of 
intronic DNA sequence surrounding a canonical ss in an annotated Refseq in UCSC hg17. 
This choice of sequence length is attributed to the sequence window used by Alex‘s splice site 
scoring tool. This includes 2 nt of the exon and 6 nt of the intron for donor ss. For acceptor ss, 
it requires 14 intronic nt and one exonic nt. To be included in subsequent analyses, a SNP had 
to have a minor allele frequency of  10% in the HapMap CEU samples. All SNPs in the 
highly conserved AG and GT dinucleotides were discarded except for nine SNPs used as 
‗positive controls‘ (Table  3.2). The variants were scored in three categories: acceptor SNPs, 
donor SNPs and NAGNAG SNPs (Hiller et al., 2004). For acceptor ss containing a 
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NAGNAG motif (Hiller et al., 2004), the identity of the obligatory AG dinucleotide was not 
clear a priori. In total, 1096 putative donor splice SNPs, 1451 putative acceptor splice SNPs 
and 28 SNPs within NAGNAG motifs were identified (step 1 in Figure  3.10) (ElSharawy et 
al., 2008). 
 
In fact, no interpretation guidelines were available at Alex‘s splice site calculator, which 
meant that it was left to the user to decide when a prediction is positive (i.e., expected splice-
relevant SNP) or negative (SNP has no influence on splicing process). This absence of 
interpretation guidelines can be explained by the fact that splicing outcome does not only 
depend on variation in ss consensus sequences but rather on combinatorial control of many 
factors involved in the splicing process (Hertel, 2008). In order to facilitate this in silico 
interpretation, score variations were considered rather than the scores themselves. Next, the 
absolute score difference (∆S) between the two alleles was calculated using Alex‘s splice site 
score calculator (Shapiro and Senapathy, 1987; Senapathy et al., 1990). The absolute 
difference between scores was used because the presumed ‗wild-type‘ allele yielded a lower 
score than the other allele in 48% of cases so that any assignment of wild-type status to one 
allele or the other would have highly been ambiguous (ElSharawy et al., 2008). The following 
step was to set a limit of significance for score variations. Based on the distribution of the 
absolute allelic difference (S) of the splice site scores, shown in Figure  3.8, and scores of 
published donor ss SNPs (Roca et al., 2005), all 58 SNPs with ∆S>8 were selected as 
candidate splice SNPs. Three donor SNPs (rs482082:C>T, rs820329:A>T and rs540819:A>T) 
with 8S>5 were included because of their proximity to protein domains (WD40, IG and 
CARD, respectively) that are duplicated in many gene families. Proximity to such duplicated 
domains was thought to increase the probability of allele-dependent splicing (ElSharawy et 
al., 2008). Domain contexts containing such repetitive protein domains are involved in ligand 
and pathogen recognition. These and other domains are primarily directed towards 
inflammation and innate immunity, and are of great in-house interest in the study of 
inflammatory barrier diseases (Schreiber et al., 2005). Therefore, SNPs in these domain 
contexts were also favored for in-depth investigation. All 28 NAGNAG SNPs were also 
retained as candidates, thereby yielding a total of 58+3+28=89 SNPs. 
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Figure ‎3.8 Distribution of the absolute allelic difference S of the splice site scores. 
This was obtained for 1115 acceptor and 798 donor SNPs using Alex‘s splice score calculator (Shapiro and 
Senapathy, 1987; Senapathy et al., 1990). The tails of the distributions were used to select candidate SNPs for 
allele-dependent splicing. 
 
 
All 89 candidate splice SNPs retrieved from dbSNP were genotyped in a panel of 92 gDNAs 
using either SNPlex, TaqMan or direct sequencing, depending upon technical feasibility (step 
2 in Figure  3.10; see also Appendix Table  8.1). Twenty-four donor, nine acceptor and 24 
NAGNAG SNPs were found to be sufficiently polymorphic in the DNA panel so that at least 
four heterozygotes were present, leaving 24+9+24=57 SNPs for RT-PCR evaluation. All nine 
acceptor SNPs were located at position –3 whilst the 24 donor SNPs occupied positions –2 to 
+6 (ElSharawy et al., 2008). Sixteen cDNAs were selected on the basis of SNP genotypes as 
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described in the Methods section. If available, one or two homozygotes for the rare allele 
were included in the tested 16 matching cDNAs of known genotype. These cDNAs were 
subjected to nested RT-PCR using the primers reported in Appendix Table  8.1. The resulting 
PCR-products were sequenced directly and screened for differential splicing as described in 
the Methods section (ElSharawy et al., 2006). Putative splicing effects were confirmed by 
cloning and sequencing of the respective PCR-products. Allele-dependent splicing was 
considered to be established if the effect of a given polymorphisms could be demonstrated in 
all investigated samples. An overview of the selection procedure and output from the first 
screening round is provided in Table  3.2. 
 
As expected, all the nine selected SNPs impacting the highly conserved AG or GT 
dinucleotides at ss, i.e. the positive controls, were correctly predicted as deleterious and 
showed allele-dependent splicing patterns (Table  3.4). None of the nine candidate SNPs at 
acceptor splice sites exhibited allele-dependent splicing of the adjacent transcript. Of the 24 
donor SNPs, two (i.e. 8%) occupied positions -1 and +5 exerted an influence upon splicing 
(ElSharawy et al., 2008). Four confirmed splice effects (4/24, corresponding to a positive 
predictive value of 17%) were observed for SNPs at acceptor sites containing a NAGNAG 
motif. Post hoc analysis of their splice site scores revealed that splicing was only affected if 
the AG dinucleotide with the higher impact on the splice score was changed by the SNP 
(ElSharawy et al., 2008). An overview of the NAGNAG SNPs and the corresponding splice 
site score differences is given in Table  3.5. The six SNPs with a confirmed splicing effect are 
listed in Table  3.4. 
 
3.2.2. Putative splice SNPs at ESEs 
As a fourth category of SNPs, polymorphisms located in ESE motifs were also evaluated. All 
exonic SNPs located in RefSeqs in UCSC hg17 were screened with ESEfinder and a 
prediction was made regarding their likely effects upon splicing (Cartegni et al., 2003). 
Owing to the large number of potential ESEs, candidate splice SNPs were further required to 
be located within 30 nt of the nearest exon-intron boundary, as suggested previously  
(Fairbrother et al., 2004a); see Appendix Figure  8.2. The scores for the different ESE motifs 
were normalized to unity, using the respective score thresholds proposed by the ESEfinder 
tool (Cartegni et al., 2003), and the respective score differences ∆ESE were calculated in 
analogy to signal differences at canonical ss. Based on the obtained distribution of the 
absolute allelic difference (∆ESE) of SNPs at ESE sites (Figure  3.9) and the established ESE 
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splice SNPs from literature (Liu et al., 2001; Cartegni and Krainer, 2002; Colapietro et al., 
2003; Zatkova et al., 2004), an arbitrary ∆ESE cut-off of 0.8 was chosen for the selection of 
SNPs for experimental follow-up. This resulted in the inclusion of 106 SNPs in the 
genotyping stage 2, which was carried out as described above. Five of the 106 SNPs 
(rs2228173:T>C, rs3763840:G>A, rs974144:C>T, rs2188383:C>G and rs736795:G>A) with 
0.8SE>0.5 were also included on the basis of their proximity to WD40, LRR and DEATH 
domains (ElSharawy et al., 2008). These potentially repetitive protein domains were thought 
to be more likely to be subject to allele-dependent splicing and involved in ligand and 
pathogen recognition (Appendix Table  8.1). Forty-two of the genotyped SNPs were 
sufficiently frequent in order to be evaluated by RT-PCR. 
 
For none of the 42 investigated SNPs at ESE sites could an effect upon splicing be observed 
(ElSharawy et al., 2008). One instance of putative allele-dependent splicing at an ESE was 
detected by chance (Table  3.4): SNP rs2274987:T>C was identified as a splice SNP when 
analyzing nearby SNP rs3816989:G>A, located at a canonical donor splice site (ElSharawy et 
al., 2006). SNP rs2274987:T>C itself is located 25 nt downstream of the acceptor splice site, 
of the newly inserted exon (Figure  3.7), but creates a novel ESE, as suggested by ESEfinder 
(Cartegni et al., 2003; Smith et al., 2006). 
 
 
 
Figure ‎3.9 Distribution of the absolute allelic difference (∆ESE) of SNPs at ESE sites. 
The tail of the distribution was used to select candidate SNPs for allele-dependent splicing. A random ESE cut-
off of 0.8 was chosen for the selection of SNPs for experimental follow-up. 
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Table ‎3.2 Overview of the selection stages and output from the first screening round (web-based tools) 
 
Genome-wide filtration 137
*
 ~ 63,000 SNPs Total 
Stage I  28 1115 798 1495 - 3436 
Stage II  28 23 38 106 - 195 
Stage III 24 9 24 42 9 108 
Location  NAGNAG
*
 Acceptor Donor ESE AG/GT
**
 - 
Allele-dependent splicing effect 4 (17%) 0 (0%) 2 (8%) 0 (0%) 9 (100%) - 
- SNPs at selection stage (I) were fulfilling the following criteria: i) HapMap validated,  ii) Caucasian, iii) ≥ 10% Heterozygosity, iv) SNPs at 
acceptor and donor ss located within 9-nt window (6 nt intronic and 3 nt exonic, 3 nt exonic and 6 nt intronic, respectively), and V) 
SNPs at ESE sites were chosen from normalized scores from ESEfinder that located in a 30-nt window of exon borders. 
- At selection stage II top-scoring SNPs were selected after applying the suggested cut-offs of each group. 
- To be included in the subsequent analyses, at least four heterozygotes had to be available for each genotyped SNP (stage III).  
-  
*
: SNPs located at NAGNAG-tandem acceptor ss were obtained from Hiller et al. (Hiller et al., 2004). 
- 
**
: Expected positive control SNPs, as they disrupt the obligatory AG or GT dinucleotides at canonical acceptor and donor ss, respectively. 
 
 
3.3. Second screening-round: Neural network assessment of canonical splice sites 
First-round screening results of allele-dependent splicing revealed that the performance of in 
silico web-based tools, i.e., Alex‘s splice score calculator and ESEfinder tool, was weak 
(ElSharawy et al., 2008). Therefore, we decided to carry out a second screening second round 
using a recently reported neural network (Krawczak et al., 2007) in order to predict the 
splicing effects of SNPs at canonical donor and acceptor ss. The neural network applied here 
has shown the ability to facilitate the recognition of higher-order sequence features that would 
not be detectable by the sequential consideration of consensus sequences. Moreover, it was 
highly efficient at recognizing the effect of SNPs at ss, achieving 91.3% and 96.1% sensitivity 
on SNP-containing acceptor and donor ss, respectively (Krawczak et al., 2007). In fact, the 
applied neural network achieved sensitivity and specificity values that are comparable to 
those provided in other reports of neural network–based ss recognition (e.g., (Ogura et al., 
1997; Ho and Rajapakse, 2003)). Technically, a multilayer, back-propagation neural network 
(Wasserman, 1989) was trained for the purpose of ss recognition (Krawczak et al., 2007) in 
the present study. The term ‗back propagation‘ refers to the principle that calculation of 
synaptic weight changes proceeds in the reverse direction (from the output layer towards the 
input layer). More technical details that defined the basic mathematical algorithms of the 
artificial neural network are reviewed in (Papik et al., 1998).  
 
The neural network emits a signal between 0 and 1, where 1 corresponds to the classification 
of a sequence motif as a functional splice site. Similar to the score-based approach, SNPs 
located in a 20-nt window around a canonical splice site were extracted from dbSNP build 
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125, using essentially the same criteria as above (see Table  3.4; Figure  3.10). This choice of 
sequence length represented a compromise between the constantly improving efficiency of 
neural networks, which was obtained by taking an increasing number of nucleotide positions 
into account, and the fact that the specificity of the DNA sequence context of ss outside the 
chosen range was marginal (Zhang, 1998; Eden and Brunak, 2004). The number of SNPs 
selected for genotyping (N=202, 101 each for donor and acceptor) was chosen so as to match 
the available laboratory resources. For both splice site types, the selected 101 SNPs came 
from the top (N=52), middle (N=23) and bottom (N=26) range of the absolute allelic signal 
difference  for the neural network. The 52 top SNPs corresponded to a  range between 
0.998 and 0.1224 for donor sites, and between 0.993 and 0.140 for acceptor sites. The SNPs 
from the middle range were chosen at random and comprised  values between 0.026 and 
110-4 for donor sites, and between 0.060 and 210-4 for acceptor sites. For the bottom 
category, the 26 SNPs from the lower end of each distribution were chosen, all of which 
had a  value of zero. All of the selected SNPs were subjected to genotyping. As described 
above, all variants with at least four heterozygotes in the DNA panel were further investigated 
with RT-PCR and validation. These were included 81 SNPs at donor splice sites (43 at top, 13 
at middle, and 25 SNPs at bottom range) and 70 SNPs at acceptor splice sites (35 at top, 17 at 
middle, and 18 SNPs at bottom range) (ElSharawy et al., 2008). The selected nine positive 
controls were also occurred to produce, as expected, high ∆N ranged which from 0.80319 to 
0.99659 (Table  3.4). A complete list of SNPs and the corresponding  values are provided in 
Appendix Table  8.1. 
 
Here, allele-dependent splicing could be demonstrated for two donor site SNPs (5%) and 
three acceptor site SNPs (9%) from the top range of the neural network signal difference. Two 
acceptor site SNPs from the middle range (rs1558876:C>G and rs5248:A>G) exhibited allele-
dependent splicing too, although the actual  values were small (0.00305 and 0.00244) 
(Table  3.4). Both SNPs were located at NAGNAG motifs. No allele-dependent splicing was 
observed for donor site SNPs with a  value below the threshold for the top range (0.1224) 
(ElSharawy et al., 2008). Five instances of experimentally verified allele dependent splicing 
were predicted by both the neural network screen and Alex‘s splice site score calculator. As 
expected, no impact upon splicing could be detected for any of the tested SNPs at the bottom 
range for both donor and acceptor ss. An overview of the selection procedure and results from 
the neural network analysis (second round) is provided in Table  3.3. 
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Table ‎3.3 Overview of the selection procedure and output from the neural network (second round) 
 
Genome-wide filtration ~ 8,000 SNPs Total 
Stage I 4039 3940 7979 
Stage II 2209 2255 4464 
Stage III 1240 1311 2551 
SNPs at top-middle-bottom list 52- 23- 26 52- 23- 26 104- 46- 52 
At least 4 heterozygotes 43- 13- 25 35- 22- 18 78- 35- 43 
Location  Donor Acceptor - 
Allele-dependent splicing effect 2 (5%)– 0 (0%)– 0 (0%) 3 (9%)– 2 (12%)– 0 (0%) - 
- At stage I, the neural network was operated for SNPs located at 20- nt window of splice site (15 nt intronic and 5 nt exonic at acceptor ss; 5 
nt exonic and 15 nt intronic at donor ss).  
- At selection stage II only unique donor and acceptor ss were considered; i.e., repetitive Genbank accession numbers were thus removed. 
- SNPs were filtered to stage III after fulfilling the following criteria: i) HapMap validated, ii) Caucasian, iii) ≥ 10% Heterozygosity. 
- Candidate SNPs were chosen from top, middle, and bottom of scoring list of respective donor and acceptor splice site, to better evaluate the 
performance of neural network and to match to the available laboratory resources. 
- Genotyped SNPs with at least 4 heterozygotes in the tested DNA panel were experimentally validated by nested RT-PCR and direct 
sequencing.  
 
 
3.4. Combined outputs and observations from both screening rounds 
A schematic overview of the selection procedure of candidate splice SNPs and results from 
both screening rounds of allele-dependent splicing are simultaneously presented in Figure 
 3.10. A total of 344 SNPs were genotyped in the panel of 92 DNAs. The numbers in the 
figure sum up to 397 (89 from Alex‘ splice site score calculator, 101 for each acceptor and 
donor from the neural network and 106 SNPs from the ESEfinder). The difference is due to 
53 SNPs that were retrieved both with Alex‘ splice site score calculator and the neural 
network. As a result of genotyping, 223 non-redundant variants (including the 9 ‗positive 
controls‘ at AG or GT canonical dinucleotides, 99 and 115 SNPs from the first and second 
round, respectively), which were frequent (i.e., at least 4 heterozygotes were available for 
each SNP) in the tested DNA panel, were tested by nested RT-PCR and direct sequencing at 
step 3 (ElSharawy et al., 2008). All the investigated SNPs and primers used for nested RT-
PCRs in both screening rounds are provided in Appendix Table  8.1. 
 
3.4.1. Observed splice effects 
Five of the 18 instances of allele-dependent splicing (28%) resulted in exon skipping. 
Insertions and deletions consequent to alternative or cryptic ss utilization were observed in the 
remaining 13 cases (72%). In particular, the majority of differential splicing events at donor 
sites comprised of exon skipping (4/7 = 57%) whereas cryptic splice site usage was 
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predominant at acceptor splice sites (10/10 = 100%). As for the occurrence, however, the 
computational prediction of the consequences of allele-dependent splicing was found to be 
poor (ElSharawy et al., 2008). An overview of all confirmed allele-dependent splicing events 
is given in Table  3.4. In spite of the mutational imbalance at the lawful AG or GT ss (positive 
controls), the results outlined in Table  3.4 may indicate that mismatch at positions (+3, +4, 
+6, +14, +15, and –2) to donor and (–3, –6) to acceptor ss were not critical to splicing process 
compared to other positions (+1, +5, –1 and +2) and (–1, –2, –4, –7, –9, +2 and +3), 
respectively. The experimentally observed splicing effect of theses 18 SNPs has been 
submitted to dbSNP, and the technical prerequisites to accommodate this information are 
currently being established at dbSNP. 
 
3.4.2. Allele-dependent splicing at NAGNAG tandem acceptors  
In agreement with previous reports (Hiller et al., 2004; 2006a; Hiller and Platzer, 2008), 
confirmed splicing effects of SNPs at tandem acceptor sites with a NAGNAG motif resulted 
in 3-nt insertions or deletions due to the use of the alternative AG dinucleotide. Four of the 
acceptor site SNPs chosen at NAGNAG tandem motifs exhibited allele-dependent splicing. In 
fact, post hoc analysis of the ss scores revealed that splicing was only affected if the stronger 
of the two AG dinucleotides was changed by the SNP (ElSharawy et al., 2008). An overview 
of the NAGNAG SNPs and the corresponding ss score differences is given in Table  3.5. 
 
3.4.3. Evaluation of the performance of F-SNP tool 
The present study provided an opportunity to assess the postulation as to whether or not the 
combination of the 16 integrated bioinformatics tools and databases in F-SNP tool (Lee and 
Shatkay, 2008) (with each tool running its own distinct algorithms) was mandatory to achieve 
maximum sensitivity and was overall sufficient as a decision-making tool to screen for allele-
dependent splicing, since their relative strengths might be additive while compensating for 
their weaknesses (Houdayer et al., 2008). Thus, all the confirmed allele-dependent splicing 
effects in the present study (Table  3.4) were fed into the web-based server of F-SNP and the 
output was concurrently outlined in the same Table  3.4. As for the occurrence, the 
experimentally verified effects of allele-dependent splicing coincided with the computational 
predictions by F-SNP for only five of the 18 SNPs (28%) (ElSharawy et al., 2008). 
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Figure ‎3.10 Graphical overview of splice SNP prediction in both screening rounds. 
Different classes of putative splice SNPs are described in different columns; the time line of the study flows from top to bottom. The experimental steps and the main selection 
criteria employed in each step are given in the boxes on the left. In step 1, SNPs were selected from dbSNP if they (i) had a minimum allele frequency of 0.1 in Caucasians and 
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(ii) were located near splice sites according to the criteria given in the top row. In step 2, SNPs were scored using the bioinformatic tools given in the open block arrays in the 
middle panel. A total of 344 SNPs were genotyped in the panel of 92 DNAs. The numbers in the figure sum up to 397 (89 from Alex‘ splice site score calculator, 101 for each 
acceptor and donor from the neural network and 106 SNPs from the ESEfinder). The difference is due to 53 SNPs that were retrieved both with Alex‘ splice site score calculator 
and the neural network. As a result of genotyping, 223 non-redundant variants (including the 9 ‗positive controls‘) were tested by RT-PCR and sequencing in step 3. Five of the 
positive splice SNPs overlap between the splice site scoring and neural network selection, which corresponds to the 13 events listed in this figure (8 unique splice events + 5 
duplicates = 13). The ESE SNP (rs2274987:T>C) identified by chance is not marked in this figure but listed in Table  3.4. A detailed overview is provided in Appendix Table  8.1. 
The SNPs at the experimental validation stage in this figure add up to 255, which is due to the fact, that certain SNPs (N=41) overlapped between the neural network and splice 
scoring evaluations. Of the 24 donor SNPs, two (i.e. 8%) exerted an influence upon splicing. A notably higher rate of differential splicing (4/24, corresponding to a positive 
predictive value of 17%) was observed for SNPs at acceptor sites containing a NAGNAG motif. For none of the 42 investigated SNPs at ESE sites and 9 SNPs at position -3 of 
acceptor ss, an effect upon splicing could be observed. The positive predictive value of the neural network ranged from 5% (2 of 43) for donor to 9% (3 of 35) for acceptor ss 
SNPs. Two out of the 17 acceptor site SNPs from the middle range of the neural network (rs1558876:C>G and rs5248:A>G) were identified to exert an effect upon splicing 
despite a small allelic signal difference (0.00305 and 0.00244, respectively) (Table  3.4). In contrast to acceptor site SNPs from the middle range, no allele-dependent splicing was 
observed for donor site SNPs with a ∆N value below the threshold for the top range (i.e. 0.1224). All the tested donor and acceptor SNPs from the bottom range of the neural 
network showed no effect upon splicing. 
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Table ‎3.4 Confirmed allele-dependent splicing events 
 
The number given in the first column corresponds to the numbering used in Appendix Table  8.1. ―NN scoring‖ refers to the neural network scoring approach. ―Donor scoring‖ 
refers to the donor splice site score approach. 
 
# SNP ID S N Splice Effect 
- simple annotation  
- annotation according to HGVS 
F-SNP prediction  
(Lee and Shatkay, 
2008) 
Site Position 
relative to 
splice site 
Screening Category 
 
Exon 
number/  
size of 
adjacent 
exon 
Gene  Refseq 
15 rs1152522:A>G 16 0,97073 3-nt deletion 
r.394_396del  
stop_gained NAGNAG -2 AG-variation at NAGNAG and 
NN scoring at top-acceptor 
4/102 C14orf105 NM_018168 
3 rs1558876:C>G n/d 0,00305 3-nt deletion 
r.705_707del  
frameshift_ coding; 
ESE-changed 
NAGNAG +3 AG-variation at NAGNAG and 
NN scoring at middle-acceptor 
5/197 ARSG NM_014960 
11 rs2290647:G>A n/d 0.0023 3-nt deletion 
r.1070_1072del  
synonymous NAGNAG +2 AG-variation at NAGNAG 10/144 GRAMD1A NM_020895 
17 rs5248:A>G 0 0,00244 3-nt insertion 
r.[210-3_210-1ins; 210-4a>g] 
frameshift_coding NAGNAG -4 AG-variation at NAGNAG and 
NN scoring at middle-acceptor 
3/136 CMA1 NM_001836 
35 rs12857479:G>A 16.1 0,98135 278-nt insertion* 
r.[313-278_313-1ins; 313-1g>a] 
stop_gained Acceptor  -1 Positive control at acceptor 4/157 C13orf26 NM_152325 
36 rs10774671:G>A 16.1 0,97416 98-nt deletion 
r.1039_1136del  
no functional 
information  
Acceptor  -1 Positive control at acceptor 6/514 OAS1 NM_016816 
37 rs3818780:C>G 16 0,89773 2-nt deletion 
r.-10_-9del  
stop_gained Acceptor  -1 Positive control at acceptor 2/297 AVPI1 NM_021732 
38 rs1805377:G>A 16 0,80319 6-nt deletion 
r.894_899del    
stop_gained Acceptor  -1 Positive control at acceptor 8/589 XRCC4 NM_022406 
34 rs11658717:G>A 0.1 0,99341 6-nt ins 
r.[288-7_288-1ins; 288-7a>g]  
stop_gained Acceptor  -7 NN scoring at top-acceptor 6/211 STXBP4 NM_178509 
71 rs330924:G>C 3.8 0,14027 8-nt insertion 
r.[-17-8_-17-1ins; -17-9c>g]    
conserved Acceptor  -9 NN scoring at top-acceptor 2/5,414 PPP1R3B NM_024607 
91 rs3816989:G>A 18.2 0,99659 Exon 4 skipping 
r.212_336del 
stop_gained Donor  +1 Positive control at donor  4/125 TCTEX1D1 NM_152665 
117 rs764497:T>A 18.2 0,9901 Exon 1 skipping stop_gained Donor  +2 Positive control at donor 1/136 CCDC149 NM_173463 
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r.-238_-103del 
90 rs10101626:G>T 18.2 0,98826 Exon 19 skipping 
r.2641_2835del 
stop_gained; 
conserved 
Donor  +1 Positive control at donor 19/195 WDR67 NM_145647 
119 rs2276611:G>A 18.2 0,97768 7-nt insertion 
r.[-70+1_-70+7ins; -70+1g>a] 
stop_gained Donor  +1 Positive control at donor 1/151 PPIG NM_004792 
120 rs482308:G>A 18.1 0,94543 111-nt deletion 
r.6512_6622del  
stop_gained Donor  +1 Positive control at donor 35/305 ZAN NM_003386 
96 rs2298839:A>G 14.4 0,78973 Exon 7 skipping** 
r.714_843del 
frameshift_coding Donor  +5 Both NN and donor scoring  7/130 AFP NM_001134 
99 rs2076530:A>G 12.5 0,12612 4-nt deletion 
r.1075_1078del    
nonsynonymous; ESE-
changed 
Donor  -1 Both NN and donor scoring  5/348 BTNL2 NM_019602 
- rs2274987:T>C - - New exon insertion from 
intron2 
r.119_120ins119+903_119+996 
no functional 
information 
ESE +25 Donor SNP (rs3816989:G>A)  3new/94 TCTEX1D1 NM_152665 
- del: deletion; ins: insertion; ss: splice site; skip: skipping; NN: neural network; Refseq: reference sequence; HGVS: The Human Genome Variation Society; nt: nucleotides. 
- S : absolute allelic difference ss scores as calculated for each SNP using Alex‘s online splice score tool; : absolute signal difference as calculated from the signals emitted from the neural network. 
- n/d: score cannot be determined because the SNP is located outside of the scope of Alex‘s splice site score calculator, which includes only one exonic nucleotide for the acceptor;  
- 
**
: A 116- nt insertion (r.[843+1_843+116ins; 843+5g>a]) was also observed but in only one heterozygote and exon 7 skipping (r.714_843del) was observed in all other cDNA samples with allele A. In total, five 
homozygotes for both alleles and six heterozygotes were tested.  
- 
*
: this 278 nt insertion was only seen in one heterozygote with rare allele A at rs12857479 that disrupts the canonical acceptor ss of exon 4 at C13orf26 gene. 
- SNP rs2274987:T>C is the only instance of allele-dependent splicing at an ESE site; it was identified by chance while analyzing a nearby donor site at rs3816989:G>A. 
- HUGO HGNC-approved gene symbols (http://www.genenames.org/) were used in this table.  
-  The mutation and splice effect nomenclature appears in this table to follow the format indicated in the HGVS (see the website http://www.hgvs.org/mutnomen/ ). 
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Table ‎3.5 Functional effects and splice site scores of NAGNAG SNPs 
 
A splice site score was calculated for both alleles. In the column with the post hoc score, the experimentally verified splice site was used for the prediction. The difference in 
scoring can be attributed to the sequence window used by the splice site scoring tool, which includes 2 nt of the exon and 6 nt of the intron for donor sites and 14 and one nt for 
intron and exon at the acceptor, respectively. Thus, the score depends on the a priori position of the splice site. One column comments on the post-hoc scores in many instances, 
an alternative splice site as compared to the one annotated in the RefSeq was used. This is described in the respective column. However, these splice events were mostly 
invariable (except #19) and not genotype-related. The number given in the first column corresponds to the number in the Appendix Table  8.1. 
 
# SNP ID Observed splice 
effect 
Exon 
No. 
SNP in scored sequence  Initial scores* 
Allele1/allele2/ S 
Post-hoc sequence  Post-hoc Scores* 
Allele1/allele2/ S 
Comment on post-hoc scores Gene 
symbol 
15 rs1152522:A>G CAG del  
(r.394_396del)  
4 GTTGTCTTTCATRGC 81.7/65.7/16 
 
GTCTTTCATRGCAGG 91.7/65.7/26.0  Scores after CAG del C14orf105 
17 rs5248:A>G CAG ins 
 (r.[210-3_210-1ins; 
210-4a>g]) 
3 CTTCTTCCTCACARC 75.4/91.4/16 CTTCCTCACARCAGG 75.4/91.6/16.2 Scores after CAG ins CMA1 
11 rs2290647:G>A CGG del 
(r.1070_1072del)  
10 TCTGTCTCCAGCRGA 73.7/89.8/16.1 TCCTCTGTCTCCAGC 73.7/87.7/14.0 Score after CGG ins GRAMD1A 
3 rs1558876:C>G CAC del 
(r.705_707del)  
5 TCCTGTTTCAGCASC 70.4/86.4/16 TTCTCCTGTTTCAGC 70.4/89.6/19.0 Score after CAC ins  ARSG 
1 rs17105087:A>G None 7 CTCTTCTGCAGCARC 69.5/85.5/16 TCTCTCTTCTGCAGC  89.6  Score after CAR ins SLC25A21 
2 rs11597439:C>G None 2 TGTCCCTTCAGAASA 61.0/77.0/16 CTGTGTCCCTTCAGA  90.9  Score after AAR ins CUEDC2 
4 rs9606756:A>G None 2 TCTTTTCTAAGAART 63.1/79.1/16 TTTTCTTTTCTAAGA 83.9  Score after AAR ins TCN2 
5 rs1152888:A>G None 5 TCCTTCCTAAGGART 58.2/74.2/16 CTTTCCTTCCTAAGG 83.6  Score after GAR ins IRAK3 
6 rs17036879:G>A None 8 AATAACTTTAGGARC 62.1/46.0/16.1 GTAAATAACTTTAGG 66.4  Score after GAR ins TSEN2 
7 rs2156634:G>A None 3 TTTTGCTGCAGGARA 75.4/59.4/16 CAGTTTTGCTGCAGG 89.7  Score after GAR ins GRIK4 
8 rs3014960:G>A None 14 TCTTTATACAGCARA 87.4/71.4/16 ATTTCTTTATACAGC 91.0  Score after CAR ins COG3 
9 rs4822258:G>A None 8 CCCGTCACCAGGARG 70.7/54.6/16.1 TTTCCCGTCACCAGG 92.2  Scoe after GAR ins TTLL1 
10 rs2243603:C>G None 5 CTGATTTCCAGAASC 54.8/70.8/16 TCCCTGATTTCCAGA 88.8  Score after AAS ins SIRPB1 
12 rs2273431:G>A None 10 TACTCATGCAGARGA 51.3/67.3/16 CTCTACTCATGCAGA 88.1  Score after ARG ins NID2 
13 rs7862221:A>G None 14 TTTCTCTTCAGARGA 80.4/64.4/16 TTGTTTCTCTTCAGA 94.5 Score after ARG ins TSC1 
14 rs2275992:A>G None 5 CTTATTTTTAGTRGT 81.2/65.2/16 TTACTTATTTTTAGT 81.5  Score after TRG ins ZFP91 
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16 rs2307130:A>G None 2 TTCAAATCCTCTRGA 76.1/60.1/16 TTTTTGTTTCATAGG 90.7 Score after 60 nt  ins AGL  
18 rs2292402:T>A None 2 TGTGTTTGGWGCAGT 81.1/75.0/6.1 - Exon 2 skipping Scoring is not possible ACPL2 
19 rs2071558:C>T None 6 AGTGTCCCYAGCAGG 84.5/86.0/1.5 CACAGTGTCCCYAGC 73.3/65.0/8.3 Scores after CAG ins; Exon 
skipping and intron retention 
independent of the SNP 
genotype were observed 
AMHR2 
20 rs12905385:C>T None 20 CTTCACTGATAYAGG 87.2/78.9/8.3 CACTGATAYAGGAGA 60.7/62.1/1.4 Scores before GAG ins CDAN1 
21 rs2250205:C>T None 5 TCTTTGATTGAYAGG 92.4/84.0/8.4 TTGATTGAYAGGAGA 64.6/66.0/1.4 Scores before GAG ins EIF6 
22 rs2174769:T>C None 3 TGTTTGAATTTYAGG 81.5/89.9/8.4 TTGAATTTYAGGAGC 68.5/67.1/1.4 Scores before GAG ins SNIP1 
23 rs12944821:G>C None 3 CTTTATATTTTCAGS 97.0/91.3/5.7 TATATTTTCAGSAGG 79.2/91.0/11.8 Scores before SAG ins AP1GBP1 
24 rs879022:G>A None 3 TCCCAGGACAGRAGG 62.7/63.0/0.3 TTTTCCCAGGACAGR 90.2/86.8/3.4 Scores after RAG ins REG1P 
- Ins: insertion; del: deletion; S : absolute allelic difference ss scores. 
- * : Splice site scores are provided here according to allele-order occurrence from left to right as annotated in SNP-ID column. 
- The splice site score is calculated with Alex‘s splice site score calculator (http://violin.genet.sickkids.on.ca/~ali/splicesitescoreForm.html) 
- The consensus AG dinucleotides in RefSeq, as listed in supplementary Table S1, are given in bold type. 
- The SNP ambiguity codes are underlined and given in bold type. 
- HUGO HGNC-approved gene symbols (http://www.genenames.org/) were used in this table. 
- The mutation and splice effect nomenclature appears in this table to follow the format indicated  in the the Human Genome Variation Society (see the website for HGVS: http://www.hgvs.org/mutnomen/ ). 
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3.5. Establishment of a novel in vitro splice reporter system 
In order to overcome the shortage of the currently available prediction tools of allele-
dependent splicing, a new reporter system was designed in the present study. The reporter 
system should meet three main required features. First, it should be suitable for high-
throughput screening of alterantive splicing. Second, it should have a broad dynamic range, 
allowing measurement of impact of cis-acting DNA variations at different splice-related 
locations, such as donor and acceptor splice sites, ESE, etc. Third, the system should 
distinguish changes in AS patterns from changes in transcription and translation. Toward this 
end, a number of pilot experiments were done in the present study. 
 
3.5.1. Insertion of test genomic region and coding sequence of RFP: Optimization 
The test genomic region, which comprised exon 7 to exon 9 (1864 bp) of PGM2L1 gene was 
inserted at the MCS of pEGFP-N1‘ vector (Figure  2.5). The ATG-start codon of GFP of the 
resulting hybrid vector was then eliminated using site-directed mutagenesis, in order to avoid 
any internal translation initiation. The FACS analysis of the produced construct (‗PGM2L1-
pEGFP-N1‘ vector) revealed no green fluorescence. This might be due instability of the 
transcript or a mis-splicing of the inserted genomic region. To overcome this problem, the 
coding sequence of the RFP was amplified by PCR from pDsRed2-N1 vector and inserted at 
the XhoI site at the 5´ end of the genomic region in the MCS of the produced construct. The 
plasmid map of this construct, namely ‗RFP-PGM2L1-pEGFP-N1‘, is provided in Figure 
 3.11. Using FACS analysis, the last construct showed the typical green-fluorescence pattern 
of GFP, which confirmed the correct splicing of the inserted test genomic region and the 
‗stabilizing‘ function of the cds of RFP. 
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Figure ‎3.11 Insertion of the cds of RFP into the MCS of pEGFP-N1 vector. 
The cds of RFP (672 bp) amplified by PCR from pDsRed2-N1 vector was inserted at the unique XhoI restriction 
site at MCS of the produced PGM2L1-pEGFP-N1 vector. Here, the MCS is located between 591 and 1343 bp. 
The resulting hybrid vector (7.270 kb) contains the cds of RFP at position 619-1290 bp and of GFP at 1354-2073 
bp. 
 
 
3.5.2. Functional validation: A fluorescence-based detection method for comprehensive 
analysis of splice site mutations 
To test the validity of the developed splice reporter construct (RFP-PGM2L1-pEGFP-N1), 
respective donor and acceptor ss of the test exon 8 of the inserted PGM2L1 genomic region, 
were separately mutated. In one construct, the original GT dinucleotides at donor ss (at the 
start of intron 8) were knocked out and mutated to CA dinucleotides. This mutation was 
predicted (by Alex‘s Splice ss calculator) to diminish the conservation level at this donor ss 
with 36.5 points (donor ss score with obligatory GT was 76.3 and with CA-dinucleotide was 
39.8). In the second construct, the obligatory AG dinucleotides at acceptor ss (at the end of 
intron 7) were mutated and converted to TC dinucleotides. Due to the last modification, a 
similar decrease of the saturation at this acceptor ss was also predicted by Alex‘s ss score 
calculator (acceptor ss score with AG was 85.6 and with TC was 53.6 points; resulting delta 
score was 32 points). After transfection of the constructs into human Hela cells, the FACS-
analysis of the respective fluorescence signals (Figure ‎3.12) indicated that, transcripts that 
retained wild-type PGM2L1 expressed functional GFP. In contrast, both types of ss mutations 
(-acceptor and -donor of exon 8 of PGM2L1) exhibited almost completely abolished 
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expression levels of GFP as a result of the frame shift introduced into ORF of GFP. To 
confirm these results, expression of the protein, which spans RFP, PGM2L1, and GFP, was 
confirmed by immunoblot analysis (Figure  3.13). Here, the expected protein was only 
expressed with the wild-type PGM2L1, and not with other mutated constructs (-acceptor and 
-donor of exon 8 of PGM2L1; Figure  3.13. Thus, the modulation of GFP expression level 
can be readily interpreted and used as a sensitive screening tool to access the impact of 
variations at different splice-relevant positions (exonic and intronic) on measuring splicing 
efficiency. 
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Figure ‎3.12 A fluorescence-based detection method for comprehensive analysis of splice site mutations: 
Results of FACS analysis. 
HeLa cells were separately transfected with wild-type (WT-PGM2L1 of RFP-PGM2L1-pEGFP-N1 construct) 
and mutant (-acceptor and -donor of exon 8 of PGM2L1) constructs, EGFP, and dsRed2 vectors. 
Untransfected (mock) cells were used as a negative control. Fluorescence channel FL1 for detection of GFP 
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(emission 53015 nm) is plotted on the X-axis against the FL2 fluorescence channel (emission: 58515nm) on 
the Y-axis. The percentages of cells exhibiting a defined fluorescence signature were calculated by applying 
quadrant statistics. This data indicate that, 1) GFP-fluorescence level can be used to differentiate between wild 
type and mutant constructs (mutant of either acceptor or donor ss markedly reduced, or abolished, the number of 
cells with GFP green fluorescence as shown in the lower right quadrant of each window); 2) the red fluorescence 
of RFP was not detected in channel FL2 in the presence of GFP. 
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Figure ‎3.13 Immunoblot analysis of wild-type and mutant constructs. 
The HeLa cells were separately transfected with wild-type splice reporter (WT-PGM2L1 of RFP-PGM2L1-
pEGFP-N1 construct) with and without the ATG-start codon of the GFP coding sequence, and mutant splice 
reporter (with atg of GFP) at acceptor (-Acceptor) and donor (-Donor) ss of exon 8 of PGM2L1. In addition, 
EGFP vector was transfected as a positive control and dsRed2 vector and untransfected HeLa cells (mock) were 
used as negative controls. After protein lysate preparation, western blot analysis was performed using A.V. GFP 
monoclonal antibody (JL-8; 1:1000) (A) and the blot was then stripped and reported for -actin (B). The blot (A) 
shows the expression of the GFP-fusion protein (69 kDa; spans dsRed2 cds-PGM2L1 ex7/ex8/ ex9- GFP cds) 
from the WT reporter and not from the mutant ones. 
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4 DISCUSSION 
4.1. Characteristics of the applied approach 
After the sequencing of the human genome and the ongoing large-scale SNP-discovery 
programs, the annotation of SNPs with putative biological effects is one of the largest 
remaining genomic challenges. Here, the impact of SNPs on the RNA-phenotype is one of the 
major mechanisms under intense investigation. In the present study, a systematic, SNP-
centered approach has been followed in order to identify germline genetic variations that have 
a potential effect upon pre-mRNA splicing (ElSharawy et al., 2008). The applied approach is 
similar to that of an epidemiologist. Whereas a genetic epidemiologist first identifies 
candidate mutations in a disease gene and then looks for functional interpretation, the applied 
approach identifies the SNP and evaluates the SNP‘s effect on splicing. These marker-driven 
research paradigms pose a daunting challenge. Genome-wide association studies, e.g. for 
colon and prostate cancer (Tomlinson et al., 2007; Zanke et al., 2007; Zheng et al., 2008), 
have discovered a multitude of genetic loci, only a few of which have lent themselves to an 
immediate functional interpretation. 
 
Despite many focused studies on the functions and mechanisms of alternative splicing (AS) 
that are associated with specific transcripts, high-throughput experimental approaches for 
systematically elucidating the extent of functionally relevant AS events are only very recently 
beginning to be used (Blencowe, 2006). The possible impact of germline polymorphisms on 
mRNA splicing has previously been analysed from a transcript or exon perspective. In these 
early studies, transcripts were screened for evidence for AS by bioinformatics or experimental 
means, and candidate variants were tested for AS using isoform-specific PCR (Hull et al., 
2007) or chip-based methods (Kwan et al., 2007; Kwan et al., 2008). Integrated analysis of 
genomic polymorphisms at EST and exon array data also revealed evidence of allele-specific 
splicing (Nembaware et al., 2008). These studies have unequivocally established the 
relevance of common SNPs for mRNA splicing. Other systems-wide experimental profiling 
methods of AS, such as splice junction or tiled genomic arrays, have very recently started to 
define how global splicing regulation shapes complex biological properties and pathways 
(Ben-Dov et al., 2008; Moore and Silver, 2008). The main goals of such efforts are producing 
comprehensive catalogs of splice variants in different organisms and cell types, defining 
cis/trans-acting splicing factors, and characterizing the response of splicing to signaling 
pathways, differentiation, and disease states (Moore and Silver, 2008). However, variation in 
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splicing pattern across tissues is probably controlled by the availability of trans-acting 
splicing factors, and the use of public transcript data, such as ESTs, to estimate either the 
tissue-specificity or the allele-dependent splicing of transcript isoforms is complicated by the 
fact that multiple overlapping ESTs from the same individual are present in dbEST 
(Nembaware et al., 2004). EST data often have poor coverage (i.e. only a small number of 
ESTs from a given tissue for a region of interest in a gene) and many sampling artefacts. For 
example, there can be dramatically different numbers of ESTs from different libraries or 
tissues, creating sample bias (Xu et al., 2002). Despite this drawback, EST sequences provide 
information on the structure of alternative isoforms and include data from different gene 
expression contexts. However, this information is highly biased towards ends of genes and is 
sparse for all but the most highly expressed genes (Nembaware et al., 2008). 
 
To this end, a high-throughput methodology (Figure  3.1) based on using a panel of 92 
matching pairs of individual-specific DNA and cDNA samples (ElSharawy et al., 2006), was 
established in the present study in order to: i) assess the impact and overall importance of 
naturally occurring SNPs on differential splicing; and ii) to evaluate (ElSharawy et al., 2008) 
and improve, current prediction tools of allele-dependent splicing if necessary. The 
established approach combined the use of optimized wet-lab protocols and computational 
facilities. Combining technologies has been very fruitful to identify regulatory sequences, 
including motifs involved in tissue-specific AS (Ben-Dov et al., 2008). The applied method is 
supported by a package of four helpful softwares, which were created during the course of the 
present study (see Methods and Results sections). Indeed, correlating splicing patterns and 
SNPs is a labor-intensive undertaking. There are several competing methods available for the 
evaluation of potential splicing effects of naturally occurring genetic variations. The direct use 
of cDNAs from sources with known genotypes provides a very attractive option, especially 
for the investigation of SNPs in larger scale systematic experiments (ElSharawy et al., 2008). 
Due to the current lack of precise prediction methods for the splicing effects of SNPs, and in 
order to make the selection of candidate SNPs an efficient process, it was necessary to 
develop new software. Therefore, SNPSplicer screening tool was created (ElSharawy et al., 
2006) to evaluate whether a potential site-specific splice effect is present in a given sequence. 
If allele-dependent splice variation occurs, homozygotes show clean traces that substantially 
differed depending on the underlying splicing effect. Heterozygote traces show an apparent 
breakdown of sequence quality starting from the site of splice effect, due to an overlay of two 
very different sequences. Depending on the relative amounts of the alternative transcripts, the 
87 
trace pattern may resemble one of the underlying homozygote sequences (ElSharawy et al., 
2006). Because of the potentially large deviations of the observed sequence from the cDNA 
reference, alignment and interpretation of such trace collections is extremely labor intensive 
with standard sequence alignment software (e.g. Sequencher). SNPSplicer facilitates easy 
visualization of potential splicing patterns, which can then be experimentally verified by 
subcloning and sequencing of PCR products, especially in the case of complex splice effects. 
 
The presented experimental approach therefore incorporates several required advantages: 
 
 Modern high-throughput genotyping methods (SNPlex/TaqMan) are used to determine 
genotypes. cDNAs corresponding the respective genotypes were robotically or 
automatically selected (using SpliceTool). This minimizes the required number of 
corresponding matched cDNA samples for RT-PCR (ElSharawy et al., 2008), thereby 
making the correlation of an RNA-phenotype with a SNP-allele easier, cheaper and 
faster. 
 SNPSplicer software rapidly interprets whether or not an allele-dependent splicing 
signal is present. This helps to focus resources on the most promising splice SNPs for 
future functional and/or mechanistic analyses (ElSharawy et al., 2006). 
 The splicing effects are directly evaluated in the tissues of interest. This eliminates the 
confusion resulting from the induction of trans-acting splicing regulatory factors (Xu 
et al., 2002; Grosso et al., 2008). Here, the splicing patterns can be evaluated for 
robustness across tissues (ElSharawy et al., 2006). 
 The insert size restrictions for construct-based splicing assays do not apply; therefore 
potentially more complex splicing events can be detected and investigated (ElSharawy 
et al., 2006; ElSharawy et al., 2008). 
 
Clearly, minigene constructs provide a more defined and experimentally controlled system, 
which may need to be used for ultimate mechanistic clarification to determine the effects of 
SNPs on splicing (Niksic et al., 1999; Pagani et al., 2002; Baralle et al., 2003; Lewandowska 
et al., 2005). This classic mechanistic approach has certain limitations, especially low 
throughput, limited insert size, and thus incomplete detection of long-range effects. The 
problems associated with the PCR amplifications of cDNA samples containing differently 
spliced isoforms, are also known. In such cases, a preferential amplification of one or few, 
mostly the shorter isoforms, may be observed (Zhu et al., 2003). However, especially for 
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SNPs with weak a priori evidence of a splicing effect, the approach described above may 
represent a very effective screening method (ElSharawy et al., 2008). On the other hand, 
microarray-based approaches can analyze the splicing patterns of many thousands of exons 
and have been used to distinguish splicing patterns seen in different tissues. Interpretation is 
complex, and for some arrays sensitivity is low and false positive rates are high. Although it is 
likely that the technology will improve, these approaches have not yet been shown to have the 
sensitivity to detect the level of variation particularly for low-abundance isoforms (Hull et al., 
2007). The advantage of the system described in the present study is targeted amplification of 
the splicing event of interest, which may provide greater sensitivity. On the other hand, 
depending on the exact location of probesets in a given gene, many of the transcript isoforms 
that occur, particularly those that affect donor or acceptor sites but do not cause exon skipping 
or inclusion, are undetectable using exon arrays. When alternative isoforms are 
distinguishable using the exon arrays, they still provide little information on the nature of the 
isoforms, and this may need to be inferred either by integrating information from other 
sources or experimentally (Nembaware et al., 2008). The combination of the array-based 
approach, supplemented with splice junction probes and replication of the produced positive 
hits using the approach developed in the present study, comprises a strategy to improve 
interpretation of results, increase sensitivity and provide a means of accessing the causes of 
differential gene expression in a genome-wide scale. 
 
Direct sequencing of PCR products from cDNAs with sources of known genotype was used 
as a screening tool within the established methodological pipeline (ElSharawy et al., 2006; 
ElSharawy et al., 2008). The application of this approach was mainly based on: (1) the 
observation that the degree of NMD is moderate and only one-third of reliably inferred 
alternative mRNA isoforms are suggested to be candidates of NMD (Stamm et al., 2000; 
Lewis et al., 2003); and (2) the in-house control experiments, which showed that potentially 
down-regulated (minor) splice variants with a frequency as low as 20%-10% of the total 
transcripts can be clearly detected by direct sequencing (Appendix Figure  8.1). In the present 
study, the presence of a second, alternatively spliced transcript was readily detectible in 
heterozygote state down to the 80%:20% or 90%:10% range (Results section  3.1.4; 
(ElSharawy et al., 2006)). Even if this was not true in some instances, the analysis of 
homozygotic cell lines, one for each allele, allowed clear-cut detection of allele-dependent 
splicing (ElSharawy et al., 2008). Thus, direct sequencing is a robust and sensitive screening 
tool, even in the presence of NMD. In fact, the use of this approach helped to reduce the 
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number of cloning and clone-based sequencing experiments, thereby saving time and labor. 
Combining RT-PCR and direct sequencing-based approach has also been successfully applied 
in many other studies. For instance, it has been used to distinguish functional from non-
functional GYNGNY tandem donors, without affecting the detection of alternative transcripts 
that were expressed at a low level (down to 10%) (Hiller et al., 2006b). 
 
The method presented here is not restricted to variations in particular components of the 
splicing recognition sequences. As long as a robust RT-PCR spanning the site of a potential 
splicing effect can be designed, the approach presented in the current effort is applicable in 
principle. This is demonstrated in the Results (section  3.1.4) for donor ss and ESE variation 
(ElSharawy et al., 2006); but, in addition, intronic SNPs and long-range cis-acting effects 
were also accessible as long as a putative site of effect in the transcript could be predicted 
(ElSharawy et al., 2008). The requirement of a robust RT-PCR, however, precludes the 
analysis of the transcription start site (i.e., promoter inactivation through SNPs) and variation 
affecting the polyadenylation site (i.e., RNA stability in general). For these SNPs, methods 
such as the analysis of allelic imbalance through pyrosequencing, for instance, are more 
appropriate (Cowles et al., 2002; Wojnowski and Brockmoller, 2004). 
 
The methodology of the present study was careful to avoid bias against certain candidate 
genes. Thus candidate splice SNPs were evaluated regardless the reported splice variants at 
specific loci, suggesting that the scoring-based approach together with the laboratory-
observed RT-PCR products from different genotypes is the key direction for correlating any 
splice variation to a SNP under investigation (ElSharawy et al., 2008). Depending only on 
available gene/mRNA annotations, or the exclusion of genes with only one documented or 
observed transcript isoforms as has been considered in a similar recent study (Hull et al., 
2007), might negatively influence the detection of splice-relevant SNPs. For instance, splicing 
variation around the location (exon 35) of one of the confirmed allele-dependent splicing 
effect in the present study (rs482308 at zonadhesion (ZAN) gene) is neither reported (Gasper 
and Swanson, 2006), nor yet documented at UCSC genome browser. The resulting splice 
effect is quite predictable, as the minor A-allele at rs482308 disrupted the obligatory G nt at 
position +1 of exon 35 and associated with the utilization of a cryptic donor ss 111 nt 
upstream of this exon (ElSharawy et al., 2008) (Table  3.4). ZAN protein is also of biological 
importance, since it is involved in the acrosome reaction, which is a key recognition event in 
animal fertilization process (Vacquier, 1998; Tanphaichitr et al., 2007). Yet again, the wide 
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range for the predicted frequency of splicing mutations (15-60%), which expose the fact that 
mRNAs from mutant alleles are rarely assayed for splicing abnormalities (Wang and Cooper, 
2007), promotes the application of a rational strategy similar to that of the present study. 
Moreover, a significant fraction of mutated alleles in both recessive and dominant conditions 
has not been identified, and the availability of RNA samples from affected individuals and 
their families is often problematic (Buratti et al., 2007). 
 
Taking the advantages of the applied approach in mind, broad application of this methodology 
is anticipated to help in the functional annotation of SNPs, thereby providing an important 
contribution to the understanding of the impact of genetic variation on natural phenotypic 
variability and disease susceptibility in a high-throughput fashion. 
 
4.2. Prediction rate of allele-dependent splicing 
Predicting potential splicing effects of SNPs is currently complicated by several factors. Most 
information on the sequences involved in splicing has been obtained from the alignment of 
genomic sequences to expressed sequence tags (ESTs) and known gene models (Krawczak et 
al., 1992; Clark and Thanaraj, 2002). Splice mutations of known disease relevance have also 
been investigated (Stenson et al., 2003). Specific ss have been studied mechanistically in 
depth (Pagani et al., 2000; Wang et al., 2004a; Zuccato et al., 2004), mostly because the 
affected genes were of particular disease importance. Overall, the available empirical data on 
allele-dependent splice variation is still limited. 
 
Using current in silico splice prediction tools to decide if a biallelic SNP has an impact on 
splicing process requires an analytical attitude, given that no interpretation guidelines are 
available. This means that the user must decide himself when a prediction is reliable (i.e., 
likely allele-dependent splicing effect) or not (no expected influence on splicing). This 
absence of interpretation guidelines is in part explained by the fact that efficient recognition 
of ss in higher eukaryotes by the spliceosome is mediated through multiple parameters other 
than the strength of the ss, such as the exon/intron architecture, the presence or absence of 
splicing enhancers or silencers, the presence or absence of local RNA secondary structures, 
and the process of pre-mRNA synthesis by RNA polymerase II. Each component contributes 
to the overall affinity of spliceosomal components to the exon, and thus, the level of exon 
inclusion (Hertel, 2008). As a result, splicing outcome does not only depend on the nucleotide 
variation of these consensus sequences (Houdayer et al., 2008). In this respect, delta splice 
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site scores (∆S and ∆ESE for web-based tools, and ∆N for neural network) were considered to 
determine whether a SNP had an effect upon splicing, rather than looking at the ss scores per 
se (ElSharawy et al., 2008). The score may not reflect the true strength of the ss because of 
the other contributing components involved in splicing process. In particular, this is especially 
important when interpreting effects of SNPs at loosely defined positions (i.e., with expected 
low splice scores). A similar score strategy has been considered and applied in a concurrent 
recent study (Houdayer et al., 2008) for evaluating in silico splice tools for decision-making 
in molecular diagnosis. 
 
In the present study, the non-redundant 223 candidate splice SNPs retrieved from dbSNP 
were experimentally tested using the established approach in a panel of 92 matching gDNAs 
and cDNAs (ElSharawy et al., 2006). The rate at which allele-dependent splicing was 
correctly predicted in the present study was low; the positive predictive value of the 
respective bioinformatics tools ranged from 0% to 9% (ElSharawy et al., 2008). At least in 
part, these surprisingly small success prospects may be explicable in terms of the design of 
the present experiment. Since naturally occurring genetic variation formed the basis of the 
analysis, only candidate splice SNPs with a sufficiently high degree of heterozygosity could 
be verified experimentally in the utilized gDNA-cDNA panel. Furthermore, the type of source 
tissue (mainly lymphoblastoid cell lines and peripheral blood) may also have played an 
important role (ElSharawy et al., 2008). However, the existence of allele-dependent splicing 
was readily confirmed for nine SNPs affecting the conserved AG or GT dinucleotides of 
canonical ss, thereby corroborating the scientific rational of the applied approach (ElSharawy 
et al., 2006). The concordance between the in vitro splicing findings and in silico prediction 
tools at the obligatory AG/GT dinucleotides, is not surprising, as anomalous splicing is highly 
expected when the disruption occurs at these canonical dinucleotides. This deleterious impact 
has widely been recognized for a long time and this knowledge was taken into account when 
designing the algorithms running in these tools (Houdayer et al., 2008). As outlined in Table 
 3.4, Alex‘s splice score tool, as well as the neural network approach, provided reliable scores; 
all mutant canonical donor and acceptor ss showed strong score variations (18.2 ≥ ∆S ≥ 16.0 
and 0.99659 ≥ ∆N ≥ 0.80319, respectively) compared to the applied arbitrary threshold in both 
screening rounds (∆S > 8.0, and ∆N > 0.1224/0.14, respectively) and splicing defects were 
supported by in vitro evidence. 
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The performance of the bioinformatics tools used in the present study was primarily 
dependent upon the degree of conservation of the corresponding target sequence. Splicing-
relevant motifs are often short and poorly conserved. This inherent drawback is highlighted 
by the fact that a notably higher positive predictive value was obtained when a better-defined 
sequence like the tandem acceptor (NAGNAG) is included in a screen for splice SNPs. Thus, 
17% of the SNPs initially selected at NAGNAG acceptor ss showed allele-dependent splicing. 
This result was likely due to the alteration of the highly conserved AG dinucleotide motif in 
least some cases. In fact, a post-hoc analysis of the ss scores at acceptor sites showed that 
splicing was only affected if the stronger of the two AG dinucleotides was altered by the SNP 
(Table  3.5). For the less well-defined canonical donor and acceptor ss lacking a tandem 
structure (Hiller et al., 2006b; Hiller et al., 2007a), the positive predictive value of the 
bioinformatics tools was generally poor (ElSharawy et al., 2008) ( Table  3.4, Figure  3.10). 
 
The lowest positive predictive value was obtained for putative splice SNPs in exonic splicing 
enhancers (ESEs). Indeed, the single instance of allele-dependent splicing due to such a SNP 
was serendipitously found while analyzing a nearby donor site variant (rs3816989:G>A) 
(ElSharawy et al., 2008). As argued above, the failure to detect splicing-relevant SNPs at ESE 
is most likely due to the poor definition of enhancer motifs, both with regard to their sequence 
and position. The available information is integrated in ESEfinder (Liu et al., 2001; Cartegni 
and Krainer, 2003; Cartegni et al., 2003; Smith et al., 2006). Retrospectively, this software 
tool would have been capable of identifying the one splicing effect that may have resulted 
from SNPs interfering with ESE functionality because one of the two alleles generated a de 
novo ESE motif. Indeed, other recent studies (Pfarr et al., 2005; McVety et al., 2006) argue 
against the efficiency of ESEfinder to predict functional outcomes of splice SNPs. For 
example, McVety et al. (McVety et al., 2006) were able to authenticate their ESE-dependent 
splicing mutation at the 5 end of exon 3 of MLH1 gene by in vitro splicing assay, which was 
not recognized by all available motif-scoring matrices including ESEfinder. Likewise, the 
allele-specific skipping of exon 5, at phosphomannomutase 2 gene (PMM2), is due to a SNP 
that disrupts an ESE that was not detected by ESEfinder (Nembaware et al., 2008). On the 
other hand, a more recent study revealed that, a cryptic ss usage in exon 7 of the human 
fibrinogen beta-chain (FGB) gene is regulated also by a naturally ‗silent‘ SF2/ASF binding 
site within this exon (Spena et al., 2006). This may also imply that, not all ESE motifs are 
actual functional splicing enhancers (Cartegni et al., 2002) and not all nucleotide variations in 
93 
functional ESEs disrupt their function (Cartegni and Krainer, 2002; Fackenthal et al., 2002; 
Pollard et al., 2002). 
 
4.3. Efficiency of in silico splice SNP prediction tools 
For practical reasons, the discussion has so far focused upon the limitations of the available in 
silico tools in terms of their positive predictive value, i.e. of the proportion of predicted splice 
SNPs that indeed showed allele-dependent splicing. It is worthwhile remembering, however, 
that the poor performance observed in the current study does not per se devaluate the tools in 
question. Both algorithms could still have a high sensitivity and specificity even if the prior 
probability of differential splicing was simply too small in the present study for them to be 
able to make reliable positive predictions (ElSharawy et al., 2008). In view of the recent 
global assessment of alternative splicing using exon tiling arrays, allele-dependent splicing at 
SNPs indeed seems to be a relatively infrequent event (Kwan et al., 2007; Kwan et al., 2008). 
Out of 17,897 genes screened (Kwan et al., 2008), only 324 exhibited a significant association 
between transcript levels and flanking SNPs. Of these instances, 55% involved isoforms that 
we would have considered the result of ‗allele-dependent splicing‘ in the context of the 
present study. Therefore, assuming an average number of 10 exons per gene, the prior 
probability of alternative splicing at a given exon would be approximately 10
-3
. This implies 
that, even with a specificity as high as 99%, a positive predictive value of 8% would still 
correspond to a sensitivity of 80% or higher. With a lower specificity, even higher 
sensitivity values would be compatible with the small positive predictive values observed in 
the present study, given that the prior probability of allele-dependent splicing was indeed of 
the order of 10
-3
. Finally, it must be remembered that the present study was confined to 
relatively frequent SNPs which, due to a likely absence of strong evolutionary pressure, may 
have had a lower a priori probability of allele-dependent splicing anyway. 
 
As mentioned in the introduction, a variety of bioinformatics tools for the prediction of splice-
related SNPs other than those used in the present study are now available, including 
RESCUE-ESE, ExonScan and MaxEntScan (Fairbrother et al., 2004b; Yeo and Burge, 2004; 
Nalla and Rogan, 2005). However, the choices of suitable tools had to be made at the 
beginning of the experimental validation, which was in early 2005. Three years later, the need 
for further experimental data on SNP allele-dependent splicing remains- a recently published 
splicing tool (F-SNP; (Lee and Shatkay, 2008)) combines use of 16 different bioinformatics 
tools and databases and still lacks predictive efficacy (ElSharawy et al., 2008). Other recent 
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studies (Buratti et al., 2007; Houdayer et al., 2008) similarly concluded that existing in silico 
predictions are neither adequate to identify allele-dependent splicing effects particularly at 
loosely defined consensus positions, nor to classify unknown variants as deleterious or neutral 
especially at exonic sites. The shortage of available bioinformatics tools were also viewed in 
the context of the results from Hull et al. (Hull et al., 2007). In the Hull study, allele-specific 
alternative splicing was observed in 6 out of the finally selected 70 exon-skipping events. 
However, sequence analysis of the relevant ss and of the regions surrounding SNPs correlated 
with the splicing events, observed in the Hull study, failed to identify any predictive 
bioinformatic signals. 
 
4.4. Current understanding of allele-dependent splicing 
Earlier studies suggested that gene expression constituted an important piece of human 
variation, and although it remains a significant aspect, the added complexity of transcript-
processing variations and the potential outcome of these differences greatly alter our earlier 
perceptions (Kwan et al., 2008). Genetic variation, through its effects on gene expression, 
influences many aspects of the human phenotype. Understanding the impact of genetic 
variation on human disease risk has become a major goal for biomedical research and has the 
potential of revealing both novel disease mechanisms and novel functional elements 
controlling gene expression. Recent large-scale studies have suggested that a relatively high 
proportion of human genes show allele-specific variation in expression. Effects of common 
DNA polymorphisms on mRNA splicing are less well-studied. Variation in splicing patterns 
is known to be tissue-specific, and for a small number of genes has been shown to vary 
among individuals. What is not known is whether allele-dependent splicing is an important 
mechanism by which common genetic variation affects gene expression (Hull et al., 2007). 
 
A careful reading through the accessible findings and observations, from the present study 
(ElSharawy et al., 2008) and three other concurrent related studies (Hull et al., 2007; Kwan et 
al., 2007; Kwan et al., 2008) that have focused on finding a clear relationship between 
genotype and splice phenotype constitute an important change in way we view the effects of 
common genetic variation in humans: 
  
 It is likely that allele-dependent splicing is a vast underestimate of the true extent of 
this phenomenon (Graveley, 2008). This can be explained on the basis of the nature of 
these studies on the one hand, and the (mis)interpretation of microarrays on the other. 
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The present study considered only relatively frequent splice SNPs for evaluation 
(ElSharawy et al., 2008). Excluding the perfect matching at canonical AG/GT 
dinucleotides of canonical ss would reduce the prediction rate to an half (4% of 8/214, 
and 8% of 17/223, after and before exclusion, respectively). Hull et al. (2007) and 
Kwan et al. (2007) only identified nine exons that are differentially spliced in an 
allele-specific manner that correlates with SNPs that are common in the human 
population (Hull et al., 2007; Kwan et al., 2007). While Hull et al. focused on only 
one form (exon skipping) of splicing variation in a relatively small number of genes 
(250), Kwan et al. validated only a small subset (20 of ~ 1000 candidate events) from 
their exon-based arrays. Similarly, Kwan et al. (2008) were able to show significant 
association between transcript levels and flanking SNPs of only 324 out of 17,897 
genes screened using a global exon tilling arrays (Kwan et al., 2008). Of these events, 
only 55% represented splicing-associated isoform changes. The problems that 
complicate interpretations of the results from microarrays are also well known. First, 
these arrays have difficulty in identifying cases where the splicing changes are subtle, 
even though they might be significant, both statistically and functionally. Second, the 
arrays can be ‘noisy‘ or have a high degree of false positives and false negatives - for 
instance, the study by (Kwan et al., 2007) had a 55% false-discovery rate (Graveley, 
2008). Another point to bear in mind is that, allele-dependent splicing analysis was 
restricted in all of the previously mentioned studies to SNPs, as they constitute the 
most common type of genetic variation in humans. However, other types of allele-
specific splicing events could be due to other types of polymorphisms such as indels 
(Romano et al., 2002), polymorphism at VNTR (variable number tandem repeat) such 
as G/A substitution at position +8 in the coding sequence of exon 2 of MUC1 gene 
(Ligtenberg et al., 1991; Pratt et al., 1996), or allele-specific polyadenylation due to 
differential CpG island methylation (Wood et al., 2008). The estimation of allele-
specific splicing is further complicated by the observation that, specific haplotype 
differences is correlated with differential expression and alterantive splicing such as 
that of microtubule-associated protein tau (MAPT) locus (Caffrey et al., 2007; Caffrey 
and Wade-Martins, 2007). 
 The possibility that allele-dependent splicing effects may be at least as prevalent in the 
genome as those on overall gene expression is raised from the work of Kwan et al. 
(2008). Kwan and co-authors classified their studied 324 genes from the exon-based 
arrays on the basis of expression changes at the exon and/or transcription level. They 
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found that 26% of genes showed changes at alternative splicing of a cassette exon, 
versus 39% reflected changes at the whole transcript level. The rest was either 
transcription initiation or termination changes (11% or 17%, respectively), or complex 
changes of multiple event types (7%). This means that about 55% of gene expression 
variation was isoforms-based (Kwan et al., 2008). 
 Although the contribution of heritable variation to the observed diversity of mRNA 
splice isoforms is well established from these studies, the resulting gene expression 
variation patterns from the Kwan study (Kwan et al., 2008) further indicate that the 
regulatory effects of genetic variation in a normal human population are far more 
complex than previously observed. Thus, it is postulated here that allele-dependent 
splicing phenomenon is not uncommon in the human population, but it seems that 
splice SNPs exert their impact rather through complex effects. A recent survey showed 
association of 21% alternatively spliced genes with closely linked SNPs (Nembaware 
et al., 2004) and among these events, there is evidence of two different types of allele-
specific splicing: 1) pure (complete) allele-dependent splicing, in which one allele 
gives rise to one isoform and another results in the alternative form (as detected in the 
present study). This type was later suggested to be less common (Nembaware et al., 
2008). 2) Complex (partial) allele-specific splicing in which different alleles result in 
distinct relative isoform abundance. In fact, all of the readily available studies only 
examined RNA isolated from small number of different cell lines, which means that 
many of the common human haplotypes were not examined. 
 Identifying SNPs that correlate with heritable changes in alternative splicing but do 
not cause disease added a new twist to the link between genetic variation and pre-
mRNA splicing. This suggests that allele-dependent splicing is a mechanism that 
accounts for individual variation in the human population (Graveley, 2008). 
Furthermore, SNP-driven transcript variation may serve to increase proteome 
variability and maintain a heterozygote advantage on the population level. On the 
other hand, SNPs that predict splicing phenotypes are likely to be important markers 
to include in genetic association studies of complex diseases (ElSharawy et al., 2008), 
since estimates from monogenic disorders, as mentioned in the introduction, indicate 
that up to 30% of phenotypically relevant mutations actually act through allele-
dependent splicing. 
 Allele-dependent splicing events are likely more frequent around exon-intron junction. 
For most uncovered instances in the various studies, SNPs with the strongest 
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correlation were those closest to the intron-exon boundaries of the splicing events. The 
present study was rationally looking for such events at ss junctions, since assembly of 
the splicing machinery around the ss comprise the foundation for efficient exon 
definition (Hertel, 2008) and mutations in the pre-mRNA that disrupt RNA-RNA base 
pairing at ss will, in turn, decrease the efficiency of exon recognition. Kwan et al. 
(Kwan et al., 2007) also found a SNP located at the 5 ss of the affected exon in CAST 
gene, suggesting that this SNP most likely impacts the efficiency of U1 snRNP 
binding. In addition, Hull et al. (Hull et al., 2007) found that for five out of six of these 
events, the strongest correlation was found with the SNP closest to the intron-exon 
boundary. Knowing that the ratio of SNPs affecting splicing located intronic in a very 
tight window, i.e. at exon-intron borders, increase the possibility of SNPs near this 
junction higher influence splicing. The SNPs that reside outside this frame may 
increase the extensive flexibility of spliceosome to identify and process within a given 
pre-mRNA and AS (Hertel, 2008). A certain level of variability is still tolerated, 
which leads the splicing process to occur normally even if the extent of base pairing is 
not fully satisfied, and this variability can be compensated by recognizing different ss 
with different spliceosomal factors (Rekha and Mitra, 2006). The contributions of the 
other parameters will vary significantly from case to case, augmenting or reducing the 
overall affinity of the splicing machinery (Hertel, 2008). 
 
In actual fact, regulation of splicing is incompletely characterized and complicated by the fact 
that additional cis-elements that control splicing are still being discovered (Yeo et al., 2007), 
and allele-dependent splicing needs also to be considered with regard to inter-population 
variation (Jakobsson et al., 2008)—common splice SNPs in Caucasian populations, for 
instance, are not necessarily frequent in other populations. This highlights again the need for 
larger-scale whole genome studies investigating all possible splicing patterns/motifs, to 
determine the actual extent of SNP-associated splicing phenotypes in different populations. 
 
4.5. Remarks on the impact (nature) of the observed splice-relevant SNPs 
Another important aspect of allele-dependent splicing, in addition to its mere occurrence, is 
the need to predict its outcome in terms of either exon skipping or cryptic ss utilization. In 
accordance with previous reports (Nakai and Sakamoto, 1994; Baralle and Baralle, 2005; 
Krawczak et al., 2007), the majority of differential splicing events at donor sites in the present 
study were comprised of exon skipping (4/7 = 57%) whereas cryptic splice site usage was 
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predominant at acceptor splice sites (10/10 = 100%) (ElSharawy et al., 2008). Reported 
results from the recent neural network (Krawczak et al., 2007) also indicated that donor ss 
mutations, screened in a region of 50 nt upstream of all the affected donors, were basically 
leading to exon skipping by a total of 85%. In accordance with previous knowledge 
(Krawczak et al., 2007; Houdayer et al., 2008), the dramatic effect of splice SNPs at a donor 
(exon skipping) rather than at an acceptor ss (indel), would support the view that the correct 
recognition of the donor ss represents the key step in splicing (exon recognition). 
Furthermore, the disruption of conservation balance at donor ss is quite noisy in a distance-
dependent manner. Once again, this high probability of alternative 3'-ss activation in close 
proximity of the dominant 3'-ss suggests that the second step of the splicing may be prone to 
violating splicing fidelity (Dou et al., 2006). On the other hand, it seems that the probability 
of cryptic ss utilization increases as a function of the saturation of the local DNA sequence 
environment with such motifs. For example, only one (rs330924:G>C) out of the 4 SNPs 
(including rs3763131:A>G, rs181390:T>C, and rs3745503:A>C) that have been screened at 
position (-9), was able to create a cryptic ss with a novel ‗AG‘ consensus with surrounding 
nucleotides, while the rest resulted in a ‗non-AG‘ consensus (C[A/G]T, C[C/T]G, C[A/C]C 
motifs, respectively). Likewise, the choice between exon skipping and cryptic ss utilization 
upon 5 splice site abolition could depend on the presence of a strong putative cryptic 5 splice 
site and/or the degree of local saturation of cryptic motifs for 5 ss (Krawczak et al., 2007; 
Wimmer et al., 2007). 
 
In the present study the vast majority (78%; 14/18) of the detected allele-dependent splicing 
events was occurred in intronic sequences, namely 6 of 7 (85.71%) at donor, 6 of 6 (100%) at 
acceptor, and 2 of 4 (50%) at NAGNAG-tandem acceptors (Table  3.4) (ElSharawy et al., 
2008). At first, this indicates that non-coding SNPs are potentially contributing to ss 
alterations (ElSharawy et al., 2006; Skotheim and Nees, 2007). A similar lower tendency 
(14.9%; 71/478) of exonic disease-causing single base-pair substitution within a verified 
effect upon splicing is recently reported from the neural network (Krawczak et al., 2007). 
Once more, four of the identified allele-dependent splicing events in the present study were 
occurred at loosely defined consensus positions, namely positions (-7 and -9) upstream of 
acceptor and (-1 and +5) up- and downstream of donor ss, respectively (see Table  3.4). 
Taking both of these observations together, this may imply that the information required for 
splicing is contained in the consensus outsized 6-8 nt at both regions, contrary to what has 
been suggested in previous reports (Rekha and Mitra, 2006; Koren et al., 2007). The results 
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from a comparative study suggest that the conserved intronic elements— 100 bases in length 
flanked of the alternatively spliced exons— possibly function in alternative splicing 
regulation (Sorek and Ast, 2003). However, another study revealed that the most common 
alternative acceptor or donor ss used in the human genome are located within 6 nt of the 
dominant ss (Dou et al., 2006). Nevertheless, the number of detected cryptic 5 ss decreased 
with increasing distance from the authentic 5 ss (Roca et al., 2003). It seems that, a plausible 
tendency for the splicing apparatus to use a cryptic ss depending very much upon the distance 
from the site of mutation for donor, but not for the acceptor (Krawczak et al., 2007). This was 
explained on the basis that the successful functional recognition of an acceptor ss depended 
upon the presence of DNA sequence elements that have a less stringent consensus than donor 
ss (e.g., the polypyrimidine tract or the branch point). 
 
Buratti et al. (Buratti et al., 2007) provided statistical evidence that the frequency of intronic 
position +5 of donor ss is significantly higher than that observed in the Human Gene Mutation 
Database, suggesting that alterations of this position are particularly prone to aberrant 
splicing, possibly due to a requirement for sequential interactions with U1 and U6 snRNAs. 
Buratti and co-workers also showed that all point mutations at position +5 of authentic 5 ss 
that activated cryptic 5 ss were substitutions of G, and not any other nucleotide, raising the 
possibility that 5 ss with +5G are more susceptible to aberrant ss activation than 5 ss with 
+5H (non-G). Furthermore, the same study provided evidence that for cryptic donor ss, point 
mutations appeared in the following order: +1 (39.4%); +5 (21.6%); +2 (14.7%); -1 (14.3%); 
and (+3, +4, +6, -2) <3%. In fact, these results are consistent with the findings from the 
present effort. The present study showed that the mismatches at positions -2, +3, +4, and +6 to 
donor ss were not critical to splicing compared to mismatches at other positions (-1, +1, +2, 
and +5) (ElSharawy et al., 2008). This finding is well documented in other reports (Zhuang 
and Weiner, 1986; Stephens and Schneider, 1992). In addition, Krawczak et al. (Krawczak et 
al., 2007) found that the disease-associated mutations clustered more closely around the exon-
intron junction in donor ss, with 70% of the 110 lesions being located at either exonic position 
-1 or intronic position +5. Furthermore, position +5 has recently gained great concern as a hot 
spot of disease-causing mutation. For example, a famous mutation at +5 of donor ss 
(IVS3+5GC, 5-GUAACU-3) and resultant exon 3 skipping was reported as a disease-causing 
mutation in the NF1 gene (Baralle et al., 2003). Also, exclusion of exon 2 at HMSD gene due 
to AS was completely controlled by an intronic SNP (rs9945924) at IVS+5 (Kawase et al., 
2007). 
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To further investigate position -3 upstream to acceptor ss, a total of 24 SNPs were screened at 
this location in both screening rounds, namely 9 SNPs (with delta scores >8 points) at the 
web-based round and 15 SNPs at the neural network round (of them 4 SNPs located at the top 
and 11 located at the middle range of the generated scoring list). All of the experimentally 
verified instances (24/24; 100%) had no effect on splicing outcome (Appendix Table  8.1). 
This finding may indicate that this acceptor position (-3), albeit its close neighbourhood to the 
consensus AG dinucleotides, has less effects on splicing events than expected from the recent 
neural network prediction efforts (Krawczak et al., 2007). The Krawczak study observed 14 
of the 40-acceptor ss mutations (35%) to occur within the 38 analyzed genes at intronic 
position -3. Further analysis is thus required to preclude this controversy and provide a more 
comprehensive view of the effect of genomic variations at this and other splice-relevant 
locations. 
 
Another different concept to bear in mind, especially in explaining allele-dependent splicing 
occurrence at ESE sites, is the natural selection. As natural selection removes deleterious 
mutations from the population, variations that persist as SNPs were largely suggested to be 
neutral and appeared to avoid ―functional‖ elements, such as ESEs (Pfarr et al., 2005). It is 
proposed that a coding exon is subjected to at least three different selection pressures: (1) 
preserving the coding sequence, (2) preserving the sequence of splicing motifs, and (3) 
preserving an appropriate structural context for these splicing motifs. Selection on the coding 
sequence is likely to be the strongest pressure (Hiller et al., 2007b). Analyzing the set of SNPs 
that overlap RESCUE-ESE hexamers showed that, nearly one-fifth of the mutations that 
disrupt predicted ESEs have been eliminated by natural selection. This selection was strongest 
for the predicted ESEs that were located near ss (Fairbrother et al., 2004a). Evidence of 
purifying selection against synonymous mutations in mammalian ESEs has been recently 
reported (Parmley et al., 2006). A unique discovery that a synonymous SNP in exon 5 of 
MCAD gene protects from deleterious mutations in a flanking ESE, suggests yet another 
complication of evaluation of potential deleterious effects of mutations on splicing in the 
context of the relevant haplotype (Nielsen et al., 2007). Additionally, recent results 
demonstrated that a decision to include or exclude sequences adjacent to splicing mutations in 
mature transcripts is influenced by their ESS/ESE frequencies (Kralovicova and 
Vorechovsky, 2007). 
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4.6. Hypotheses on the functional consequences of putative splice SNPs 
Natural genetic variations in the splicing machinery might contribute to the predisposition of 
different individuals to human diseases and to the severity of their phenotype. An estimated 
20%–30% of disease-causing mutations is believed to affect pre-mRNA splicing (Faustino 
and Cooper, 2003), through the disruption of ss, exonic and intronic splicing enhancers and 
silencers, or RNA secondary structure. Deviations from a normal AS pattern—either through 
isoform expression imbalance or presence of aberrant isoforms—initiate many diseases 
(Caceres and Kornblihtt, 2002; Garcia-Blanco et al., 2004; Lopez-Bigas et al., 2005; Garcia-
Blanco, 2006). The current progress in understanding the role of splicing modulation as a 
genetic modifier opens new avenues towards developing treatments for many human diseases 
and availability of functional annotations for these events will in turn lead to targeting the 
correct splice isoforms (Talavera et al., 2007). For example, splicing modulation therapy has 
been used in the treatment of Duchenne‘s muscular dystrophy (DMS). An antisense-mediated 
exon skipping approach was used in a clinical trial to restore dystrophin synthesis in the 
muscles of patients with DMS. In this approach, local intramuscular injection of a 20-nt 
antisense oligoribonucleotide induced exon skipping in exon 51, which subsequently restored 
the disrupted reading frame, and thus introduced dystrophin protein in the muscle in all 4 
patients who received therapy (van Deutekom et al., 2007). The introduction of dystrophin 
protein would convert a severe DMS into a milder Becker muscular dystrophy phenotype 
(Aartsma-Rus and van Ommen, 2007). 
 
The present study identified 18 splice SNPs, of which 15 were novel and 3 had known 
functional relevance (ElSharawy et al., 2008). Splice SNPs with a known phenotypic impact 
include rs2076530, which is located in the BTNL2 gene (butyrophilin-like 2) and which has 
been shown to be associated with sarcoidosis (Valentonyte et al., 2005). SNP rs1805377 is 
located in the XRCC4 gene (X-ray repair complementing defective repair in Chinese hamster 
cells 4) and has been reported to be associated with bladder cancer (Figueroa et al., 2007). 
Host susceptibility to viral infection in type I diabetes has been shown to be associated with 
variation in the OAS1 gene (oligoadenylate synthetase 1), for which a splice SNP, 
rs10774671, was identified (Field et al., 2005). The remaining 15 splice SNPs have not been 
reported to be associated with a specific phenotype, but the information provided here may 
contribute to a better understanding of the functional relevance of the respective loci, 
particularly since an increasing number of disease-associated loci are being identified in 
hypothesis-free genome-wide association studies (ElSharawy et al., 2008). Three of the novel 
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splicing polymorphisms, representing acceptor, NAGNAG tandem and donor ss, are 
described in more detail below. 
 
The first candidate SNP is rs11658717 at STXBP4 (syntaxin binding protein 4 or synip) gene. 
First, this SNP located at a loosely defined position (-7) at acceptor ss of exon 6 (refseq 
NM_178509) and its minor allele ‗G‘ is associated with 6 nt insertion upstream of that 
acceptor. Second, the SNP minor allele-G generated a competitive alternate or cryptic 
acceptor ss with score of 83.7, whereas the other SNP allele-A produced only a score of 67.7. 
Third, the 6 nt insertion is predicted to create a novel SC35 motif (GGTTAGAA; ESEfinder 
score: 2.79115) with the best score at the upstream half of exon 6, which might support its 
insertion. Fourth, analogous to NAGNAG tandem, a ‗NAGNACNAG‘ motif is identified, 
which might offer plasticity at the acceptor ss. Finally, using domain-prediction SMART 
Tool, this 6-nt insertion is predicted to result in a shorter PZD domain (by 6 amino acids) and 
consequently leucine 99 (with hydrophobic side chain) replaces serine 99 (which in turn 
converted to serine 101). Generally, synip protein contains an N-terminal PDZ domain, a 
central region with EF and coiled-coiled domains, and a C-terminal WW motif (Min et al., 
1999). It is known that synip protein represents a potential target of insulin signaling, which 
may regulate the fusion of glucose transporter 4 (GLUT4) storage vesicle (GSV) with the 
plasma membrane, where the transporter facilitates the diffusion of glucose into striated 
muscle and adipocytes, and thereby, enhances glucose uptake (Watson and Pessin, 2007). 
According to the existing model, synip undergoes phosphorylation at ‗serine 99‘ in response 
to insulin stimulation, and this leads to the dissociation of the synip-syntaxin 4 complex, thus 
freeing syntaxin 4 and allowing productive VAMP2-syntaxin4 complex formation and 
subsequent fusion (Yamada et al., 2005; Okada et al., 2007). This data, therefore, highlights 
the need for further investigation of the functional impact of rs11658717 at glucose uptake 
pathway and opens many questions of biological interest to be addressed: 1) does the splice 
effect regulate synip/syntaxin4 interaction, thereby modulating GLUT4 translocation and 
glucose uptake, or further modulate human insulin resistance? 2) Is serine 101 phosphorylated 
by insulin? And if it does, does synip still dissociate from syntaxin 4? Last but not least, 3) 
does the modified PDZ domain predicted here pose normal function? 
 
The second candidate SNP is rs5248, which is located at NAGNAG acceptor ss of exon 3 at 
the chymase (CMA1) gene of chr 14. This SNP affected the upstream G nucleotide at the 
NAGNAG tandem and encouraged 3-nt (CAG-motif) insertion, which generated a new 
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competitive acceptor ss with score (91.4) similar to that of the downstream one (score: 91.6). 
The insertion itself seems to be advantageous as it led to a simultaneous creation of a novel 
SC35 (GGTCTATA) motif with the highest predicted exonic score (3.3968) by ESEfinder, 
which might encourage the insertion incidence. Indeed, a differential expression of tandem 
allele at rs5248 was also noticeable in a recent study (Hiller et al., 2006a). In addition, CMA1 
locus is reported in a famous linkage, at 14q11-12, to inflammatory bowel disease (IBD) 
(Duerr et al., 2000). Particularly, it might have an impact in susceptibility to Crohn‘s disease 
(CD) in active mucosa (Andoh et al., 2006). Moreover, CMA1 has been suggested to play a 
role in modification of the functional outcome of pulmonary sarcoidosis (Kruit et al., 2006), 
susceptibility to atopic asthma (Sharma et al., 2005), and has been pointed out as a candidate 
gene for atopic eczema (Weidinger et al., 2005). 
 
The third novel splice SNP is rs482308. Here, the minor allele ‗A‘ disrupted the obligatory G 
nt at position +1 to exon 35 of zonadhesion (ZAN) gene (NM_003386), and resulted in the 
utilization of a cryptic donor ss 111 nt upstream of exon 35. Using Expasy Translation Tool 
and domain-prediction SMART Tool, this 111-nt deletion was predicted to result in deletion 
of 37 aa and the possibility of skipping of two Pfam TIL (Trypsin inhibitor like cysteine rich) 
domains and remodeling of VWD (homologous to the D domains of the von Willebrand 
factor) domains. The VWD domains are recently reported to be involved in direct contact 
with zona pellucida (ZP; egg‗s extracellular matrix) in a species-specific manner (Gasper and 
Swanson, 2006). Yet, there is no reported splicing variation around this location at UCSC, 
which supports the novelty and significance of the detected splice effect. Indeed, the current 
status indicates that the human ZAN protein exists as six splice variants among exons 41-43 
(not around exon 35), ranging in length from 2,600 to 2,724 codons and many of these 
variants are derived from testis EST data (Gasper and Swanson, 2006). Despite the multiple 
(20–30) candidate sperm proteins that have been proposed over the years (Brewis et al., 2005; 
van Gestel et al., 2007), zonadhesion is still considered the major sperm membrane protein 
that has ZP binding ability (Tanphaichitr et al., 2007). Based on the facts that 1) ZAN-ZP 
binding is essential for acrosome reaction, which occurs in the acrosome of the sperm as it 
approaches the ZP, and 2) the glycoprotein nature of the ZP, it would be interesting to further 
investigate the effect of the predicted domain remodulation of ZAN protein in the fertilization 
process. It is hypothesized here that the novel splice finding might alter the efficiency of 
acrosome reaction by changing the ability of the sperm to fuse to the oocyte, thereby lowering 
the chance of fertilization. Another observation is that the minor allele (A) at rs482308 is 
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distributed differently among populations (see dbSNP), and shows more abundance in 
Caucasian populations. Again, what is the impact of this abundance in Caucasian? Translating 
the identified splice effect at ZAN into comprehensive biological meaning using functional 
analyses might therefore provide a new perspective in tackling the issue of primary sperm-
zona interaction. 
 
4.7. Need for an alternative system: A proof of concept and outlook 
Correlating naturally occurring human genetic variations to functional impacts on pre-mRNA 
splicing presents a current challenge, which is accompanied by the development of numerous 
systems and tools to achieve this goal. The putative impact of unknown variants on splicing is 
also one of the routine challenges faced by molecular geneticists in their everyday practice. 
Unfortunately, RNA studies cannot be performed in each case and a compromise must be 
found between the time and cost required by RNA analysis and the risk of missing a 
deleterious mutation (Houdayer et al., 2008). Indeed, the current task is further complicated 
by the impact of many other factors. First, the available in silico bioinformatic tools for 
prediction of allele-dependent splicing effects are limited by their derivation from mostly EST 
data from different and/or disease tissues. Second, there is a lack of an effective high-
throughput screening assay to identify potential positions of splice-relevant SNPs and 
differentiate between SNPs that cause primary pathogenic effects and SNPs that simply 
modulate plasticity of the ‗splicing-code‘. Third, tissue resources are limited and the 
availability of RNA samples from disease-relevant tissues and affected individuals and their 
families is often problematic (Buratti et al., 2007; Wang and Cooper, 2007). Fourth, in spite 
of efforts to discover trans-acting tissue-specific splicing signatures (Xu et al., 2002; Grosso 
et al., 2008), correlation of cis-regulatory motifs occurrences with gene expression and AS 
levels across tissues (Yeo et al., 2004; Das et al., 2007) is still in its infancy. To overcome 
these difficulties, a novel in vitro expression reporter system for alternative splicing was 
designed and tested in the present study. This system is mainly based on a splice-dependent 
expression model of GFP and provides a tool to screen a randomly mutagenized plasmid bank 
by FACS sorting and subsequent anaylsis using the second generation sequencing technology. 
 
The inserted test genomic region was chosen to meet several requirements: relatively small 
exon (190, 98 and 181 bp for exon 7, 8 and 9, respectively) and intron (318 and 1082 bp for 
intron 7 and 8, respectively) sizes that fitted to the cloning strategy. Second, the internal test 
exon (exon 8) had to be accommodated with its flanking introns. Third, the genomic region 
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had to be inserted while preserving the ORF of GFP. The site-directed mutagenesis 
experiments and data obtained from FACS-based (Figure  3.12) and immunoblot analyses 
(Figure  3.13) confirmed the efficiency of the current construct (RFP-PGM2L1-pEGFP-N1; 
Figure  3.11) to report splicing modulation as a result of splice-specific variations. Thus, GFP 
(the experimental reporter gene) represents an indicator of splicing efficiency of the inserted 
genomic region from PGM2L1 gene—correct splicing of primary transcript leads to 
expression of functional GFP (green fluorescence). Although the RFP, which is located in the 
front of the genomic region (Figure  3.11), stabilized the splicing of the test genomic region, 
there is still a need for an independent transfection control. It is imperative that the second 
reporter gene to be expressed by the same vector, in order to allow the normalization of 
transfection efficiency and cell number. Small perturbations in the growth conditions for the 
transfected cells can dramatically affect gene expression and transfection efficiency. Thus, the 
second reporter would help to determine if the effects are due to the treatment of the cells or a 
response from the experimental reporter. Indeed, our initial experiments showed that dsRed1, 
but not dsRed2, could serve as transfection control, but the use of RFP for this purpose 
requires cloning of all of its regulatory elements (promoter, Kozak consensus, poly A tail), 
which will result in a very large vector. Another ongoing strategy is to fuse either c-myc 
(using the mutagenic primers EGFP_myc_f and EGFP_myc_r) or a FLAG tag (using the 
mutagenic primers (EGFP_flag_f and EGFP_flag_r) to the N-terminal of neomycin resistance 
gene of the produced construct (Figure  3.11). This will allow an independent expression of 
the fused protein using the SV40 promoter. This epitope tagging technique provides an 
efficient means for recognition of the obtained fused protein by readily commercially 
available tag-specific antibodies (mouse monoclonal anti-c-myc (clone 9E10) IgG or mouse 
monoclonal anti-FLAG
®
 (clone M2) IgG; Columbia Biosciences). Both of these antibodies 
are conjugated with red-Phycoerythrin dye (RPE) (excitation max. : 565>498 nm; emission 
max. : 578 nm) that is also suitable for flow cytometry/FACS analysis, for which standard 
protocols are adaptable and available. 
 
Indeed, several other strategies to identify splicing-regulatory factors are currently in wide 
usage. These include RT-PCR, reporters producing luciferase or GFP, and a topoisomerase I 
phosphorylation assay. Each of these assays has limitations in the high-throughput screening 
of large chemical libraries. RT-PCR is costly and scales up poorly. Most in vivo splicing 
reporters have poor dynamic range or do not distinguish compounds affecting splicing from 
those altering transcription or translation (Stoilov et al., 2008). Indeed, three recent studies 
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demonstrate the utility of dual-color reporter systems in improving the dynamic range and 
discriminating changes in alternative splicing from changes in transcription or translation. 
Two of these systems (Newman et al., 2006; Orengo et al., 2006) may require modification of 
a test exon to adapt it to the reporter, which may change its regulatory properties (Stoilov et 
al., 2008). The last evolved system argued for its flexibility to accommodate a variety of test 
exons from different genes in a high-throughput trend (Stoilov et al., 2008). However, it is not 
always possible to house whole flanking introns to each test exon, especially in case of 
flanking introns exhibiting large sizes. In this regard, the reporter system engineered in the 
present study is advantageous, since the inserted test genomic region, comprises an integral 
‗permanent‘ part of the reporter system. 
 
Incorporating the advantage of using second generation sequencing technology, together with 
the use of the FACS-based reporter system with its dichromatic readouts, would meet many 
several requirements and features. 
 
 The presence of all possible (un)known splicing regulatory motifs around the test 
middle exon 8 of PGM2L1 gene are favorable. In addition to its ability to distinguish 
changes in AS patterns from changes in transcription and translation, the natural and 
proper assembly of the splicing machinery around the nascent pre-mRNA transcripts 
only allows the impact of cis-acting splicing motifs to arise and to be measured. 
 The system has a broad dynamic range, allowing ease of access impact of cis-acting 
variations in a variety of splicing sites (such as at donor ss, acceptor ss, ESE, ESS, and 
others) at the mRNA level—it is not restricted to variation in particular components of 
the splicing recognition sequences. 
 It combines the advantages of minigenes constructs (a defined and experimentally 
controlled system) and second generation sequencing technology (ultra-high-
throughput), and therefore it provides a means for quantitative analysis of sequence-
dependent splice variations. As a result, the abundance of splicing motifs could be 
correlated to corresponding variation and splicing efficiency. 
 Ease of manipulation; the same construct can be tested in different tissue panels. 
Therefore, tissue-specific splice motifs/variations, context-dependent weight matrix of 
splice motifs (donor, acceptor, ESEs, etc.) together with the potential position of 
splice-relevant DNA variation could be more precisely identified. 
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 The present system has the ability, although not recommended, to accommodate other 
test exons or other specific motifs-containing SNPs obtained from association studies 
in order to explore their impact on mRNA phenotype and/or corresponding protein. 
 
In this way, the described experimental system in the present study provides a suitable high-
throughput screening tool of variations that modulate AS and presents an improvement of 
prediction tools of allele-dependent splicing. This, in turn, would improve our understanding 
of mammalian ss anatomy and invent a means for future mechanistic and functional analyses. 
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5 SUMMARY 
Background: The evolutionary and biomedical importance of differential mRNA splicing is 
well established, especially with regard to pathophysiological conditions. Up to 60% of 
mutations that contribute to disease development have been proposed to do so by disrupting 
splicing events. Erroneous splice site usage is also observed in numerous diseases. 
 
Problem: Identification and functional annotation of single-nucleotides polymorphisms that 
interfere with splicing mechanisms (‗splice SNPs') is a major challenge and needs to be 
supported by an efficient method. 
Solution: 
1) A high-throughput methodology was established to facilitate the screening of allele-
dependent splicing in a high-throughput fashion (ElSharawy et al., 2006). The 
method integrated a package of four new software tools and was mainly based on 
using a panel of 92 matched pairs of individual-specific gDNA and cDNA samples. 
For each SNP, 16 cDNAs providing a balanced representation of the genotypes at the 
respective SNP were investigated by nested RT-PCR and subsequent sequencing. 
Putative allele-dependent splicing events were verified by cloning and sequencing. 
2) A systematic, SNP-centered approach was followed and the database dbSNP was 
screened to filter a group of common SNPs at either canonical splice sites or ESEs 
that were classified as putatively splicing-relevant by bioinformatics tools. This was 
completed in two screening rounds using web-based tools (Alex‘s splice site score 
calculator and ESEfinder) and neural network, respectively. A group of SNPs at 
NAGNAG tandem repeat sites was also tested (ElSharawy et al., 2008). 
 
Results and conclusion: As a result of genotyping, the 223 non-redundant candidate SNPs 
were experimentally tested, and 18 allele-dependent splicing events were identified, of which 
15 were novel and 3 exhibited an already known functional relevance. However, the positive 
predictive value of the bioinformatics tools turned out to be low, ranging from 0% for 
ESEFinder to 9% (in the case of acceptor site SNPs) for the neural network. Overall, the 
currently available bioinformatics tools contribute little to the understanding as to how 
common genetic variation impacts mRNA splicing. Therefore, there is a need for an 
alternative system. 
A proof of concept and outlook: The present study made some preliminary steps to develop 
a novel in vitro fluorescence-based splice reporter system. The ongoing systematic and 
hypothesis-driven experiments, which combine the advantages of FACS-based reporter 
constructs with a dichromatic readout method (a defined and experimentally controlled 
system) and ultra-high-throughput second generation sequencing technology, will serve to 
establish an efficient means to address many splice-related topics, and thus, would improve 
our understanding of mammalian splice site anatomy. 
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6 ZUSAMMENFASSUNG 
Hintergrund: Die weitreichende evolutionäre und physiologische Bedeutung des 
differentiellen mRNA-Spleißens ist allgemein bekannt, besonders im Hinblick auf 
pathophysiologische und biomedizinische Fragestellungen.  Man geht davon aus, dass bis zu 
60 Prozent aller krankheitsverursachenden Mutationen auf eine Zerstörung von Spleißstellen 
zurückzuführen sind. Eine fehlerhafte Nutzung von vorhandenen Spleißstellen ist bereits für 
eine Vielzahl von Krankheiten bekannt. 
 
Problemstellung: Die Identifizierung und funktionelle Annotation spleißrelevanter SNPs 
stellt eine große Herausforderung dar und bedarf der Unterstützung durch eine effiziente 
Methodik. 
Lösungsansatz: 
1) Zur Erleichterung des Screenings nach allelabhängigen Spleißereignissen wurde eine 
neue Hochdurchsatzmethodik entwickelt (ElSharawy et al., 2006). Diese umfasst 
vier neue Software-Anwendungen und basiert hauptsächlich auf der Nutzung eines 
Panels von 92 übereinstimmenden Paaren individuenspezifischer gDNA- und cDNA-
Proben. Für jeden der zu untersuchenden SNPs wurden 16 cDNAs mittels RT-PCR 
und anschließender Sequenzierung untersucht. Allelabhängige Spleißereignisse 
wurden durch Klonierung und Sequenzierung verifiziert. 
2) In einem systematischen, SNP-zentrierten Ansatz wurden häufige SNPs an 
kanonischen Spleißstellen sowie an ESEs aus dbSNP gefiltert und mittels 
webbasierter Anwendungen als potentiell spleißrelevant klassifiziert. In einem 
zweiten Ansatz erfolgte die Klassifizierung der SNPs mittels eines neuronalen 
Netzwerkes. Die als spleißrelevant klassifizierten SNPs wurden im Anschluß mit der 
oben beschriebenen Methode untersucht. Zusätzlich wurde eine Gruppe von SNPs an 
NAGNAG Tandems Repeats getestet (ElSharawy et al., 2008). 
 
Ergebnisse und Schlussfolgerungen: Insgesamt wurden 223 nicht redundante Kandidaten-
SNPs experimentell getestet. Dabei wurden 18 allelabhängige Spleißvorgänge identifiziert, 
von denen 15 neuartig waren und für 3 die funktionelle Relevanz bekannt ist. Dabei stellte 
sich die korrekte positive Vorhersagefähigkeit der bioinformatischen Tools als äußerst gering 
heraus - von 9% (für Spleißakzeptor-SNPs) für das neuronale Netzwerk bis zu 0% für den 
„ESEFinder―. Zusammenfassend konnten die verwendeten bioinformatischen Anwendungen 
nur wenig zum Verständnis beitragen, wie häufige genetische Variationen das mRNA-
Spleißen beeinflussen. 
Ausblick: In der vorliegenden Arbeit wurden entscheidende vorläufige Schritte zur 
Entwicklung eines neuartigen fluoreszenzbasierten in vitro-Spleißreportersystems geleistet, 
welches zur Zeit getestet und im Hinblick auf gezielte Fragestellungen validiert wird. Die 
momentan durchgeführten systematischen und hypothesenorientierten Experimente 
kombinieren die Vorteile FACS-basierter dichromatischer Reportersyteme mit denen der 
Hochdurchsatz-Sequenziertechnologie (second generation sequencing technology) und 
könnten ein effizientes Mittel zur Aufklärung vieler spleißrelevanter Fragestellungen 
darstellen und unser Verständnis des allelabhängigen Spleißens entscheidend verbessern. 
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7 MATERIALS 
Table ‎7.1 Kits, Enzymes, vectors, antibodies, and Chemicals 
 
Product  Manufacturer 
100 bp DNA ladder  Invitrogen; Karlsruhe, Germany 
15 ml reaction tubes  Sarstedt, Nümbrecht, Germany 
2.2 ml 96 deep well  MTP ABgene, Epsom, UK 
2-Mercaptoethanol Sigma, Munich, Germany  
37% Formaldehyde  Sigma, Munich, Germany 
384 deep well storage plate (max. 300 µl)  ABgene, Epsom, UK 
384 well PCR MTP  Eppendorf, Cologne, Germany 
384-well MT plates  Greiner Bio-One GmbH, Frickenhausen, Germany 
384-well MT plates  Sarstedt, Nümbrecht, Germany 
50 ml reaction tubes BD Biosciences, Heidelberg, Germany 
96-well MT plates  Costar Corning Incorporated, Cambridge, MA, USA 
96-well MT plates  Sarstedt, Nümbrecht, Germany 
Advantage RT-for-PCR  (100 reactions) BD Biosciences Clontech, Palo Alto, CA, USA 
Aequorea victoria  GFP (A.v. GFP)  
monoclonal antibody  (JL-8)  
Clontech, Heidelberg, Germany 
Agarose  Eurogentec, Cologne, Germany 
Alkaline phosphatise (CIP); 10,000 U/ml New England Biolabs, Bad, Schwalbach 
AmpliTaq Gold
®
 with GeneAmp 10x PCR 
Buffer II & MgCl2 solution 
Applied Biosystems, Foster City, CA, USA 
 
BamHI enzyme New England Biolabs, Bad, Schwalbach 
BigDye
®
 Terminator Ready reaction kit v1.1  Applied Biosystems, Foster City, CA, USA 
Biosphere® Filter Tips (10/200/1000 µl)  Sarstedt, Nümbrecht, Germany 
Bromphenol blue  Sigma, Munich, Germany 
BSA (Bovine Serum Albumin) New England Biolabs, Bad, Schwalbach 
Cell culture flasks (250 ml; canted neck)  BD Biosciences, Heidelberg, Germany 
DNase enzyme Qiagen, Hilden, Germany   
dNTP set (100 mM solutions, each 100 µM)  GE Healthcare UK Limited, Buckinghamshire, UK 
and Amersham, Piscataway, NJ 
DsRed monoclonal antibody Clonethech, Heidelberg, Germany 
Dulbecco‘s PBS (1X) PAA Laboratories GmbH, Pasching, Austria 
Easy peel heat seal foil  ABgene, Epsom, UK 
ECL-Plus Western Blotting Detection System   Amersham Pharmacia Biotech, Amersham Labs, UK 
EDTA  Sigma, Munich, Germany 
EDTA blood vial 10 ml  Sarstedt, Nümbrecht, Germany 
Ethidium Bromide solution (10 mg/ml)  Invitrogen, Karlsruhe, Germany 
FuGENE
®
 6 Transfection reagent Roche, Mannheim, Germany 
G3PDH (Human Amplimers; 200 µl: 10 µM 
each) 
Clontech, Mountain View, USA 
GenomiPhi v1, v2, and high yield WGA Kit  GE Healthcare UK Limited, Buckinghamshire, UK 
Glycerol  Sigma, Munich, Germany 
GoTaq DNA polymerase (2.500 u: 5u/µl) Promega, Madison WI, USA 
Invisorb Blood Universal Kit  Invitek, Berlin, Germany 
Isopropanol  Merck, Darmstadt, Germany 
LiChrosolv® double distilled water  Merck, Darmstadt, Germany 
M13 universal primers Carl Roth GmbH and Co.KG, Karlsruhe, Germany 
MagAttract DNA Blood M48  Qiagen, Hilden, Germany 
MicroAmp® optical 96-well reaction plate  Applied Biosystems, Foster City, CA, USA 
MicroAmp® single strips  Applied Biosystems, Foster City, CA, USA 
MicroAmp® single tubes  Applied Biosystems, Foster City, CA, USA 
Microtiter plates, 96-well, round bottom w/ lid  Sarstedt, Nümbrecht, Germany 
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Minielute Gel Extraction kit from  Qiagen, Hilden, Germany 
MOPS (10 X): 3-[N-morpholino] 
propanesulfonic acid  
Sigma; Munich, Germany 
Mouse anti--actin monoclonal antiobody, 
Clone AC-15 (A5441-2ML; 107K4800) 
Sigma, Steinheim, Germany 
pDsRed2-N1 vector BD Biosciences Clontech, Palo Alto, CA, USA 
pEGFP-N1 vector BD Biosciences Clontech, Palo Alto, CA, USA 
Phosphate inhibitor cocktail II Sigma-Aldrich Chemie, Munich, Germany 
PicoGreen®  Invitrogen, Karlsruhe, Germany 
Pipette tips with filter (10 / 200 / 1000 µl)  Sarstedt, Nuremberg, Germany  
Primers Metabion, Martinsried, Germany 
Eurogentec, Seraing, Belgium 
Microsynth laboratory, Lindau, Germany   
Proteinase K  Molecular Research Center, OH, USA 
PWO SuperYield DNA polymerase PCR buffer  Roche Diagnostics GmbH, Mannheim, Gemrnay 
PWO SuperYield DNA polymerase; 250 U 
(5U/µl) 
Roche Diagnostics GmbH, Mannheim, Gemrnay 
QIA Filter
TM 
Plasmid Maxi Kit Qiagen, Hilden, Germany   
QIAamp® DNA Micro Kit  Qiagen, Hilden, Germany 
QuikChange® Lightning Site-Directed 
Mutagenesis Kit  
Stratagene, La Joll, CA 
Rabbit polyclonal to Mouse IgG antibody - 
H&L (HRP) (ab6728) 
Abcam, Cambridge, UK  
RC-DC Protein Assay Kit BioRad, Munich, Germany 
Reaction tubes (0.5/1.5/2.0 ml)  Eppendorf, Cologne, Germany 
RevertAid H Minus First Strand cDNA 
Synthesis Kit  
Fermentas Life Sciences, St. Leon-Rot, Germany 
RNeasy mini RNA extraction kit  Qiagen, Hilden, Germany 
RPMI 1640 medium without FCS PAA Laboratories GmbH, Pasching, Austria 
SacII enzyme New England Biolabs, Bad, Schwalbach 
SAP shrimp alkaline phosphatase  Amersham Biosciences; Freiburg, Germany  
Sephadex powder (G-50 superfine)  GE Healthcare UK Limited, Buckinghamshire, UK 
Sephadex spin column plates MAHVN 4550  GE Healthcare UK Limited, Buckinghamshire, UK 
Serological pipettes with filter (5/10/25 ml)  Sarstedt, Nümbrecht, Germany 
SmartLadder DNA marker  Eurogentec, Cologne, Germany 
SNPlex™ System Core Kit  Applied Biosystems, Foster City, CA, USA 
T4 DNA ligase New England Biolabs, Bad, Schwalbach 
TAE Buffer 25x ready pack  Amresco, Solon, OH, USA 
Taq DNA polymerase  Qiagen, Hilden, Germany 
TaqMan® Universal PCR Master Mix  Applied Biosystems, Foster City, CA, USA 
TBE Buffer 10x ready pack  Amresco, Solon, OH, USA 
TRIZOL Invitrogen, Karlsruhe, Germany 
Wizard
®
 Plus SV Minipreps DNA Purification 
System  
   
Promega, Madison WI, USA 
Wizard
®
 SV Gel and PCR clean-up system  Promega, Madison WI, USA 
XhoI enzyme New England Biolabs, Bad, Schwalbach 
 
 
Table ‎7.2 Primers used in establishment of the splice reporter system 
 
Primer abbreviation  Primer sequence (5-3) 
dsRed_Xho_f  cagcgactcgagATGGCCTCCTCCGAGAACGTC 
dsRed_XhoI_r  ctggctcGAGGAACAGGTGGTGGCGG 
dsRed2-578-f  TACTACGTGGACGCCAAG 
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GFP_rem_ATG_F  ccggtcgccaccgtgagcaagggc 
GFP_rem_ATG_R  gcccttgctcacggtggcgaccgg 
GFP_RT_F TAAACGGCCACAAGTTCAGC 
GFP_RT_R CGGCCATGATATAGACGTTGT 
NM173582_PCR_f  TTGTGCCTACATACAGGAAC 
PGM_GFP_F_Seq  TACAGTGGTTGTTGGAAAGTT 
PGM_int7_TC_F ctttttgggtcactgtttctcgaactttccttgagactgg 
PGM_int7_TC_R ccagtctcaaggaaagttcgagaaacagtgacccaaaaag 
PGM_int8_CA_F  gcagcagcagaacttcaggagaacaatgtagaatctgttatttga 
PGM_int8_CA_R tcaaataacagattctacattgttctcctgaagttctgctgctgc 
PGM_R_BamH  CGGTGGATCCTCAAAATGAAATCCTTCTTTAAGTGC 
PGM_SacII_F  GGACCCGCGGTTAAACTCGAAGACCACCTTGAA 
EGFP_myc_f  caggatgaggatcgtttcgcatggagcagaaactcatctctgaaga
ggatctgattgaacaagatggattg 
EGFP_myc_r gcgtgcaatccatcttgttcaatcagatcctcttcagagatgagtt
tctgctccatgcgaaacgatcctcatcctg 
EGFP_flag_f caggatgaggatcgtttcgcatggattacaaggatgacgacgataa
gattgaacaagatggattgcacgc 
EGFP_flag_r gcgtgcaatccatcttgttcaatcttatcgtcgtcatccttgtaat
ccatgcgaaacgatcctcatcctg 
 
 
Table ‎7.3 Solutions and Media 
 
Name Description 
0.1% TBST 10x TBS = 200mM Tris pH7.6, 1.37M NaCl  200ml 1M 
Tris pH7.6 , 80.1g NaCl, autoclaved dist water ad 1 l 
TTBS = 1x TBS+ 1ml/l Tween20 (=0.1%) 
10 X DNA gel loading buffer  50% v/v glycerol, 0.1% bromophenol blue (w/v) 
5X SDS-loading buffer ( for SDS-PAGE 
electrophoresis) 
5x SDS-Loading Buffer: 312.5mM Tris pH6.8, 10%SDS, 
50% Glycerin, 10%-ME , Brome-phenol-Blue  1563 µl 
1M TrisHCl pH6.8, 2.5 ml Glycerin, 0.5 g SDS, 500 µl -
ME (TOXIC), a few crystals Bromophenol-Blue , A.bidest 
ad 5 ml, aliquots of 500 µl  -20°C 
DEPC treated water  1 mL DEPC in 1 L DDW, shake vigorously and autoclave 
LB media  
 
10g Tryptone, 5g Yeast Extract, 10 g NaCl (Carl Roth 
GmbH, Karlsruhe, Germany), complete dissolving in 1 
litre distilled water and autoclaving for 15 min at 121°C. 
Separating gel for Western blotting (12%)  3.5 ml autoclaved dist water, 2.5 ml 4x separation Buffer, 
4 ml (Bis) acrylamid and 10 l TEMED. Then, mix by 
inverting the tube 5x and quickly add  100 l 10% APS. 
(4X separation buffer: 1.5M Tris pH8.8, 0.4%SDS 
36.4g Tris in 140 ml A.bidest, pH with HCl  8.8,  
+ 8ml 10%SDS, autoclaved dist. Water ad 200 ml)   
Stacking gel for Western blotting (12%) 3.9 ml autoclaved dist water, 1.5 ml 4x stacking buffer, 0.6  
ml (Bis) acrylamid and 6 l TEMED. Then, mix by 
inverting the tube 5x and quickly add 30 l 10% APS. 
(4x Stacking Buffer: 0.5M Tris pH6.8, 0.4%SDS 
 50 ml 1M Tris pH6.8, +4 ml 10%SDS, ad 100 ml) 
TE (pH 7.5, 8.0)  10 mM Tris-HCl, 1 mM EDTA 
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Table ‎7.4 Machines 
 
Name Manufacturer 
Centrifuges 
 
Heraeus Biofuge ‗fresco‘ and ‗pico‘  Kendro, Hanau, Germany 
Heraeus Labofuge 400 Kendro, Hanau, Germany 
Heraeus Multifuge 3S-R Kendro, Hanau, Germany 
Heraeus Varifuge 3.2RS Kendro, Hanau, Germany 
Micro Centrifuge Roth, Karlsruhe, Germany  
Thermocyclers 
 
ABI Prism™ 7700 Sequence Detector Applied Biosystems Inc., Foster City, CA, USA 
ABI Prism™ 7900HT Sequence Detection 
System 
Applied Biosystems Inc., Foster City, CA, USA 
Biometra® T Gradient Whatman Biometra GmbH, Göttingen, Germany 
Biometra® T1 Thermocycler Whatman Biometra GmbH, Göttingen, Germany 
GeneAmp® PCR System 9700 Applied Biosystems Inc., Foster City, CA, USA 
Electrophoresis and Western blotting 
 
Bandelin Sonopuls GM 70 Bandelin electronics, Berlin, Germany 
BioDoc Analyzer Biometra, Göttingen, Germany 
Bio-Rad ChemiDoc XRS System Bio-Rad, Munich, Germany 
Gel Doc XR Bio-Rad, Munich, Germany 
Gibco BRL Electrophoresis Power Supply 250 
EX 
BioRad, Munich, Germany 
Gibco BRL Horizontal Gel Electrophoresis 
Apparatus 
BioRad, Munich, Germany 
High Performance UV Transilluminator VWR, Hamburg, Germany 
Horizontal Electrophoresis Apparatus Bio-Rad, Munich, Germany 
KERN 440-47N scale Kern & Sohn, Balingen, Germany 
Microwave R-2V18 Sharp Electronics, Hamburg, Germany 
Multigel SDS-PAGE Vertical Electrophoresis 
Apparatus 
Whatman Biometra, Göttingen, Germany 
Power Pac 300 Electrophoresis Power Supply Bio-Rad, Munich, Germany 
Roller mixer (Stuart; SRT6D) Barlworld Scentific limited, Stone, UK 
Semidry Electroblotter  PeqLab Biotechnologie GmbH, Erlangen, Germany 
Shaking incubator (Stuart; S|500) Barlworld Scentific limited, Stone, UK 
Pipetting Robots 
 
Hydra 384 Robbins Scientific Dunn Labortechnik, Asbach, Germany 
Hydra 96 Robbins Scientific Dunn Labortechnik, Asbach, Germany 
Power Washer PW384  Tecan, Deutschland GmbH, Crailsheim, Germany 
Tecan Carousel for Evo 150  Tecan, Deutschland GmbH, Crailsheim, Germany 
Tecan Freedom Evo 150 Tecan, Deutschland GmbH, Crailsheim, Germany 
Tecan Freedom Evo 200 Tecan, Deutschland GmbH, Crailsheim, Germany 
Tecan Genesis RSP 150 Tecan, Deutschland GmbH, Crailsheim, Germany 
Tecan Genesis Workstation 150 Tecan, Deutschland GmbH, Crailsheim, Germany 
Tecan Genesis Workstation 200 Tecan, Deutschland GmbH, Crailsheim, Germany 
Tecan Spectrafluor Plus Tecan, Deutschland GmbH, Crailsheim, Germany 
Te-MO Tecan, Deutschland GmbH, Crailsheim, Germany 
Te-MO with cooling rack Tecan, Deutschland GmbH, Crailsheim, Germany 
WRC96 washing station Tecan, Deutschland GmbH, Crailsheim, Germany 
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Other Machines  
 
3700 DNA Analyzer Applied Biosystems Inc., Foster City, CA, USA 
3730xl DNA Analyzer Applied Biosystems Inc., Foster City, CA, USA 
Axiocam Zeiss, Jena, Germany 
Axiophot microscope Zeiss, Jena, Germany 
Bambi Compressor DT/23Q Bambi, Birmingham, UK 
FACSCalibur
TM
 cytometer Becton-Dickinson, San Jose, CA 
GFL 1086 shaking waterbath GFL, Burgwedel, Germany 
Hemocytometer Brand, Wertheim, Germany 
Heraeus 3 incubator Kendro, Hanau, Germany 
IMPLEN Nanophotemeter Implen GmbH, Munich, Germany  
Mini Vortexer VM-3000 VWR, Darmstadt, Germany 
NanoDrop® ND-1000 Spectrophotmeter  NanoDrop Technologies, Wilmington, DE, USA 
PCR chambers  Bä-RO
®
 Technology, Leichlingen, Germany 
Platesealer ALPS-300 Abgene, Epsom, UK 
Shaking incubator (GFL 3033)  Gesellschaft für Labortechnik mbH, Burgwedel, Germany 
Thermomixer 5437 Eppendorf, Cologne, Germany 
TiMix Control incl. TH15 hood Edmund Bühler Labortechnik, Hechingen, Germany 
Vortex-GENIE 2 G-560E  Scientific Industries, Bohemia, NY, USA 
 
 
Table ‎7.5 Electronic Data Processing 
 
Name Source 
Laboratory information management 
system (LIMS) at ICMB 
Details and description of the used database system at ICMB 
(Kiel, Germany) are given in Hampe et al. (Hampe et al., 2001), 
and Teuber et al. (Teuber et al., 2005). 
Software 
 
Alex‘s splice site score calculator http://violin.genet.sickkids.on.ca/~ali/splicesitescoreForm.html 
CellQuestPro
TM
 software package Becton-Dickinson, San Jose, CA 
ESEfinder http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home 
F-SNP http://compbio.cs.queensu.ca/F-SNP/ 
Gemini 4.28  Tecan, Deutschland GmbH, Crailsheim, Germany 
Genemapper 4.0  Applied Biosystems, Foster City, CA, USA 
Motif SNPs Input Page (beta v1.0) www.ikmb.uni-kiel.de/motifsnps 
Primer Express 2.0 
 
 http://www.applied-biosystems.com 
Applied Biosystems, Foster City, CA, USA 
Primer3 (v.0.4.0)  http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 
Sequence Detection System 2.1 Applied Biosystems, Foster City, CA, USA 
Sequencher 4.2 and 4.5 http://www.genecodes.com 
(Gene Codes Corporation, Ann Arbor, MI, USA) 
SNPSplicer http://www.ikmb.uni-kiel.de/snpsplicer/ 
ICMB, Kiel, Germany 
SpliceTool ICMB, Kiel, Germany 
Web Resources 
 
AB Applied Biosystems http://www.appliedbiosystems.com/ 
Alternative splicing Gallery http://statgen.ncsu.edu/asg/ 
BLAST  http://www.ncbi.nlm.nih.gov/BLAST/ 
BLAT http://genome.ucsc.edu/cgi-bin/hgBlat?command=start 
CEPH http://www.ceph.fr 
Columbia Biosciences http://www.columbiabiosciences.com/ 
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EBI-Alternative splicing Database Project http://www.ebi.ac.uk/asd/ 
Ensembl  http://www.ensembl.org 
ExPASy Translation tool http://www.expasy.org/tools/dna.html 
Fast DB http://www.fast-db.com/fastdb2/frame.html 
FirstEF: first-exon and promoter prediction http://rulai.cshl.org/tools/FirstEF/ 
Genecards  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed 
HapMap http://www.hapmap.org 
InterProScan sequence search http://www.ebi.ac.uk/InterProScan/ 
Microsynth Laboratory http://www.microsynth.ch 
NCBI dbSNP http://www.ncbi.nlm.nih.gov/SNP/ 
Pfam  http://www.sanger.ac.uk/Software/Pfam/ 
PubMed http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed 
RepeatMasker http://woody.embl-heidelberg.de/repeatmask/ 
Smart  http://smart.embl-heidelberg.de 
SNP-BLAST http://www.ncbi.nlm.nih.gov/SNP/snp_blastByOrg.cgi 
SPIDY, mRNA to genomic alignments http://www.ncbi.nlm.nih.gov/IEB/Research/Ostell/Spidey/ 
UniProt  http://www.uniprot.org 
 
 
Table ‎7.6 TaqMan Assays and SNPlex Pools 
 
TaqMan Assays 
rs ID Assay code 
rs2076530 hcv2488471 
rs2228173 hcv11764349 
rs2295773 hcv2144407 
rs2298839 hcv3212434 
rs5248 hcv2796264  
rs540819 hcv962479 
 
SNPlex Pools 
Pool code (Applied Biosystems) Design Name Designed SNP-count per pool 
For first (web based) round 
w0510100067-0001 Q1-A01 47 SNPs 
w0510100067-0002 Q2-B01 48 SNPs 
w0510100067-0003 Q3-A02 48 SNPs 
w0510100067-0004 Q4-B02 47 SNPs 
For second (neural network) round 
w0609104034-0001 Pool1-D2M 47 SNPs 
w0609104034-0002 Pool2-D2M 40 SNPs 
w0611104666-0001 Pool1-ACC2 48 SNPs 
w0611104666-0002 Pool2-ACC2 29 SNPs 
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8 APPENDIX 
8.1. All experimentally validated SNPs and primers used for the nested RT-PCR 
Table ‎8.1 List of all tested candidate splice SNPs and primers used for the nested RT-PCRs  
 
The 41 SNPs, that overlapped between the ss score and NN approach are marked with an rs-number in bold print. 
 
# SNP ID Site and 
experiment 
category 
S or 
ESE  
N 
 
 
Position SNP-in-sequence* Exon #/ 
size of 
adjacent 
exon 
Gene symbol Refseq 
annotation 
Round 1 RT-PCR 
Forward‎5′-3′ 
Reverse‎5′-3′‎ 
Round 2 RT-PCR 
Forward‎5′-3′ 
Reverse‎5′-3′ 
Ampli
-con 
Size 
Genotyp-
ing 
Method 
Genotypes 
availability 
(11-22-12) 
1 rs17105087:A>G AG variation at 
NAGNAG 
- - (+3) TTCTCTCTTCTGCAGCARCC 7/165 SLC25A21 NM_030631 GAAATTGCTGGGATATGTGTCA 
AAGTCTCATAATCTTGGGAAGCAG 
TCTGGACTAACAGAAGCCATTGTA 
AAATCCCTTCTTCCTGATAGACTG 
436bp SNPLex 2-78-12 
2 rs11597439:C>G AG variation at 
NAGNAG 
- - (+3) TCTGTGTCCCTTCAGAASAG 2/84 CUEDC2 NM_024040 TGGCAGAAGCTCCTCCTCA 
GGGATGAGAGCTGCACCG 
AGCAGCCGAAGACCTAGTCTCT 
- 
451bp SNPLex 32-16-44 
3 rs1558876:C>G AG variation at 
NAGNAG/ NN-
middle-acceptor 
- 0.00305 (+3) GTTCTCCTGTTTCAGCASCA 5/197 ARSG NM_014960 TACTGATACTCCAGGCTACAACCA 
CTGGTGACATTAACTGGAACTCTG 
CTCCCTCTTTATGAAAACCTCAAC 
AGTTTGCCAAAATCCAGTGAAG 
375bp SNPLex 25-19-48 
4 rs9606756:A>G AG variation at 
NAGNAG/ NN-
middle-acceptor 
- 0.00494 (+3) ATTTTCTTTTCTAAGAARTA 2/193 TCN2 NM_000355 GAGGATTAATCAGTGACAGGAAGC 
GATCAATGTAGGTCTTGTGGTTCA 
GATTCTTGCTCACTGCTCACC 
AAAGGTTCCACAGCATACAGAAGT 
592bp SNPLex 74-1-17 
5 rs1152888:A>G AG variation at 
NAGNAG 
- - (+3) ACTTTCCTTCCTAAGGARTA 5/152 IRAK3 NM_007199 CAGTGTTGAGTCCTTCAGAGAAGA 
GTCTCTGTAAAATATGCAGCCAAC 
GAAGAGTTATCAGGAAGGTGGATT 
CTCTGTAAAATATGCAGCCAACTC 
361bp SNPLex 0-77-15 
6 rs17036879:G>A AG variation at 
NAGNAG 
- - (+3) TGTAAATAACTTTAGGARCC 8/139 TSEN2 NM_025265 GCAAACAAGATGCTCTCATCC 
CATACATTCTGGTGACTCCATTTC 
GGTCTATGCTCTGGGATGTTTAAG 
AGAGACATTAACGGAAACTCTGCT 
325bp SNPLex 0-90-2 
7 rs2156634:G>A AG variation at 
NAGNAG/NN-
middle-acceptor 
- 0.01286 (+3) CCAGTTTTGCTGCAGGARAA 3/204 GRIK4 NM_014619 AGAGGTCCAACTACGCTTTGAA 
GAGTACTGGTTCACCAGGAGGTT 
GGTCCAACTACGCTTTGAAAAT 
AGATAGGCTAGAAGCATGAAGAGC 
556bp SNPLex 2-63-25 
8 rs3014960:G>A AG variation at 
NAGNAG/NN-
middle-acceptor 
- 0.0044 (+3) GATTTCTTTATACAGCARAT 14/106 COG3 NM_031431 ATGATATCCACCAGTGTTACCTTG 
TGATAGACTCTGACGCTCCAAGTA 
TAGAGACTCTGTCGGAACTTTGTG 
- 
540bp SNPLex 71-2-19 
9 rs4822258:G>A AG variation at 
NAGNAG/NN-
middle-acceptor 
- 0.00496 (+3) CTTTCCCGTCACCAGGARGA 8/144 TTLL1 NM_012263 TTCCTTATCAACAAGCTCTCACAG 
GTAATTGCCGAGGACTTCCTTA 
AGTACCAGTGAGCTGGACAACAT 
GTTGTACTTGAGGATTCGGTCATT 
354bp SNPLex 51-9-32 
10 rs2243603:C>G AG variation at 
NAGNAG/NN-
middle-acceptor 
- 0.00036 (+3) TTCCCTGATTTCCAGAASCA 5/115 SIRPB1 NM_006065 ATAGAGAACAAGGATGGCACCTAC 
AAGTCCTGGTGTGTTTAGATTTGG 
CAAGCAGTCAGCAAAAGCTATG 
AGATTTGGAGTGTTTCTCACCTTC 
449bp SNPLex 4-57-31 
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11 rs2290647:G>A AG variation at 
NAGNAG 
- - (+2) CTCCTCTGTCTCCAGCRGAC 10/144 GRAMD1A NM_020895 GACAGACACAAGTAACTCCTCTTCA 
CCAGATGGTGGAAATAGTCTTCA 
CACAAGTAACTCCTCTTCATCCAC 
GGCAGTGTAGAAGTAGTCCTGGTA
G 
394bp SNPLex 41-6-40 
12 rs2273431:G>A AG variation at 
NAGNAG 
- - 
 
(+2) CCTCTACTCATGCAGARGAT 10/144 NID2 NM_007361 ACTTGACCCAGAGAACTACCTGAG 
CTTCCAGGCAAGTTGATACATACA 
CCAGAACATCACTTACCAGGTGT 
CCAGGCAAGTTGATACATACAGAG 
366bp SNPLex 0-79-13 
13 rs7862221:A>G AG variation at 
NAGNAG 
- - (+2) TTTGTTTCTCTTCAGARGAG 14/105 TSC1 NM_000368 TACACAGACAACACCATCTTCTGA 
GCTTTCTTTAACAGCTCCTCAGTC 
ACAACACCATCTTCTGAATGACAG 
AGGTCTATGGGAGTAAAGGCTTG 
369bp SNPLex 1-68-22 
14 rs2275992:A>G AG variation at 
NAGNAG/NN-
middle-acceptor 
- 0.0002 (+2) TTTACTTATTTTTAGTRGTG 5/105 ZFP91 NM_053023 - 
TCTCACAACGGACATACTGGATT 
TGGCGTAGTAGTAGGACATCTGTT 
GACATACTGGATTGGAGGCTTTT 
480bp SNPLex 47-5-40 
15 rs1152522:A>G AG variation at 
NAGNAG/ NN-
top-acceptor 
- 0.97073 (-2) TGTTGTCTTTCATRGCAGGT 4/102 C14orf105 NM_018168 AGAAAAGACTTCATATTCACTGGCAA 
TTCAAGATTTCATCAGGCAACATG 
GCAGGACCAGAATAAAGCCTTGG 
TGGTTAGAAGGTCATGGTCATCAT
TC 
473bp Direct 
sequencin
g 
5-47-28 
16 rs2307130:A>G AG variation at 
NAGNAG 
- - (-2) TTTCAAATCCTCTRGAAGCC 2/90 AGL NM_000644 GTCTACGGCAGCTATTCCAGAG 
CCTAGATAGTCCAAGAGTCTGCAA 
ACTGCTTCCCTCTGTTCTCATCT 
GTAAAATGGGGTCCACAACTATGT 
448bp SNPLex 23-23-46 
17 rs5248:A>G AG variation at 
NAGNAG/ NN-
middle-acceptor 
- 0.00244 (-4) TCTTCCTCACARCAGGTCTA 3/136 CMA1 NM_001836 AGATGCTGCTTCTTCCTCTCC 
ATTGTGGTCAAAGTCTCTGAAGTG 
CCTGCTGCTCTTTCTCTTGTG 
ATGAGTCTCAGCTTCACCTCTTG 
489bp SNPlex/ 
TaqMan 
82-1-9 
18 
rs2292402:T>A 
AG variation at 
NAGNAG 
- - (-5) GTGTGTTTGGWGCAGTGAGT 2/103 ACPL2 NM_152282 GGAGCTGGCGGCGAG 
TGGGAATGACATACAGTGGGTAC 
- 
TGGCGAATGAACACATGC 
585bp SNPLex 4-74-14 
19 rs2071558:C>T N variation at 
NAGNAG/NN-
middle-acceptor 
- 0.00932 (-6) CAGTGTCCCYAGCAGGTAAT 6/231 AMHR2 NM_020547 CTGCTACAGCGAAAGAACTACAGA 
GTGGGCAATACCTGGTTTATATTG 
TACAGCGAAAGAACTACAGAGTGC 
GGGCAATACCTGGTTTATATTGG 
482bp SNPLex 66-4-22 
20 rs12905385:C>T N variation at 
NAGNAG/ NN-
middle-acceptor 
- 0.04271 (-3) ACTTCACTGATAYAGGAGAG 20/134 CDAN1 NM_138477 AGTTTCTCTCCTTTGCTGACCAT 
CTGGGAACACAAGATCTCCAAC 
AATATTACCGGGACATCTTCACTC 
CTGCTCTTGGAGAAGTGACTCTG 
569bp SNPLex 2-66-24 
21 rs2250205:C>T N variation at 
NAGNAG/ NN-
middle-acceptor 
- 0.06068 (-3) ATCTTTGATTGAYAGGAGAC 5/177 EIF6 NM_181469 CTTCGTTCGAGAACAACTGTGA 
TTCATTCAGCTTGAAGACACTCTC 
GGAGGCTCAGAGAACTTCTACAGT 
ACTGACAGCTCTGTGCTGGTT 
390bp SNPLex 4-52-35 
22 rs2174769:T>C N variation at 
NAGNAG/ NN-
middle-acceptor 
- 0.00639 (-3) CTGTTTGAATTTYAGGAGCG 3/599 SNIP1 NM_024700 AAGTCTCCTCGCAGTAAGAGAAAC 
CCTCGTCATCTTTCCTGTCTATTT 
CACTCAACAGTCAAAGTGAAGCA 
GCAAGACGTATTCTCTGCTACTGA 
805bp SNPLex 3-68-21 
23 rs12944821:G>C N variation at 
NAGNAG 
- - (+1) TCTTTATATTTTCAGSAGGC 3/122 AP1GBP1 NM_007247 TTCATGTTTCCTGTTGCAGGT 
TCCAAAGCATCATCTCTACTCTTCT 
CTGTTGCAGGTGGGATAAGAC 
GGTTTCACACTGCTCAAAAGTCT 
385bp SNPLex 1-65-26 
24 rs879022:G>A N variation at 
NAGNAG 
- - (+1) CTTTTCCCAGGACAGRAGGC 3/114 REG1P D56494 TGCTCCTTAAGCAAGAGATTCAC 
AGCTTATCTCGAAGAACCTATGGA 
GCTCCTTAAGCAAGAGATTCACTG 
GATAATCAGGAGGTAGAAGATGCA
G 
383bp SNPLex 81-1-10 
25 rs515071:T>C Acceptor scoring/ 
DEATH/ NN-
middle-acceptor 
8.3 0.00051 (-3) CCCTTCCTTTCCYAGATCAT 41/66 ANK1 NM_020475 GGAACAAGTACCATGACTGAAGG 
GCTTGTTTTCTATCCCTCTCTCTC 
CAAGAACACCTTCACCCAAGT 
ATGCGTCTACAGTCAGTCATTCAT 
354bp SNPLex 45-10-36 
26 rs3793326:T>C Acceptor scoring/ 
NN-middle-
8.3 0.00019 (-3) TCTCCTTTTCAAYAGGTTTT 12/157 CASD1 NM_022900 CCTGTATACATGCACATTCGAGTT 
ATAACGGTCTAACCTCCATCTGAA 
GGGCATTTCTCATACTTTTGGA 
CCATCTGAACCACCATTCATATAC 
372bp SNPLex 16-29-47 
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acceptor 
27 rs9986447:T>C Acceptor scoring/ 
NN-middle-
acceptor 
8.3 0.01466 (-3) TTATTTCTCTAAYAGAGGTA 2/164 PEX6 NM_000287 GCCACTTTGGCTTTTAATCTTG 
AAGGACACTGCTAGTTCCTGTCA 
CCACTTTGGCTTTTAATCTTGG 
GAACAGGGCTCAGGGTAGAAC 
435bp SNPLex 34-16-42 
28 rs2291662:T>C Acceptor scoring/ 
NN-middle-
acceptor 
8.3 0.00774 (-3) TTTGTTGCTTCAYAGCGGTG 50/107 SMG1 NM_015092 ATCACTCCCACCTTGAAAGAACT 
TCGCTTAACCAGACTCATCTACTG 
CTGATGTCATGTCACAGAATGCTA 
CTCATCTACTGTCTTGCCATTCAC 
352bp SNPLex 12-37-42 
29 rs2070410:T>C Acceptor scoring/ 
NN-middle-
acceptor 
8.4 0.00037 (-3) TTTTAATTTCTTYAGATGCA 27/88 TIAM1 NM_003253 ATGAACAAGGTTGCCAGTCAC 
TCCTCATACTGAGCAAGATCAAAC 
GCTGAACAGACTGGTGAGAAAAA 
GAGGAGCTGTCTTCTGTGCTTATC 
540bp SNPLex 14-24-53 
30 rs3811609:T>C Acceptor scoring/ 
NN-middle-
acceptor 
8.4 0.00741 (-3) TGTTTGTTTTTAYAGGGGCT 4/99 FLJ20160 NM_017694 AGAATGCCTGGACTGTTCTCC 
AACTGAAAGTCCTCATTGAACTCC 
ACTGTTCTCCCCATGGAAGTT 
GGGTGTGAGATGAGCAGGAT 
798bp SNPLex 6-42-43 
31 rs790055:T>C Acceptor 
scoring/IG 
8.3 - 
 
(-3) TTTCTTTCTCCTYAGGCTCC 5/69 F11R NM_144503 GAGGAAACTGTTGTGCCTCTTC 
CCTCACAGCTGTATTCTCCAGTATC 
GGAAACTGTTGTGCCTCTTCATA 
CATCTTTGAACCAGGTGTATTCAG 
483bp SNPLex 65-6-21 
32 rs2255632:T>C Acceptor scoring/ 
NN-middle-
acceptor 
8.3 0.00365 (-3) TCTTTACTCTCAYAGCGGCG 34/200 KIAA0467 NM_015284 CCTGGTGCATTACTGTGCAA 
TAGGTGGTTACCGGAGAGCTAGT 
TTACTGTGCAACAGCCATGC 
TCCCATCAGTCTTGGTTTTAGG 
365bp SNPLex 16-39-37 
33 rs607755:T>C Acceptor scoring/ 
NN-middle-
acceptor 
8.3 0.0003 (-3) TCCTTTTTCTTTYAGCTGAA 6/79 RELN NM_005045 CAGTTTGGTAACCAGTTTATGTGC 
ATTTTCTCTAGCTGAATCCAGTCC 
CACAACCAACCTCAGTTTCATCT 
ATGCTGGGGTCTGAATAACTAAAG 
435bp SNPLex 20-23-49 
34 rs11658717:G>A NN-top-acceptor - 0.99341 (-7) TCTTTTTARTACTAGGTTAG 6/211 STXBP4 NM_178509 CAGCTGTTAAATCCAAGGCTACTT 
AAAGACACTGTCCCTTTTGAGTCT 
GTTAAATCCAAGGCTACTTTGGTG 
GTCCCTTTTGAGTCTGCTTGTACT 
778bp SNPLex 50-4-36 
35 rs12857479:G>A NN-top-acceptor 
(Positive control at 
acceptor) 
- 0.98135 (-1) TGTTTGCTTTGATARGACAT 4/157 C13orf26 NM_152325 CCAAAACGGTATCAGAAGATTAGG 
GTGTCACAGTGAGTACGAATAAAGC 
- 
CAGTGAGTACGAATAAAGCGATCA 
699bp¶ SNPLex 11-41-39 
36 rs10774671:G>A NN-top-acceptor 
(Positive control at 
acceptor) 
- 0.97416 (-1) GTCTCACCCTTTCARGCTGA 6/514 OAS1 NM_016816 AAAAGTACCTGAGAAGGCAGCTC 
AAGTGAGGCTGTGGAGAATGTTAT 
AGTACCTGAGAAGGCAGCTCAC 
GGCTGTGGAGAATGTTATCTATGA 
542bp SNPLex 41-15-36 
37 rs3818780:C>G NN-top-acceptor 
(Positive control at 
acceptor) 
- 0.89773 (-1) GCTTTGCATCCTCASAGCAT 2/297 AVPI1 NM_021732 GATACCCTCTGCCATGCTCTT 
CTCTTTCCCTGGATCAGTGTCT 
CTGGCCCTTGTAAGCACCT 
AGTGCAGATACTGCTCACTGGA 
502bp SNPLex 61-6-23 
38 rs1805377:G>A NN-top-acceptor 
(Positive control at 
acceptor) 
- 0.80319 (-1) TGATTTTCTTTTCARTTCTA 8/589 XRCC4 NM_022406 TAAGGAAGCTTTGGAGACTGATCT 
TTTCAAAATCTTCCCAGACAGG 
CTCAAGAACGAGAAAAGGACATC 
TCAAAATCTTCCCAGACAGGAT 
743bp SNPLex 2-71-19 
39 rs2073193:C>G NN-top-acceptor - 0.64333 (-3) CTTCCCCCAATTSAGGCCGA 3/99 IDH3B NM_006899 AAACATGGCGGCATTGAG 
ATTGTTGTGCCGAGTCATATACC 
- 
AAGTGACTTCACATGGACTACGTT 
448bp SNPLex 42-7-38 
40 rs3793809:G>T NN-top-acceptor - 0.43985 (-12) ATTKGTCCTAACTAGGGGAT 3/2198 EIF4EBP2 NM_004096 CGCAGCTACCTCATGACTATTG 
GAAAGTCAGAGTTGAACTGTTTTCC 
GACGCTCTTCTCCACCACAC 
TGTTTTCCTCTAAGGGCTGCT 
522bp SNPLex 44-7-41 
41 rs17155183:A>T NN-top-acceptor - 0.41291 (-3) TTGTTGTATTTTWAGCGGTT 2/109 PTPN12 NM_002835 CAAGTGGAGATCCTGAGGAAA 
CCTCATTAAGCTTATCATGTCCAG 
ATGAAGAGTCCTGACCACAATG 
- 
603bp SNPLex 47-6-39 
42 rs2105702:T>G NN-top-acceptor - 0.34145 (-10) TTGATKCATATTTAGTGCCC 21/135 CTNNA3 NM_013266 AAAGAGTAAGCTGGATGCTGAGAT ATGATCATGATGGAGATGACAGAC 368bp SNPLex 39-7-44 
119 
CCTCTGGCTTCTCTCTTTTAATCA ATCTTGGTTGAGGCAATGTAAGAC 
43 rs1534904:A>C NN-top-acceptor - 0.3268 (-11) CTTTMAAATCCTCAGTGGTT 6/186 SELE NM_000450 ACGGTGAATGTGTAGAGACCATC 
TCACAAACTGGGATTTGCTGT 
GGTGAATGTGTAGAGACCATCAAT 
AGGATGATTTGAAGGTGAACTCTC 
538bp SNPLex 43-13-34 
44 rs591058:A>G NN-top-acceptor - 0.3262 (-14) CRATTTCTTAAATAGGGACC 5/165 MMP3 NM_002422 CTGTTGATTCTGCTGTTGAGAAAG 
GCTCGTACCTCATTTCCTCTGATA 
TGTTGAGAAAGCTCTGAAAGTCTG 
TCGTACCTCATTTCCTCTGATAGC 
721bp SNPLex 19-23-48 
45 rs251683:C>A NN-top-acceptor - 0.32102 (-12) CACMTTCTCCCAAAGCTGCC 6/121 PLA2G4C NM_003706 GCTCTGAAGAAGCTAAGGATTGAG 
CATAAACCTTTCAGGGTCAGATTC 
CTCTGAAGAAGCTAAGGATTGAGG 
ATGACTTCAGTGTTACCAAGAGCA 
658bp SNPLex 34-14-42 
46 rs786906:T>C NN-top-acceptor - 0.31819 (+1) TTTATCTTCTATAAGYGATT 12/127 PKN2 NM_006256 GGGGAAGGCTAGTAAGAAGAGCTA 
TACTTCATCTCGAGCCACAATATC 
ACAGTAAATCATTCTGGCACCTTC 
TTCTAGGCCTGACTGAGGAGTATC 
324bp SNPLex 13-27-50 
47 rs2592828:C>G NN-top-acceptor - 0.29862 (-10) AGTCTSTTTTAAAAGCCAAC 4/1080 TACC3 NM_006342 ACAGACGCACAGGATTCTAAGTC 
CTCTCTGCTGTTGGGGTCTC 
ACAGGATTCTAAGTCCTAGCATGG 
- 
1258b
p 
SNPLex 26-21-42 
48 rs3763131:A>G NN-top-acceptor - 0.28899 (-9) CCGTGCRTGGCCCAGAGCTG 16/128 GFPT2 NM_005110 GTCAGTTCATCTCTCTGGTGATGT 
ACTTGGAACTTTCAGTATCGTCCT 
ACTACAAAACAGGAGGCAAGAGAT 
TATCGTCCTTGGAGCACAGTATAA 
380bp SNPLex 65-2-23 
49 rs1077340:G>A NN-top-acceptor - 0.27314 (-6) TGATTTGTTRAAAAGGTTTG 5/226 ELAVL1 NM_001419 TAGAAGACATGTTCTCTCGGTTTG 
GGCTTCTTCATAGTTTGTCATGGT 
- 
GGTTGTAGATGAAAATGCACCAG 
387bp SNPLex 53-6-32 
50 rs2296804:C>G NN-top-acceptor - 0.26896 (-12) GGGSCTCTGTTACAGTAAGT 6/346 GNMT NM_018960 TCAGTGCTGATAGTGAACAACAAG 
TATATTGTTTACCCTTCCGTCTGTG 
CACATGGTGACCCTGGACTATAC 
ACCCCAGCTGTAGTCTGCTCTA 
354bp SNPLex 27-19-45 
51 rs535801:G>A NN-top-acceptor - 0.23791 (-6) AATTATTTTRCATAGGCAGA 7/142 MRE11A NM_005590 TTATGGAGAAAGATGCAGTCAGAG 
CTTCCATGTTTACTCCTGTTCTGA 
CCCTCAAGGAAAACATTACATACC 
CAAGAGTTCTCATCTTCCTTTGGT 
431bp SNPLex 37-7-47 
52 rs435806:T>C NN-top-acceptor - 0.2335 (-3) CTGCCCATTACCYAGATAAT 16/151 TLE6 NM_024760 AGTCAAGAGTATCGTGGTCAAGG 
CCCCTCAGTAGGTGATCTGGT 
ACCTCTGGAGTACCAATTCAAGTC 
GTTGTTGGAAGAGACGTCACAG 
365bp SNPLex 6-44-40 
53 rs10510594:T>C NN-top-acceptor - 0.22505 (+2) GTGATATTTATATAGAYGAT 22/122 NEK10 NM_152534 GATCATCTTGGAAGTGGAGCTTT 
ACTATTTTTGTAGCCAAGGACAGC 
- 
AAGGACAGCATGTTAGTGCTGTAG 
506bp SNPLex 8-43-41 
54 rs3819255:A>T NN-top-acceptor - 0.21015 (-11) AAAAWTTTTTAATAGGTATC 6/105 CHKA NM_001277 AGAGCGTTATGTTTGCCATTCT 
CTGTTGTTTCTTGGTGGGATACTT 
GCCAAAACTCTATGGCATCTTT 
- 
547bp SNPLex 13-42-35 
55 rs2169456:C>A NN-top-acceptor - 0.19176 (-10) CCGCAMTTCTGGCAGAATTA 47/161 KIAA1529 NM_020893 AGCAAAAAGATCCTGGAGTATCAG 
ATCAGGGGTTTCTCACTCTCTTC 
AGGCAAATAAGTACCACAACTCCT 
GAGTTTCCTTCGTATGAGCATTG 
494bp SNPLex 16-24-52 
56 rs2273540:T>G NN-top-acceptor - 0.19018 (-14) CKTTTAAACTTTAAGGATAT 10/319 DEPDC7 NM_139160 ACTACTGTATTTCATGGCTGTTGC 
TGGCAGAAAGTTTTGAATCCTC 
- 
GGCAGAAAGTTTTGAATCCTCA 
382bp SNPLex 18-27-47 
57 rs181390:T>C NN-top-acceptor - 0.18899 (-9) CCTGCCYGAACACAGATTCT 7/140 BID NM_001196 CATAAGGAGGAAGCGGGTAGT 
TCACTGTTGTGTGAAAGACATCAC 
- 
ACTGTTGTGTGAAAGACATCACG 
674bp SNPLex 14-42-32 
58 rs741932:C>T NN-top-acceptor - 0.18431 (-3) CCTGCGGCCCCAYAGCGGGC 3/113 PQBP1 NM_005710.2 CTATGACGATGATCCTGTGGACTA 
GAAGCTTCAATCCTGCTGCT 
TATGACGATGATCCTGTGGACTAC 
CTTCAATCCTGCTGCTTGGT 
704bp SNPLex 30-39-20 
59 rs3745503:A>C NN-top-acceptor - 0.1786 (-9) CCACACMCTCCCCAGCTGGA 25/207 MYH14 NM_024729.3 GAAGAGGAGCGAGACCTGAAG 
CCTCATATTTGAGCCGTAGCTTAT 
GACATCATCGTCTCCTTCCAG 
TAGCTTATTGAGGCTCTTGACCTT 
722bp SNPLex 71-3-17 
60 rs2075863:G>A NN-top-acceptor - 0.16218 (-11) GGGTRTCTTCTACAGTGTTT 5/97 PFKFB2 NM_006212.2 CTTCCTCAGAACAGAACAACAACA 
TGTCATAGTTGTCTGGGTCAAGAG 
CAAGAAACTAACACGCTACCTCAA 
CAAGAGGTCGGTAGGTAACTTTGT 
449bp SNPLex 15-27-48 
61 rs3746003:C>T NN-top-acceptor - 0.15978 (-13) ACYGGGGTGTGGCAGGAGTG 5/165 CADM4 NM_145296 ACCGCAAGGAGCTGAAAG 
GCAAGTGTAGGTGCCGTTATC 
- 
CAAGTGTAGGTGCCGTTATCC 
391bp SNPLex 3-66-21 
62 rs1734432:A>G NN-top-acceptor - 0.15505 (-11) GTCTRTTTAAATCAGGAGCT 10/73 PDIA6 NM_005742 CAGCTTCAGAAGTAAAAGAGCAGA 
CTAAGTCATCAAGCTCCACATCAC 
GAAGTAAAAGAGCAGACGAAAGGA 
- 
691bp SNPLex 21-22-48 
63 rs1382543:G>A NN-top-acceptor - 0.15276 (-7) TATTTGCTRCCTAAGAGCCA 3/221 MSH3 NM_002439 ACAAAAGGAAGGAGGAAGTGATCT AAAAGGAAGGAGGAAGTGATCTG 388bp SNPLex 7-53-31 
120 
TGTAATTCTAGCGGCGTATAGATG - 
64 rs2990986:G>A NN-top-acceptor - 0.14914 (-14) TRTAAAATTATACAGAAAAC 13/86 CCDC7 NM_145023 AGCAGTGAAAAGTTGTGAAGCTCT 
TATCACTTGTCCTTTGTCCACCT 
AATTCTTAGAAGCCCACTCAACTG 
GTCTCAGTTTTCCCCTCACTTTTA 
538bp SNPLex 8-44-40 
65 rs7752421:A>T NN-top-acceptor - 0.14746 (-6) CATCTTCACWTTCAGTCTTC 16/110 SNAP91 NM_014841 TTGCTTGCTACAATGATGGTGT 
GGAGGTCCAGGAGATCACTAGAT 
TGCTTGCTACAATGATGGTGTT 
TCCAGGAGATCACTAGATGGTTTA 
429bp SNPLex 27-16-47 
66 rs783544:T>G NN-top-acceptor - 0.14702 (-11) TCCTKTCCAAAACAGACTTC 3/189 CPEB1 NM_030594 AGGATAAAAGATTGCTGGGACA 
GATGATCTGATCCAGAGCTGAAG 
TAACTGAGGGTGCTGGAAACTT 
TCTGGATTTCAGTAGAGTCTGCAC 
368bp SNPLex 4-46-42 
67 rs920791:T>A NN-top-acceptor - 0.14529 (-12) ATGWTTCTACCTTAGGAAAG 5/219 CCDC11 NM_145020 CTATCCATCAGAAGAAGGTGTGTG 
CTTCTTTGCCTTGTCTTCCTCTAA 
AGACAGAAAGAGCTGATGGAGAAC 
CTTTCTCCTGAGCTTTTTCTTCCT 
412bp SNPLex 42-19-29 
68 rs11024770:G>C NN-top-acceptor - 0.14326 (-15) SGGACTTTGATCCAGCTGGA 5/100 IGSF22 NM_173588 GTGGAGTTCTTCAGCTTAGTGACC 
CAGTTCCATTATGCAGTCAAAGAC 
TGGAGTTCTTCAGCTTAGTGACC 
CTTCTTCATCTCTTTGAGCTTCCT 
539bp SNPLex 5-63-22 
69 rs2240340:T>C NN-top-acceptor - 0.14262 (-15) YTGATGGGATTTCAGAAATC 4/68 PADI4 NM_012387 AGATTTCATACTACGGACCCAAGA 
CTCACTTTGTCCATCTCAGACCT 
GATTTCATACTACGGACCCAAGAC 
- 
357bp SNPLex 14-28-48 
70 rs2607628:C>T NN-top-acceptor - 0.1415 (-4) TAATCATTGCAYTAGATAAA 63/91 PKHD1L1 NM_177531 GACAGATGGATTGGACATAGATGA 
GGGCTACTTCCAACAATTAATGAG 
CCAGGAACCTATCAGAACAGAAAA 
ATAAATGTGCACACTCTCTGTGGT 
324bp SNPLex 8-33-51 
71 rs330924:G>C NN-top-acceptor - 0.14027 (-9) TTTCCASGGTTCTAGCCTGT 2/5.414 PPP1R3B NM_024607 ACACCGACGCTCACGTAGT 
TTTCACGGTCTTCTCAAATGC 
- 
GGTCTTCTCAAATGCGAGGT 
588bp SNPLex 46-11-33 
72 rs10511687:T>C NN-bottom-
acceptor 
- 0.00002 (+3) TTTCATGTCTTATAGGTYAG 6/205 KIAA1797 NM_017794 CTCATCCTTTGATAACTGTGCTTG 
TTAAGCTGACTTCACTGACACACA 
- 
GACTCATCTGGGTAAGCTGAATTT 
408bp SNPLex 37-11-43 
73 rs1800774:C>T NN-bottom-
acceptor 
- 0.00002 (-14) GYTTTTTTATTTCAGGATTA 13/34 CETP NM_000078 CTTCAGTGATGGTGAAATTCCTCT 
CAATCTCCATCTCCGTACTCCTAA 
AGACCAGCAACATTCTGTAGCTTA 
ATCTCCGTACTCCTAACCCAACTT 
487bp SNPLex 40-9-42 
74 rs2243396:C>T NN-bottom-
acceptor 
- 0.00002 (-6) TGTCCCTCTYTGCAGGGCCC 8/90 DTX1 NM_004416 ATCCGCATCGTCTATGACATC 
GGTAGGGAGGTTTCCAGTACTCTC 
ATCGTCTATGACATCCCCACA 
GAGGTTTCCAGTACTCTCTGCTTG 
576bp SNPLex 4-53-28 
75 rs2244182:G>C NN-bottom-
acceptor 
- 0.00002 (-12) TCTSTCTGTTAACAGGACTT 8/607 FHL2 NM_201555 AGAGTTTCATCCCCAAAGACAA 
CAGAGCTGTAAATAACAACTGGTCA 
CCTGCTATGAGAAACAACATGC 
GGGACTGAACTATCACAAAGCACT 
563bp SNPLex 3-63-25 
76 rs2290124:T>C NN-bottom-
acceptor 
- 0.00002 (-6) ACTTCCTCCYTCTAGATCTC 10/41 ACTR1B NM_005735 GACCGATTACTCAGTGAAGTGAAG 
AACTGGCTACCCAGGCATC 
ACCGATTACTCAGTGAAGTGAAGA 
GTCCATGCAGCTCAATGTTACTT 
399bp SNPLex 4-39-46 
77 rs2296160:A>G NN-bottom-
acceptor 
- 0.00002 (+3) TTGTCTTCCTTTTAGGTRCA 36/24 CR1 NM_000573 GAATGGAATCTCGAAGGAGTTAGA 
AGAACAGTGACCACCTTACAAACC 
TGTGAAGATGGGTATACTCTGGAA 
ATGTCTGCGTCTCTGTGAAGTC 
435bp SNPLex 57-5-28 
78 rs2445738:C>T NN-bottom-
acceptor 
- 0.00002 (-8) TTTTTTCYGTTGTAGGACCT 3/18 GLDN NM_181789 CGAGTGATGGTGGACCTGT 
ACTAGGGTATTAGAACCCCCTTTG 
AGTGATGGTGGACCTGTGC 
CTAGGGTATTAGAACCCCCTTTGT 
806bp SNPLex 39-10-42 
79 rs2833929:G>T NN-bottom-
acceptor 
- 0.00002 (-7) ATGTCTTTKTTCCAGGACGC 31/71 SYNJ1 NM_003895 TGACTATAGTGCTGAAGTGGAGGA 
TCAGTGGTTCAGGAAGGAAAGT 
TGCCAGTCACCTACAATATCAGAG 
TTGGCTTTCAGGAGTCAGTCTT 
522bp SNPLex 3-47-37 
80 rs4751995:A>G NN-bottom-
acceptor 
- 0.00002 (+5) TATTTCTTTGGACAGGTTGR 11/112 PNLIPRP2 NM_005396 CTTTCCAAATGGAGGAAAGGA 
GCTCAGATAGATTTATCCCACGTT 
GTATTACTCAAGCAGCGTCCTCA 
- 
434bp SNPLex 26-26-38 
81 rs1205817:T>C NN-bottom-
acceptor 
- 0.00001 (-6) CCCTTGTCTYTCCAGGCCTG 7/92 POU2F2 NM_002698 AGAAATGGACCAGACACTAATCATC 
AAAACTCTTCTCTAAGGCGAAGC 
ATGGACCAGACACTAATCATCAGA 
- 
794bp SNPLex 5-56-26 
82 rs12205497:A>G NN-bottom-
acceptor 
- 0.00001 (+3) GTTTTCTCATTTCAGATRCC 5/149 CRISP1 NM_001131 GACCAATTTAATAAGCTCGTCACC 
GATGTATCAGGATGGGAGTTAAGG 
ATTGTGATATGACAGAGAGCAACC 
CACAGACAAGTGGCTTTACAGAAT 
490bp SNPLex 3-65-23 
83 rs1264894:T>C NN-bottom-
acceptor 
- 0.00001 (-6) CTTTGTTTCYCACAGGGCTG 2/30 OVGP1 NM_002557 TCACAGCTATCAGACCATTGAGAT 
CTTCCTAGAAAGCGCACATCATA 
TATCAGACCATTGAGATGTGGAAG 
- 
623bp SNPLex 27-14-50 
121 
84 rs2932777:C>T NN-bottom-
acceptor 
- 0.00001 (-8) TTTTTTCYTTTTCAGCGTGG 4/949 MRPS36 NM_033281 GAAGAGACAATCCTAAACCCAATG 
CCCTAAAACAGCAATTCTGACTG 
- 
CCATGCCTAAACAGAAAGTAAAGT
G 
592bp SNPLex 26-13-50 
85 rs4148437:T>C NN-bottom-
acceptor 
- 0.00001 (-5) TTTTCCTCATYGTAGGTTCT 3/121 ABCC4 NM_005845 CCATAAACGGAGATTAGAGGAAGA 
TGGCCATGTTACTAAGACGAAGT 
ATATGTATTCAGTGCTGCCAGAAG 
AATCATATGGCACATGGCTACTC 
395bp SNPLex 16-40-35 
86 rs646348:G>A NN-bottom-
acceptor 
- 0.00001 (+5) TTCTTCTTTTCACAGCTTCR 9/503 CCDC90B NM_021825 AGGAAAGACATGGTCATCCTAGAG 
GGTCTGAGTGACAGCTTTTCAATA 
CAAATCTGAGAGCAGAGAATGAGA 
ATAAAGACACACACCTGCACTCAC 
565bp SNPLex 14-28-48 
87 rs2704766:C>T NN-bottom-
acceptor 
- 0 (-6) TCTTTCCTTYTGTAGCATGT 3/135 KRR1 NM_007043 AGGACAATCCCAGAGGACTTTT 
TAGATCCTTTGGGACCAATAAGC 
GACTTTTGGAGGAGAGCAGTTTC 
- 
353bp SNPLex 39-7-46 
88 rs3737498:C>A NN-bottom-
acceptor 
- 0 (-6) TTATTTTTCMTATAGGATTT 2/134 SCYE1 NM_004757 ACGGTTGTTACTGCTGTAGACTGT 
GACCTACATGCTTCCTGCTGT 
ATAGAATTAGCGTGCAGTGGAGTA 
ACCTACATGCTTCCTGCTGTG 
350bp SNPLex 64-4-22 
89 rs9822885:T>C NN-bottom-
acceptor 
- 0 (-6) TTGCTTTCCYTACAGTTACC 2/1426 ARPM1 NM_032487 CCCAGTTTATCTACCCGAACATTA 
ACAAAAGCTCTCCTTGATGTCTTC 
- 
CAGACAGTAACCCTCAAAGATGG 
431bp SNPLex 52-6-33 
90 rs10101626:G>T Donor scoring/ 
NN-top-donor/ 
WD40 (Positive 
control at donor) 
18.2 0.98826 (+1) AGAAGKTAAAAAATAGTGTT 19/195 WDR67 NM_145647 ACCTAGAAATGAGACAGCTGGAAC 
CTTAATAAGATTCTGTCCCGTGGT 
GATGCCTATAGACGAAAAGTGGAT 
GTTCTACAGCCGCATTTATCTCTT 
400bp SNPLex 13-8-67 
91 rs3816989:G>A Donor scoring/ 
NN-top-donor 
(Positive control at 
donor) 
18.2 0.99659 
 
(+1) CTGAGRTACGTGTGTGATTT 4/125 TCTEX1D1 NM_152665 CAGAGCAGCTCATTCATGGAAGA 
TCACTTTTAGGATCCCAGAGGCA 
AATCATGAATTTTGGCGAAAGGAA 
TATGCTCTGCCTGTTCAGTTGTCC 
352bp Direct 
sequencin
g 
59-2-20 
92 rs2275742:A>G Donor scoring/ 
NN-middle-donor 
14.5 0.00687 (+5) TTAAGGTAARACACATTGCT 14/126 RGS7 NM_002924 ATGTCAAAAGTCGCTGACAGTCTA 
AGGCACTGGATCTTATAAAACGTG 
ATGTCAAAAGTCGCTGACAGTCT 
GAGCATCTTCAAATGTGTATCGTC 
442bp SNPLex 30-17-45 
93 rs2584627:A>G Donor scoring/ 
NN-middle-donor 
14.5 0.00299 (+5) AAGAGGTGARAGGAGCTGGG 12/156 FTSJ3 NM_017647 GTCGCTACTAAACTGGAGAACAAA 
AGGTCACTATCCAGAGATGTGTCA 
TCGCTACTAAACTGGAGAACAAAA
C 
ATCCCCTTGTGTTACTTCCTCTAA 
399bp SNPLex 9-40-43 
94 rs3749234:A>G Donor scoring/ 
WD40/ NN-
middle-donor 
14.5 0.00171 (+5) AGATGGTAARTGAAGCATTT 8/64 TBL1XR1 NM_024665 CCCTCCTAATAAAGCTGTTGTGTT 
TGTACTACAAGAAGCAAAGGTGTTG 
CTCCTAATAAAGCTGTTGTGTTGC 
TTGTCTACTCCAGCACTTAGGATG 
391bp SNPLex 59-4-29 
95 rs11046589:A>G Donor scoring/ 
NN-middle-donor 
14.4 0.00004 (+5) AACAGGTAARTTTTACCGCA 5/33 MFAP5 NM_003480 GGAGTGGCTCTGTTCATCTTATTC 
TGTTCCTTACAGACAAGACGAGAG 
AAAGTAGGAACAGCGTAAGAGGAG 
GAGTAGAGCCTTGTGCAGGTAAAT 
368bp SNPLex 6-41-45 
96 rs2298839:A>G Donor scoring/ 
NN-top-donor 
14.4 0.78973 (+5) ATGGGGTGARGAGTCTTGCT 7/130 AFP NM_001134 TCCTGTATGCACCTACAATTCTTC 
AACACTTCTCCAATAACTCCTGGT 
CCTGTATGCACCTACAATTCTTCT
T 
TGTTTGACAGAGTGTCTTGTTGAG 
377bp SNPlex / 
TaqMan 
12-34-46 
97 rs7314152:T>G Donor scoring 14.4 - 
 
(+5) CCAAGGTAAKGAGCAGAGGA 8/78 SLC26A10 NM_133489 CTTCTGTGGACACAAGATACCAAG 
CAAAGTACAGTGGTGTTGGATAGC 
TTCTGTGGACACAAGATACCAAGT 
AGTACAGTGGTGTTGGATAGCTCA 
539bp SNPLex 8-43-41 
98 rs3213591:T>G Donor scoring/ 
NN-middle-donor 
14.4 0 (+5) TGCAGGTGAKTGCTGGTGCC 17/266 MLLT4 NM_005936 CAGTCCACTTTAAGTTGTCCCCTA 
GTTGGGATAAAAGGCTCATCA 
TTCTAGATGACCCTGAAGAGAACA 
GGAATGTCATCAGGTGCATACTTA 
357bp SNPLex 17-27-46 
99 rs2076530:A>G Donor 
scoring/NN-top-
donor 
12.5 0.12612 (-1) GGTARGTAAGAATTCTAGAT 5/348 BTNL2 NM_019602 CTGTTAACCTGCCAGCTACTCCC 
CTTAGCAATGTCTGCACGTGGA 
GATGGAGTGGAGGTGACTGAGATG 
GCTGCATTTCTCCATCTTCTTGC 
619bp TaqMan 31-20-40 
100 rs1397548:A>G Donor scoring/ 12.5 0.02413 (-1) AACCRGTAAGCAACCTACAT 17/210 LPHN3 NM_015236 GCTCCTGACAACAAATAAGACACA ACATGCTCTTGTAACCACCTAACA 399bp SNPLex 10-46-36 
122 
NN-middle-donor AGTTGCTGGTCCTATAAAACTCCA CCTACGTGAATGTTCACTCTCAAA 
101 rs7214723:A>G Donor scoring 12.4 - (-1) GAGGRGTGAGTTGTCCACCC 12/74 CAMKK1 NM_032294 GAGGACAACCTCTATTTGGTGTTT 
CTGAGTTCTTAACCTCCTCCTCTG 
ACATCAAGCCATCCAACCTG 
TGAGTTCTTAACCTCCTCCTCTGT 
488bp SNPLex 18-34-38 
102 rs12690517:A>G Donor scoring 12.4 - (-1) AAACRGTAGGAATATTTTCC 17/150 ITGA4 NM_000885 GCAGAGTCTCCACCAAGATTCTAT 
ACTGTGATACTGAGGTCCTCTTCC 
TCCAGCAGAGAAGCTAACTGTAGA 
CCAATACTGCAGTCAAGTTGTACC 
491bp SNPLex 15-25-52 
103 rs11021065:C>A Donor scoring/ 
NN-middle-donor 
11.5 0.01185 (+4) AAAAAGTAMGTGTTTCAGTA 9/145 SESN3 NM_144665 AGAAAGTCTTTTTGTGGTCTCTGG 
GACATTTTCCTTGGGTGATACTTC 
TCGGATGGTCTACAATCTCACATA 
ACGAAGAGCATAAAGAAGTTCAGC 
319bp SNPLex 44-7-41 
104 rs2297889:A>T Donor scoring/ 
NN-middle-donor 
11.3 0.00202 (+4) GAAAGGTAWGTCCTTGCATC 5/154 TRIM9 NM_015163 GATGCCCTCAACAGAAGAAAAG 
GTATGTGCTGTTGAAGTGAAGACC 
GTCAACAAGGAGCATGAGCAC 
GTTGTTGTGGGTACAACATTCCT 
357bp SNPLex 54-70-28 
105 rs3755906:A>T Donor scoring/IG/ 
NN-top-donor 
11.3 0.41651 (+4) ACAAGGTCWGTGGCACAGAC 2/110 IGFBP7 NM_001553 CTCTCCTCTTCCTCCTCTTCG 
CCATGACTACTTTTAACCATGCAG 
CTCTTCCTCCTCTTCGGACAC 
CTCATATTCTCCAGCATCTTCCTT 
670bp SNPLex 29-13-50 
106 rs2285666:G>A Donor scoring 10.8 - (+4) ACCAGGTARGCTACTAATTT 3/94 ACE2 NM_021804 TTCTCAGCCTTGTTGCTGTAACT 
GTCATAGCCATCTACCCCATTTAC 
CCGAAGACCTGTTCTATCAAAGTT 
CCCATAGTCCTCATAATGATTTGC 
494bp SNPLex 66-11-14 
107 rs4681297:G>A Donor scoring/ 
NN-middle-donor 
10.8 0.02655 (+4) GAATGGTARGAGAAACACCC 3/137 PLOD2 NM_182943 GGATTCCATCGATTTATGCAG 
CTACAGCTCCATTTAAGGTCTGGA 
TTCCATCGATTTATGCAGTCAG 
ATACGGTTGACATATGGAGCATAG 
383bp SNPLex 4-56-32 
108 rs3736185:G>A Donor scoring/ 
NN-top-donor 
10.7 0.97809 (+4) AGGAGGTCRGCAGATACAAA 27/90 ITPR2 NM_002223 CAGGTGCAATTACTGGTGTCTAA 
GTCATTACCATATCCTGGCATTTC 
AAAGTCAAGTGAAAGGTGGTGAAG 
TGTACAACTCTCTCGCTAATTTCG 
454bp SNPLex 9-48-32 
109 rs27089:G>A Donor scoring 10.7 - (+4) AAAAGGTARAAAGGGGATTT 3/87 DIMT1L NM_014473 CTCTTTGGTCCTCCTTGACG 
GGTCTGAAGTTATTCTTTCCCACT 
GAGATGCCGAAGGTCAAGTC 
GCCAACAGCTGTGTATTAATTGAG 
551bp SNPLex 22-22-48 
110 rs10741752:C>A Donor scoring/IG/ 
NN-middle-donor 
10 0.00035 (+3) GCTGGGTMAGGGCAGGGCCA 14/297 IGSF22 NM_173588 CTGAGTTGTGTGTAGTGCTGAATG 
ACTCGGAATTCATATTCTGTGTCC 
GGAAAGTGAAGCCTCTGTATTCAT 
GTCACGGCTTCTTTAGTCACATC 
384bp SNPLex 4-58-27 
111 rs2272500:C>A Donor scoring/ 
NN-top-donor 
10 0.15594 (+3) ACCAGGTMTGAAGTGGAGAA 3/123 SYT1 NM_005639 CATAGTCGCAGTCCTTTTAGTCCT 
GAATGACAACAGTCAGCTTACCAG 
ATAGTCGCAGTCCTTTTAGTCCTG 
CACTTTCACGTAAGGATCAGATGT 
357bp SNPLex 44-13-35 
112 rs482082:G>A Donor scoring/ 
WD40/ NN-
middle-donor 
7.9 0.00003 (-2) GCCRGGTAAGACTCAAGAGT 16/157 WDR78 NM_024763 GCACTGAAGAAGGTCATATTCACA 
ATGCTGATTGGTTTGACTTGG 
GCAGATTGGGGTGTTATTATATGG 
TATGCTGATTGGTTTGACTTGG 
373bp SNPLex 19-31-42 
113 rs2057413:G>A Donor scoring/ 
NN-middle-donor 
7.8 0.0002 (-2) ACTRTGTAAGTAACAGCTGA 10/226 SETDB2 NM_031915 TGTACGCTGTCTAGATGACATTGA 
GTGTTGAAAAATGGCTGTCTTG 
TAGATGACATTGACAGAGGGACAT 
GAAAAATGGCTGTCTTGGATTC 
348bp SNPLex 49-8-35 
114 rs820329:A>T Donor scoring/IG/ 
NN-middle-donor 
5.7 0.00002 (+6) GAATGGTGAGWTTCCCCCTG 12/135 MYLK NM_053028 ATGTAATCTCAAAGGAGTCGAAGC 
AAAGTGGAAGTCCTCTGACTCTTG 
GAGGTCAAGGAAAATCAAACTGTC 
TCACTCTTCCTGCTACTCTTCTTT
T 
353bp SNPLex 5-44-32 
115 rs540819:A>T Donor scoring/ 
CARD 
5.6 - (+6) AAAATGTAAGWATTGAGAGT 8/103 CASP5 NM_004347 ACTCTGGGTCAGAGACTCTCCA 
TGCAAGCTATACTGGTAAATGTGC 
GCACTCATCTCTTCACAGTCATCT 
GCAAGCTATACTGGTAAATGTGCT
C 
378bp TaqMan 38-11-39 
116 rs1859143:G>A NN-top-donor - 0.99827 (+5) CAGGGGTCCRTATCCGCTCG 1/475 COL25A1 NM_032518 AAAGAGGTGTCGGTCCTCTG 
GTTGGTTTTCACACCCAGGTA 
GGAGTCGGAAGAGCTGTCTG 
- 
382bp SNPLex 20-27- 43 
117 rs764497:T>A NN-top-donor 
(Positive control at 
donor) 
- 0.9901 (+2) GTCAGGWAAAAATCCTTTCT 1/136 CCDC149 NM_173463 CGTACTAGAGAAGGGGGCCTTA 
CAAGCCTTTGCTGAAGTTCTTT 
CCTTAGGGAAGTCTCAAAATGCT 
CGGTCCTGAGAATCTCTCAATAGT 
334bp
** 
SNPLex 4-49-38 
118 rs2255089:G>C NN-top-donor - 0.97818 (+3) ACCAAGTSAGTAAGATGGGG 3/202 CHI3L2 NM_004000 ACCACCATGGACCAGAAGTC 
AAGTCAAAGGACAGGAGGTTGAT 
CACCATGGACCAGAAGTCTCT 
CCAGTTTCTCAACTTGATAGCTGT
T 
590bp SNPLex 29-18-45 
123 
119 rs2276611:G>A NN-top-donor 
(Positive control at 
donor) 
- 0.97768 (+1) TGCAGRTAAGTGGTATGAGG 1/151 PPIG NM_004792 CTCCATGCCAGGACTGAGTT 
GTCACCACCTTGAACCATAAAATC 
- 
CCTTGACAACTCTGTGAAAGAGAC 
408bp SNPLex 4-67-12 
120 rs482308:G>A NN-top-donor 
(Positive control at 
donor) 
- 0.94543 (+1) CTGCCRTGAGTGTGCCCTGC 35/305 ZAN NM_003386 GACAGTGAATTTGTGAACAGTTGG 
GCAGTTGGTGTAGCTGCTGTAG 
GAAAGATAAGGACATTGACCCAAG 
CAGTTGGTGTAGCTGCTGTAGG 
366bp SNPLex 30-16-45 
121 rs17581728:G>A NN-top-donor - 0.9381 (+5) TGGAGGTGCRGCATCTTCCA 21/144 UNC13D NM_199242 GACGGTTGTGGGTGATGTAGT 
ACCAGTTTCTGGATGTGCTTG 
GCTGCAGAAGACGTACAACG 
CAGCTGCTCCATGTCATTCA 
336bp SNPLex 30-4-39 
122 rs366577:T>C NN-top-donor - 0.83599 (+3) CCCAGGTYGGGTGAATCTTC 1/64 ENO3 NM_053013 ACTCGGAGCTCCATCCAAA 
CACTGGGAGTATGAGGTCAGG 
- 
GGGAGTATGAGGTCAGGGTTC 
479 SNPLex 16-27-43 
123 rs13119659:T>C NN-top-donor - 0.78168 (-1) CATTYGTATCCTTTATGTTT 7/111 USO1 NM_003715 CTGTGCTGTTCTCTATTGTTTCCA 
GATGCTCTGGAATACAACTCATGT 
GCCAGTTATTATGTGGAGGTTTGT 
CTCTGGAATACAACTCATGTTTGC 
513 SNPLex 44-4-43 
124 rs11944513:C>T NN-top-donor - 0.69791 (+6) CTGTGGTAAAYGAATGCAGC 8/105 ALPK1 NM_025144 CTCCATTGTAGGATATTTGGCACT 
ATTGCTTCCTTACAGAGCTGACTT 
GTAGGATATTTGGCACTTCCTCAG 
GTGAAGCTCCTGTTTTCCAGTAAC 
393bp SNPLex 47-4-40 
125 rs612862:C>T NN-top-donor - 0.65913 (-1) AGAAYGTGAGGCTTCTGCGT 8/107 MCOLN1 NM_020533 TAACCTCCAGAGCCTCATCAATA 
ACAGAAGCAGTAGCCCAGGTAG 
- 
AGCAGTAGCCCAGGTAGATGAC 
602bp SNPLex 44-9-34 
126 rs6059183:T>C NN-top-donor - 0.52847 (+7) ATTGAGTGAGTYGTCCTAAA 3/160 PLUNC NM_016583 GAGAGAGAGGAGACCAGGACAG 
AAGGCTTAGACCTTGATGACAAAC 
AGGACAGCTGCTGAGACCTCTA 
AGGCTTAGACCTTGATGACAAACT 
830bp SNPLex 2-52-37 
127 rs12148472:A>G NN-top-donor - 0.52378 (+4) CTAAGGTCRGTGCCCAACTT 2/32 CTSH NM_004390 TGAGCGCAAGAGCCAAG 
GTACCTCGAAGGTAGTTACTTTTGGT 
- 
AGGTAGTTACTTTTGGTGGCTGAG 
360bp SNPLex 2-68-20 
128 rs3214041:G>A NN-top-donor - 0.4852 (+10) CACAGGTGTGGCTGRGAGAA 23/101 PLXNB1 NM_002673 ACCTGACTCTTTGCCTGAGTTC 
TGTCAGTGAAATACTCAAGCTTCC 
CTGACTCTTTGCCTGAGTTCAC 
CTCTCCGCATACACCTTGTAGTC 
358bp SNPLex 23-32-30 
129 rs3213451:A>G NN-top-donor - 0.48481 (-3) CARTGGTATTCTTCATCTTC 23/149 MBTPS2 NM_015884 ACTGTCGTCTACCTGACCGACT 
AAAATATCCTTAGCTGCTGGACTG 
CTGTCGTCTACCTGACCGACTT 
GAGTGGTGAACAGATCAACAAATG 
579bp SNPLex 37-33-20 
130 rs3745779:A>G NN-top-donor - 0.47897 (+10) TGGTGGTTAGTGCTRTTGTT 1/149 ZNF529 NM_020951 TATTGAGTTAAGCCTGGCGAGT 
CTGTAGTTCTCCATCATCACATCC 
- 
CTCTGAGCAGAATCCAGATATTCC 
376bp SNPLex 60-3-28 
131 rs3752703:C>T NN-top-donor - 0.45006 (-4) GYGGTGTATGTTAGCTTGCT 28/123 PTPRB NM_002837 AGTGAAGCTCTCCAATGTAGATGA 
TCTGTTGATGTAGTCCCTGACAGT 
GACTACATCAATGCCAGCTACATC 
ACAGTTCTCACAAACTGGATCAGA 
395bp SNPLex 39-12-39 
132 rs2290158:G>A NN-top-donor - 0.43618 (+3) GAGAGGTRAAGCCACAAAAT 6/163 SCRN3 NM_024583 CCCAGACATGAGAAACTATGCTAA 
CCTGTTGATGTTTTTGGTAGAGTG 
GCAGCATATTCCTATCTTGACACA 
GGTGTCTTCTGTCAGGCTTAAAAT 
376bp SNPLex 44-5-42 
133 rs11161721:G>T NN-top-donor - 0.38675 (+9) CTTCAGTAGGTTTKAACTTT 18/54 COL24A1 NM_152890 CCAGGTGACTTTGGAGACAGA 
CTTTAAGCCTTCTGGTCCTGGT 
AGGGAATAAAGGACTACCTGGAAT 
- 
406bp SNPLex 8-47-32 
134 rs3746657:C>T NN-top-donor - 0.3748 (+4) CATGGGTGYGTCCACGCAGT 12/124 OSBPL2 NM_014835 GATCCTGTTTCGTATGAATCCTTC 
GCGAACTCAGTCGTTAGAAAAGTT 
GTATGAATCCTTCAAGAAGCAGGA 
GAAAAGTTGGTTTCTGCTGTGAC 
603bp SNPLex 30-15-46 
135 rs217375:A>G NN-top-donor - 0.36602 (+14) TCCAGGTCTGCCACAGCCRA 6/245 DDX56 NM_019082 CATGTCAGCTACTTTTAACGAGGA 
GCAGACACATGGTGGAAGTCTAT 
GTACAAGCACTCAAGGAGCTGATA 
AGACACATGGTGGAAGTCTATGC 
456bp SNPLex 29-20-43 
136 rs7298440:C>T NN-top-donor - 0.34257 (+7) ATCGGGTAATCYGGTTTGGT 12/81 TCTN2 NM_024809 GATCAACCCCTAGAATTGTGAATG 
TAAGATCAGCGTAATCGGAGTTG 
CCCTAGAATTGTGAATGTGGAAG 
ACTTCTAACAGGCATCCAGAGAGT 
351bp SNPLex 39-9-43 
137 rs913742:A>G NN-top-donor - 0.34138 (+12) GCGAGGTGACTATTCTRCAT 14/54 C14orf101 NM_017799 GACCCAACCTGGAAAAAGAACTAT 
CACCTAAAATATCAGCTTGCTGTG 
GGGTCTTGTGACAAATTAGTTCCT 
TTTCTGAGAGTACAGACGGAAATG 
408bp SNPLex 57-5-30 
138 rs9352:C>T NN-top-donor - 0.31219 (-3) TGYGGGTGAGAAGGGCTGTA 14/97 CHAF1A NM_005483 TCATTTCCGAGAACTCAGTGTATG 
GACAAAGTGCTCTTTACACAGGAA 
ATCTCGCTGAAGAGGAAGTCAG 
GAGGACACCCTAAGCATTCTACAT 
312bp SNPLex 25-24-42 
124 
139 rs1584614:G>C NN-top-donor - 0.29227 (-5) STTAGGTAATCGCCGTCCTT 1/46 LSM5 NM_012322 ATGGCGGCTAACGCTACTAC 
CGGTTGTTTAAATGCACCTGT 
GCGGCTAACGCTACTACCA 
CAAACTTTGTTCCACTGGCTACT 
546bp SNPLex 3-66-23 
140 rs10134181:A>G NN-top-donor - 0.2896 (+10) CAACTGTGAGTTTTRTTTTG 2/123 TC2N NM_152332 TGGAAGTTTGTGTCTTTTGCTG 
TGGAAAGTTCTACCTTTCGATCTC 
TGTGTCTTTTGCTGGATATTGG 
GAAAGTTCTACCTTTCGATCTCCA 
378bp SNPLex 22-20-50 
141 rs759935:T>C NN-top-donor - 0.28446 (+5) TGCAGGTGTYGTATTGTCTT 15/220 GNPTAB NM_024312 CTGGGAGGCAACTAAAAGATACAT 
CTGAGCATCTTTATGATTGTGGTC 
ACATTTGCAGATTCCCTCAGAT 
CGATTTCTTCTTCTCCCATGAT 
577bp SNPLex 25-24-42 
142 rs2049129:A>G NN-top-donor - 0.26322 (+9) CAATGGTATGTCARTCCTAA 20/107 HPS5 NM_007216 TTTGGCCTATTTAGACAGTCTGGT 
CATGGCCTTAGCTAACAGAAGTG 
ACCAGAGTCTTTAAGGTTGGATTG 
GTGCTCTTGCTCTGTATGAGATGA 
378bp SNPLex 66-2-23 
143 rs2287761:G>C NN-top-donor - 0.22643 (+5) ACAAGGTGCSGGGAGGACTC 9/135 PPFIA3 NM_003660 GAAGATATGGAGGAGCGGATTAC 
CTTCTTCATGTTGGCTATCTCCTC 
GAACGAGTTAGCTAGCAAGGAGTC 
GCTCCTTGAGGTGAAGCTGTAA 
365bp SNPLex 4-56-29 
144 rs3765115:A>G NN-top-donor - 0.21477 (+3) TTCAGGTRCCAAGTATTGGT 28/238 SCAPER NM_020843 CCTTTTAACAATCGAGTTCAGGAC 
GTTGTTGTAACAAGCAGCGATAAG 
ATGTGTACACTGTGCTTTGCTGT 
GAAGGGAACAGTACTTTGATCAGC 
524bp SNPLex 18-38-36 
145 rs4799570:A>C NN-top-donor - 0.21198 (-4) GMTTTGTAAGTACTCAATTA 12/297 DSG4 NM_177986 ACATTCTTATGGGTCTCCGTTTAC 
CAATTCTCCAAGACTGCATCACT 
ATGTGGGATGTCAGATCAACAA 
CCTTCTGGCTGTCTCTGTTTG 
374bp SNPLex 2-75-13 
146 rs641018:G>C NN-top-donor - 0.18927 (+12) GAGAGGTGCTCACCCTSTGG 2/199 FIBP NM_004214 CAGTGAGCTGGACATCTTCGT 
TCCAAGGGTCCAGTTTTGG 
CCTTATCGACGAGGACGTGTAT 
CTGATGTCATCCAGGTCTTTCTT 
333bp SNPLex 54-4-32 
147 rs314359:A>G NN-top-donor - 0.16369 (-5) RCATGGTGGGTTGCCCTAAT 10/65 EPHB4 NM_004444 GTCATTGTGGTCGCAGTTCTC 
CCACATCACAATCCCGTAACT 
GTCGCAGTTCTCTGCCTCA 
CCGTAACTCCAGGCATCACT 
749bp SNPLex 16-31-45 
148 rs263042:A>G NN-top-donor - 0.16243 (+10) CTGAGGTAACCCACRTCTGC 26/80 YEATS2 NM_018023 GGTTCAGTCATTTTCTACCAGCA 
TTGGTTTTGAGGGGAGTCAG 
GTTCAGTCATTTTCTACCAGCAAG 
GTGGTGAAATCTCGGATTCTTCT 
423bp SNPLex 25-23-43 
159 rs3764913:A>G NN-top-donor - 0.16176 (+11) GCAAGGTGTGTAAAARAGGA 5/67 ACADL NM_001608 CCCAGGTTTTAGTATTCATTCAGG 
CTGTCTGTAGGTGAGCAACTGTTT 
GTATTGGTGCAATAGCAATGACAG 
GAAGCCTTTATTCTCTTCTCCAAG 
347bp SNPLex 13-38-39 
150 rs2075772:A>G NN-top-donor - 0.16032 (+13) GGAATGTATCCTTCCTCRCC 4/75 VASH1 NM_014909 GTACAATCACACAGGGACACAGTT 
ACATCCTTCTTCCGGTCCTT 
AATTAAGAAGAGCAGACCTCTGAC
A 
CAGCTTCACCTTCTTGAGCAC 
349bp SNPLex 34-12-42 
151 rs3739085:T>C NN-top-donor - 0.15407 (+4) GAGTGGTAYGTTTCCTAGAG 9/142 DPYSL5 NM_020134 ACACCAACACCTCAACCTACCT 
CTCTCTGGACCAGCTTCTTGTAG 
CCAACACCTCAACCTACCTCAT 
TTCTCATACAGGTTGAAGTCTCCT
C 
376bp SNPLex 29-11-51 
152 rs1983764:C>T NN-top-donor - 0.15323 (+12) AACAAGTGAGCCTACCYGGT 31/114 NIN NM_020921 CCAGAGATAGCTACTCATCCATCA 
GCACAAATATGAGTGTACCCTTTG 
TCAGAAAGAACAATCTCCTGCTAA
C 
ACTTCCAGAGCTTTCAACAACTG 
528pb SNPLex 9-42-39 
153 rs4252120:T>C NN-top-donor - 0.14322 (+9) AATGCGTATGTCTYTGATTT 10/160 PLG NM_000301 TGAAGGGAACAGGTGAAAACTATC 
TCTACATCTGGAAGCAGGACAAC 
ATAACAGGACACCAGAAAACTTCC 
GCTTCTGTTCCTGAGCATTTTT 
457bp SNPLex 7-45-39 
154 rs1130638:C>T NN-top-donor - 0.13898 (-1) GTAAYGTGAGCTCTTGCCCT 4/108 LASP1 NM_006148 AGAACTACAAGGGCTACGAGAAGA 
TCCTTGTAGCCACCATAGGACT 
GAACTACAAGGGCTACGAGAAGAA 
TTGTAGCCACCATAGGACTGG 
435bp SNPLex 38-14-38 
155 rs7495739:A>G NN-top-donor - 0.12707 (+9) GCAAGGTGGACACRGTTATA 5/183 MPI NM_002435 ACAACCGCATCTCACAGAAGA 
GGTAAGCAGGTTCAGGAAGTAGAT 
CTTCCTCTTCAAAGTGCTCTCAGT 
TAAGCAGGTTCAGGAAGTAGATGG 
497bp SNPLex 25-26-40 
156 rs2074189:C>A NN-top-donor - 0.1224 (+9) CCCAGGTGGGATTMTTAGAC 18/79 OSBPL7 NM_145798 GCCATGCAGAGTCTGAGAACTT 
AGCTCTGCTGTCAGCTCATTC 
CATGCAGAGTCTGAGAACTTCG 
GTGCCACTTCCCAAAGAGTC 
351bp SNPLex 18-23-49 
157 rs743128:T>G NN-bottom-donor - 0 (+14) ATAAGGTGAGTGCTGGGGKC 6/88 ACTN1 NM_001102 ACAAGATCTCCAACGTCAACAAG 
GGAAGTCCTCCAGCTTCTGTT 
TGGATTTCATAGCCAGCAAAG 
GTAGTCTTCCATAAGCTGCTCGTT 
548bp SNPLex 36-10-44 
158 rs1866846:A>G NN-bottom-donor - 0 (+14) GGAAGGTATGTACCTGCTRG 3/87 KIAA1429 NM_015496 CTCATATAGATGTGGTTCGTTTTCC TATCAATGAAGTCCGAGTCATACC 488bp SNPLex 4-56-32 
125 
TGGGCTCAAAGTAATCTTCTCTATG CAGGATCATCTTCATCATCATCAG 
159 rs2114724:A>G NN-bottom-donor - 0 (+14) CAGAGGTAAGGATGCGGCRG 22/188 DNMT1 NM_001379 TAAATGAATGGTGGATCACTGG 
CGAAGAAAGTATCGAAGATCTGGT 
AGATCTACATCAGCAAGATTGTGG 
- 
384bp SNPLex 34-17-41 
160 rs2276825:A>G NN-bottom-donor - 0 (+14) TCACTGTAAGTGTTCCCTRT 3/96 TMEM110 NM_198563 CAGAGAACCAAAGCATGAAAGAC 
CCACTGAAGTATTAGGAGGACGAT 
- 
AGTATTAGGAGGACGATGAAGACG 
357bp SNPLex 6-53-32 
161 rs2277439:G>A NN-bottom-donor - 0 (+14) AAAAGGTAAGTCCACATCRA 2/168 TNFSF11 NM_003701 GCCAGCAGAGACTACACCAAGTA 
AGGACAGACTCACTTTATGGGAAC 
GCCCTGTTCTTCTATTTCAGAGC 
GTGGCATTAATAGTGAGATGAGCA 
326bp SNPLex 59-3-29 
162 rs2279090:A>G NN-bottom-donor - 0 (+14) ACCAGGTACGTGGCCGCCRC 13/196 ADAM12 NM_003474 CCAGAAGTGTGGGAACAGATTT 
CGTGAACCCCAAAGACACTAATA 
AACAGATTTGTGGAAGAAGGAGAG 
CATGTCATCGCCCAAGTACA 
594bp SNPLex 3-76-11 
163 rs2303180:G>A NN-bottom-donor - 0 (+14) CGCTGGTGAGTGGCTGTGRT 5/210 MARCH2 NM_00100541
5 
CAGTATGTGGCACAGGTGACTT 
GAACTGTTGAAGTGGAAGTGTTGA 
AGTATGTGGCACAGGTGACTTC 
GGATCTTCAGGCGAACTTTCT 
552bp SNPLex 41-6-42 
164 rs4806711:A>G NN-bottom-donor - 0 (+14) GAGAGGTGAGTGTGATGGRG 1/341 PRPF31 NM_015629 AAGGCCTTGCTTTCTTGTCTAAC 
TACTTATCCCGGATGAACTTATGG 
- 
CTTTGGCTTGCTTGCTGATATAC 
564bp SNPLex 59-5--25 
165 rs7300317:A>G NN-bottom-donor - 0 (+14) AGACGGTGAGGACCATGGRG 4/96 KRT7 NM_005556 ACAGCTGCTGAGAATGAGTTTGT 
GGTTCATCTCTGAAATCTCATTCC 
ATGAGTTTGTGGTGCTGAAGAAG 
TGAAATCTCATTCCGGGTATTC 
353bp SNPLex 12-24-54 
166 rs11068780:G>A NN-bottom-donor - 0 (+14) AGTCGGTGAGTCTCCAGCRT 5/101 WSB2 NM_018639 ATTGGAAGTCCAGCTGTGAAAC 
GCACACAGATCTCAGTGAGCTAAT 
GACACTGCATCGTCAAACTGAT 
GTCCCACATAATCACATTGGTATC 
665bp SNPLex 61-3-26 
167 rs12141283:A>G NN-bottom-donor - 0 (+14) CCCAGGTGAGTGAAGGGGRA 4/106 NFASC NM_00100538
7 
AATTTGGGACGCTGGAGTTTA 
GTTACAACTGTAGTCGGTCTGCAT 
AACAGAGCCTCCTCTGGTGTT 
CAGCATCACGTTGGAGAAGTATAG 
735bp SNPLex 35-19-34 
168 rs31725:C>T NN-bottom-donor - 0 (+15) GCCAGGTGAGGTCCGGGTAY 17/922 PLEKHG2 NM_022835 GACCTCAATCACTGAAGAAATCCT 
ACAAAGGTATGGCAGCTTGAAC 
- 
CAAAGGTATGGCAGCTTGAAC 
1099b
p 
SNPLex 24-19-47 
169 rs421587:A>G NN-bottom-donor - 0 (+15) TCCAGGTAAGTCAACTCAAR 28/54 COL1A2 NM_000089 CAACATTGGATTCCCTGGAC 
GGTTACCAATTTCACCTCTGAGAC 
- 
GCTTCCAATAGGACCAGTAGGAC 
355bp SNPLex 39-8-45 
170 rs931479:A>G NN-bottom-donor - 0 (+15) TACAGGTGAGGGGTTAGGCR 7/221 KRT4 NM_002272 CCTGAAGAACACCAAGAGTGAAAT 
AAGCCACTACTCAGGCCAAAC 
AGATCGAGAACATCAAGAAGCAG 
ACTTCCTAATCCTCCGCTGAT 
332bp SNPLex 67-5-18 
171 rs2042792:C>G NN-bottom-donor - 0 (+15) CCCAGGTCAGTGCACAGGAS 11/144 SPAG16 NM_024532 CACCAGAAGGTCCTACTCAGAAAG 
CATGTGACCATAAAGTGACTGCTC 
GATATGCAACCAAATCCAAACC 
TGTTCTTGCATCCCATATAGACAG 
567bp SNPLex 26-14-52 
172 rs2070615:A>G NN-bottom-donor - 0 (+15) GCCAGGTGAGAGTTGGGCCR 4/116 CACNB3 NM_000725 GGTTCAGCCGACTCCTACAC 
CGCTCAATGATGGTCCTCTT 
GCCCATCTCTGGACTCAGAC 
TTGTTGAGCACAGATCGCTTT 
622bp SNPLex 17-27-48 
173 rs2240999:C>G NN-bottom-donor - 0 (+15) ACCAGGTGAGGAGGGAGTGS 7/110 SPHKAP NM_016532 GACCTCATTATCTGGTTTGGAGAC 
TTGAAGAGTAGCTGACCATCATGT 
- 
GTACGTCATGTGGCTGCTGTAG 
366bp SNPLex 3-67-20 
174 rs2241920:G>A NN-bottom-donor - 0 (+15) TGGGGGTAAGTCCTCTCCAR 1/210 MS4A14 NM_032597 ATGTTTGCTCACTCTTTCCCTTAC 
ACTGGAAAACTCTTCTTGAAGCAC 
CCATAGAATCATGGAGTCAACATC 
GGCAGGTTGTTCACTATTTTGAGT 
529bp SNPLex 34-11-45 
175 rs2248619:A>G NN-bottom-donor - 0 (+15) AGGAGGTGAGGGGCTCTCAR 4/96 KRT83 NM_002282 TTTGCTGGCTACATCGAGACT 
GTCATCATACTGTGCCTTGATCTC 
CTGGCTACATCGAGACTCTGC 
- 
386bp SNPLex 13-26-43 
176 rs2287483:C>T NN-bottom-donor - 0 (+15) CTCCGGTAAGGGGAAGTGTY 1/129 GPR160 NM_014373 TGCAGTCCGGAGACGAA 
TCTATACAAGCTGTCAGGAAAACTG 
- 
GGCAGATGTGGTATTTAGTGAACC 
576bp SNPLex 2-73-16 
177 rs3740522:G>A NN-bottom-donor - 0 (+15) AAAATGTGAGTGTTGACGGR 5/227 ARHGAP19 NM_032900 ACCTGAGATTTTCACTGAGTTGGT 
ACATGAAGCTATGAGGTCAAGGTC 
GCCCAGATATACCAACTGATTGA 
AAATAGTGCAATCTCGCACACTC 
602bp SNPLex 33-15-42 
178 rs4957318:G>A NN-bottom-donor - 0 (+15) AGCAGGTATGTGCAAGTACR 9/142 FYB NM_001465 GAACAAGACAGTGAAGGAGAAACA 
ATCAGAGGTATCCACATCATCGTA 
CTAACAGGCCCTATTCAAGTCATC 
CACATCATCGTAAACTTCATCTCC 
585bp SNPLex 48-9-34 
179 rs6510801:G>A NN-bottom-donor - 0 (+15) CCCAGGTACGGGAGCCAGCR 2/360 TMIGD2 NM_144615 GGTGATGGGCCAGGAAT - 607bp SNPLex 32-12-45 
126 
GAAGGAGGTTGAATAAATGCTCTG GGTATAGGACGTTGCTGTAGAATG 
180 rs9644114:A>G NN-bottom-donor - 0 (+15) CTAGGGTAAGTACCGGTCAR 5/150 BNIP3L NM_004331 AGAAGATGGGCAGATCATGTTT 
ATGTAAAAACAGGGTGGTAGGTTG 
GCAGATCATGTTTGATGTGGAA 
CATGCTTACAATGGTCTCAAGTTC 
446bp SNPLex 47-8-35 
181 rs17688121:G>A NN-bottom-donor - 0 (+15) CACTGGTAAGTTTCCACTGR 4/69 EVC2 NM_147127 CTGTCACTTTAAGACTGCAGTGGA 
CATGTTTCCCTTCAGACACTGATA 
GTCTTCATCCCACTCTCAACTTCT 
GTTACGTTTTCTTCTGCTGTTATG
G 
545bp SNPLex 73-2-16 
182 rs232518:T>C Normalized ESE 
scoring/IG/ NN-
middle-acceptor 
1.508 0.00508 (+5) AATCGATGTAAACAGAGCCY
GGACGGCCGTATCGAAGTCA
AAGGG 
9/151 NCAM2 NM_004540 GAGAATGGTCAAGTCACACTCGTA 
TCCAAAGTCATTGTCAGATGTAGG 
GGAGCCTATTCCAGAAATCACTT 
GGTCGTGTTTTTAGCAGGTAAGAC 
364bp SNPLex 14-34-44 
183 rs1348689:C>T Normalized ESE 
scoring 
1.508 - 
 
(+15) TTATTTTCTGTTTAGAATCC
TGGCTATGCYGGACGGCAGG
AACTC 
38/195 DNAH5 NM_001369 TGCACTGACAGGCTTGTAATAACT 
AATAGCTGGATGACCTTCAGTTTC 
CGTATTGATCTACCAGTTCTCTCG 
TCCGAAGAACTGACAGAATGTTAC 
385bp SNPLex 38-11-43 
184 rs4964287:C>T Normalized ESE 
scoring/ NN-
middle-acceptor 
1.508 0.008 (+5) TCAATGTTGTTGTAGGTCTY
GGAGGAACATGTGTGAATGT
GGGTT 
5/120 TXNRD1 NM_003330 AGGGCAGACTTCAAAAGCTACTAA 
CACTGCTGATGCAGTATTCTTTG 
TTCCCAAGTCCTATGACTATGACC 
CCCATAAGCATTCTCATAGACGA 
377bp SNPLex 44-11-37 
185 rs2274980:C>T Normalized ESE 
scoring 
1.508 - (+29) CCTTGTGGGTTTCAGGTTCT
CTTAGTGCTCGATGTGACAA
CTCYG 
3/136 LAMC2 NM_018891 GGAACTTCACAGACAAACTGGTAA 
- 
CACAGACAAACTGGTAATGGATTC 
CATCTTGATGAAAGGTAGAGGTGA 
514bp SNPLex 5-66-21 
186 rs3813795:A>G Normalized ESE 
scoring 
1.318 - (+24) CCACCTCCCGCACAGCTTCG
TGCTGCCTGATGACAGCCRG
GCCAG 
14/206 SYTL1 NM_032872 GAATCTGAATCCGGTTTTCAAC 
GTCCAGAGAGAGAGGCTTGGT 
AACATCTTTCTGGGCGAAGTT 
AGGTTGGTTCTGAGGGGTAGA 
592bp SNPLex 10-44-33 
187 rs2278211:G>A Normalized ESE 
scoring 
1.318 - (-13) ACGAAGCATGCACAGACRGA
GATCATTGAGGTGGGTGCTG
GTGGT 
5/119 INPP4A NM_001566 CAAGAAGCACATCATCACCAAT 
ATTTCAGCAAAGTGTCCTTTCG 
AAGAAGCACATCATCACCAATG 
TGATGTTACCTACACGGTCACTCT 
526bp SNPLex 65-4-23 
188 rs7603997:G>A Normalized ESE 
scoring 
1.318 - (+14) TAACATTTTCTTTAGGACTC
TGGCTGACRTTGATGGTGAT
GGACA 
10/138 ITSN2 NM_006277 CAGCCTTTACCCATTCCTTATTCT 
CTTCCTTTTCTTTCTGGGCTTTAC 
GCCTTTACCCATTCCTTATTCTTC 
ATTTCTTCTGAGGCTCCTCTTCTT 
548bp SNPLex 43-4-45 
189 rs3177168:G>A Normalized ESE 
scoring 
1.318 - (+15) ATCTTTTACGTACAGCGGAA
AGAACACCCRGAAATGAAAG
GCCAC 
2/41 MRPS35 NM_021821 AAGGACTCTGCGTGCATTCT 
CTGATGAAACATAATCAGTGCTGTC 
CATTCTCCACTGCCGTCTACT 
ATGCTTCTCACATTTCTCGTCAC 
377bp SNPLex 4-68-20 
190 rs16890979:G>A Normalized ESE 
scoring 
1.318 - (+30) TGCCTCTGTTTGCAGCCTTC
CAAACGTTCTTGGGTAAAGC
AGACR 
4/188 SLC2A9 NM_020041 TCATCATGGGCATAGATGGAG 
CCCTGTACTCAAGGTGACGTATG 
ATACCTGTTTGGAGTGATTGTGG 
CCTGTACTCAAGGTGACGTATGG 
387bp SNPLex 62-4-26 
191 rs2289043:T>C Normalized ESE 
scoring 
1.29 - (+26) GGCATGTCATTATAGGAAAT
TTTACATCTTGAGAGACAGA
YGGGA 
13/150 UNC5C NM_003728 ATGGATGACTCTCAGACACTTTTG 
GTTTCTTTGAGATCCACTCCAAAC 
ACTGGAAAATACTGCTCAAGAACC 
GAGATCCACTCCAAACATGGTAA 
465bp SNPLex 42-15-34 
192 rs1566088:C>T Normalized ESE 
scoring 
1.29 - (+21) ACTATTCCATTTTAGGATGA
TGACTTGGAAACAGAYGTGA
ACAAG 
2/117 AGBL1 NM_152336 GATGGGCCAGTGCTATAATTTG 
CCATATAAAGATAGGGATCGTGGA 
GGGCCAGTGCTATAATTTGG 
GGTACAGGTTCACTCCAGGATTT 
371bp SNPLex 34-17-41 
193 rs761422:T>C Normalized ESE 
scoring 
1.29 - (-17) CAGTGTGTGCCCAYGAGGAG
CTCCTCCGAGGTAGGAAGGC
CACCT 
8/74 MFAP2 NM_002403 CGCCTCTACTCCATACACAGG 
GTAGGAAATCCAAGCAGACCAG 
TGCAAACAGTGTCTCAACGAG 
CTGCAGTCCACTAACTTTTTCAGA 
331bp SNPLex 21-15-56 
127 
194 rs2227255:C>T Normalized ESE 
scoring 
1.29 - (+24) TGGCCCGCCCCCCAGGTCTA
CGTGTTGAAGCGTCCTCAYG
TGGAT 
5/93 CTDSP1 NM_021198 AGACAAGATCTGCGTGGTCAT 
AGCTCTGTGTCACTCATGTTGTC 
CTTCATCATCCCTGTGGAGATT 
TGTGTCACTCATGTTGTCAAACC 
357bp SNPLex 13-35-44 
195 rs767050:C>T Normalized ESE 
scoring 
1.29 - (+24) TTCCTGTGCTTCCAGACCTC
AAGCATCTGCAAGACAGCYG
TGCAC 
14/134 CRISPLD2 NM_031476 CTGCAAAGACGAACCTTCCTAC 
CACTGAACATCAGTCAAAGGAAGT 
CAAAGACGAACCTTCCTACTGG 
AAGGAAGTTTCCTGACTCTCCATA 
350bp SNPLex 33-15-44 
196 rs2279103:C>T Normalized ESE 
scoring 
1.29 - (-12) GGTCCCGAGAATCTCAGAYG
AGAAAGAAAGGTGGGTAACC
TCCTT 
3/167 CTDP1 NM_048368 GGATAAGTCAAAGTCCAGGTCAGT 
AGGACTTCCTGGAGAAGATCG 
CCATTTTCTAAAACGGGAAACC 
TAAGTCAAAGTCCAGGTCAGTGC 
526bp SNPLex 55-4-30 
197 rs1465567:T>C Normalized ESE 
scoring 
1.29 - (-28) GCYGGCCCAGTGACATCATC
CGGACCCTCTGTGAGTACCA
GGGTC 
6/167 EGFLAM NM_152403 TATCGTGTGAGCATAGCAGCTTA 
CCTAGAAATGGTCTTTGGGTTAGA 
CGCCCCTATTCAGTACTATTCTGT 
TTCTTATTCCCTCCTTTGGTAGC 
357bp SNPLex 59-6-27 
198 rs11065772:T>C Normalized ESE 
scoring 
1.29 - (-28) GAYGTTAATCTGCCGGCCGC
CCAGCTACAGGTGAGAAAAT
GGGCT 
10/171 ACACB NM_001093 CAGTATGGGAATGCTGTGTCTCT 
TGAAGTAACCCCACACGTTCTT 
GTATGGGAATGCTGTGTCTCTGT 
GGGTTTCAAAAGAAATGGGAGT 
386bp SNPLex 64-5-23 
199 rs5749104:T>C Normalized ESE 
scoring 
1.29 - (+19) CCCTCCCCCTGACAGGTGGC
AGTTCTCATCTGAYGGTGCG
GACAT 
11/170 SEC14L3 NM_174975 GTTTGCTGAAACTCATCAGTCCT 
TCACTAACGTCACAGAGTCAGGAG 
AGGTGAAGACTCAGTACGAGCAC 
AGGGGTGAGCTCCTTATCATATTT 
380bp SNPLex 14-27-51 
200 rs3741475:C>T Normalized ESE 
scoring 
1.29 - (+23) CTTGTACCTCCACAGGTGTC
ATCAGTAACTGGACAGAYGA
GCTCC 
22/170 NOS1 NM_000620 ACCAGATGGTGAAAGTGGAACT 
GCACTTCATCAGGGTACATGTCT 
AGATGGTGAAAGTGGAACTGCT 
ATCTGGATAGATGGGAACTCCTC 
298bp SNPLex 4-60-28 
201 rs17612126:C>A Normalized ESE 
scoring 
1.281 - (+25) GCGGGTCTTCTCCAGGACAT
CCGGCCACAGATCTGCCCAM
GGAGG 
14/173 IGHMBP2 NM_002180 AGGTTCATCACTGTGAGCAAGA 
GAGCTCACTCAGCTTCTTATCCA 
GCAGCAGAAACTTCCAGAAAAG 
CAGCTTCTTATCCAGCCTCCT 
361bp SNPLex 9-46-37 
202 rs3828323:G>A Normalized ESE 
scoring 
1.191 - (+15) CTGTTCTTGTTCTAGATACT
TCTGGACACRGTGTAAATAC
ATCTG 
24/239 PLA2R1 NM_007366 TTCCAAGTCACAATACCACTGAAG 
GGAATAGATGTTTCTGAGCACAAC 
GGTATTTTGAAGACTGTGGAAAGG 
GTGTTCAGATTGTCTTGTTTCAGG 
485bp SNPLex 23-25-42 
203 rs2071624:C>T Normalized ESE 
scoring 
1.188 - (+16) ATCTCTCTCTGACAGTTGCT
GGGATACAAAYGACCACAGT
GTGCC 
9/70 VIPR2 NM_003382 GTCAAGGACGACGTTCTCTACTC 
GCACAGCTCAAACAGTATCTGGTA 
AAGCTGAGCCTGGTCTTCCT 
TATCTGGTATTTGGAGGAGATGCT 
465bp SNPLex 57-4-31 
204 rs10950854:C>T Normalized ESE 
scoring 
1.188 - (+13) TCTTAATGTTTGTAGGCCAC
CGTCAAAYGAAAGGATAATA
CTTCA 
4/190 DNAH11 NM_003777 GTTGTCTCTTGGACATGTATCTGC 
ACTCCAGATCAGACAGATGGTATG 
GACATGTATCTGCTTTCCTTGATG 
CCAGATCAGACAGATGGTATGAAA 
647bp SNPLex 26-20-46 
205 rs12386051:G>A Normalized ESE 
scoring/IG 
1.115 - (+8) TCTCATCTCCTCTAGTTCCC
ACRGTCCCTCCGGGCAATGT
GCACG 
12/116 SDK2 NM_019064 ATTCTCAAGGGTTACATCATCAGG 
GTGTTGGTTCGATTGTACTCCTC 
GGGGTACCAGTTTAAGAACATCAC 
ATGTGTCCAGGATCTCACTGAAG 
518bp SNPLex 60-5-36 
206 rs2295773:T>C Normalized ESE 
scoring/ WD40 
1.078 - (-19) GAAGTCCAGCAYATGAGACA
GGCTGACAAGGTTTGAAGGG
CTTGG 
9/162 SEC31B NM_015490 CAACACATTCTGTCTTCTGCTCA 
TTCAGATTCTGTGGTGACTTGACT 
GGATCTCAGGAAGAATGAACCTAT 
TTCAGATTCTGTGGTGACTTGACT 
582bp TaqMan 60-4-28 
207 rs1878061:G>A Normalized ESE 
scoring/IG 
0.981 - (-26) CACCRGGGAGGTGTTGACCC
AAAATTCAGGGTAAGCACGC
AGGGC 
3/109 CD300E NM_181449 AGAAGAGAAGGTGGAGAGGAATG 
CATCCAGTCTGAAAGGTTGACTC 
AAATTCAGACAGTGTGGGTCCT 
ATCCAGTCTGAAAGGTTGACTCC 
383bp SNPLex 33-16-42 
128 
208 rs12593397:G>A Normalized ESE 
scoring 
0.977 - (-11) GGTGCCCAGAGCCTTCACCR
CAAGCACAAGGTAATAGCCC
TCTTC 
24/187 SPTBN5 NM_016642 CCCTACAGAGCTCGGAAACA 
CCAGTAAATGGCTAGTTCCTCCT 
CATCCTGGAAGAGACCCAGA 
CAGTAAATGGCTAGTTCCTCCTGT 
567bp SNPLex 36-12-29 
209 rs7669741:C>T Normalized ESE 
scoring 
0.974 - (-15) CGAAGCCCTAGTGCAYCTGC
TCCACAGATGGTATGAAGAC
TTTTT 
18/110 KIAA0922 NM_015196 GAGCCTTTCTCTGGATCAATCTAC 
TAACTTTTCCATAGTCAGCAGGTG 
CAATCTACCTGGAATGTGGATTCT 
AACTTTTCCATAGTCAGCAGGTGT 
516bp SNPLex 49-11-32 
210 rs3762672:G>T Normalized ESE 
scoring 
0.948 - (-30) KCTAGTAAACCAAGTGACAT
GTCAGTACAGGTGAGGCTAA
AACCT 
36/75 DNAJC13 NM_015268 ACTTCAGATGACCTCCTTTTCTCA 
AGCAAGTTTTCTAGCAACATAGGG 
CAGAGCTAGCTTTCCATACTGTCA 
TAGGTGTGTCTGTAGCCAGAAATC 
347bp SNPLex 25-21-46 
211 rs842823:A>G Normalized ESE 
scoring 
0.93 - (+11) TTTCCTTCTTTATAGGGCCT
ATTCCRCTAGAAGCAAGATG
GCTGA 
3/61 LOC26010 NM_015535 TTCAGGAACATTGCTGTGGAT 
GATCTTCTTCACGGAACTATCCAC 
TCAGGAACATTGCTGTGGATT 
GATAAGGGCTGGTTTTTCGTTAG 
432bp SNPLex 41-11-40 
212 rs1001420:C>T Normalized ESE 
scoring 
0.893 - (-22) GATTTCTAYAGGCAATTCTG
TGTGAAACTGGTGAGTGTCC
AATAG 
40/132 FLJ40243 NM_173489 TATCATCAGAGGCCTGTATCACC 
CTAGTAACTCCACATATTGGCTGGT 
CTAACAGGAAGAAGGTGGAAGATT 
AGTAACTCCACATATTGGCTGGTC 
380bp SNPLex 9-44-39 
213 rs7303113:A>G Normalized ESE 
scoring 
0.892 - (+19) TCTGTTTTATTCCAGACATG
CTGGTGTCTACACRGCAGAA
GAAGT 
5/168 C12orf41 NM_017822 GGTCTCAGGAACCTCTGTCTTG 
GTCTGGTCATTGGAAGAGACTGAT 
GCTGAGCTCATATGCTAAGACAGA 
GCTTTAAGTTCTCTCGTTCTTTGG 
416bp SNPLex 8-37-46 
214 rs10787428:A>G Normalized ESE 
scoring 
0.892 - (-22) TGTGACTGRAAATGTGCTGA
ACAGCAGTAGGTAAGGGCGG
GGCAA 
6/114 GPAM NM_020918 ATCAGAATACAGTGTTGGTCGATG 
AGCTTTAACCATCTCAAGTTGACC 
AATACAGTGTTGGTCGATGTAAGC 
ACTTCTGCAATTGCCTCTTGTACT 
375bp SNPLex 40-13-39 
215 rs9288938:G>T Normalized ESE 
scoring 
0.892 - (-20) CAGATTACAAKTTCTAAACA
GATTAAACAGGTAAGAAAAC
CTTAA 
18/150 SLC9A10 NM_183061 TGCCTGGAACATATTCGAGTTAG 
AGCAATTTCTGGGTGATCATACTC 
CCTGGAACATATTCGAGTTAGCA 
GCAATTTCTGGGTGATCATACTCT 
385bp SNPLex 8-48-36 
216 rs9438:G>C Normalized ESE 
scoring 
0.888 - (+30) ATGTTTTTATTTTAGGTATG
TTCCAGAACAAAAAGAACAC
AGATS 
10/141 DHX36 NM_020865 CTGTACAACAGGAATCATCCTTCA 
CCTCCATCTATCACATAAACGACA 
GACCTTCTCAATTTTCGATCTGAC 
TGTAGGCATCAGTGAATGTAAAGG 
537bp SNPLex 20-33-38 
217 rs989902:T>G Normalized ESE 
scoring 
0.86 - (-20) TGCAGCAGGAKACTCCTGTG
GTCCAGGTACGTGAACCAGA
TGAAT 
39/138 PTPN13 NM_080684 TTCCTACAGTGTGGGGTCTTG 
GTGTATTTACCAGAGGGAAGCACT 
GATAAAGGGATCACCAAACTTGAC 
TGTTCTCTCTATTGGCAACTCATC 
400bp SNPLex 24-15-53 
218 rs1898883:C>G Normalized ESE 
scoring 
0.854 - (+20) CTCCTCTCTTCCTAGCACCC
AGACCAAGGCTGTGSCCCCT
GAGGC 
2/330 DISP2 NM_033510 GAAGGGGAGCAACGGC 
CACAGAAGAAGTTCTCTTGCCTTC 
- 
CTCTCCTGGGCACTGCCT 
713bp SNPLex 47-7-38 
219 rs2228173:A>G Normalized ESE 
scoring/ WD40 
0.669 - (-19) ACCATGGCAGARTTGAATGC
CATCATCGGGGTACGTGGCC
TACCA 
6/75 TLE1 NM_005077 CCAGCCCTTCAAGTTCACTATC 
GAAGCTGGACTGCTAGAAGCAT 
CTTCAAGTTCACTATCCCGGAGT 
TCCTCATTAGACACATCCACAACT 
717bp TaqMan 71-1-18 
220 rs2188383:C>G Normalized ESE 
scoring/ LRR 
0.646 - (+19) TTCTCTAAACCATAGTTTCA
TAAGTACAAGCCASACCTTT
GATTT 
2/121 MOSPD2 NM_00101811
3 
GAGGTTTGGAGCAGATGGATAC 
TTCCAGTTCTGAAATCTGACACAC 
GGTTTGGAGCAGATGGATACC 
GGGTGTTTTTGTAGGCTCTTTATC 
376bp SNPLex 28-39-24 
221 rs736795:C>T Normalized ESE 
scoring /DEATH 
0.58 - (-15) CCACCTGGGGCTTTGYGGCA
TGAAGATCCGGTAGGAAGAG
GGGTG 
8/114 UNC5CL NM_173561 GAGAATGAGGACTGTTCAGCACTA 
CTCTTAGGCGTAGGAGAACAACC 
GCTTGGAGACCAAGTATATGGAAA 
GTCCCACTCAGGTAGTTCTGGAT 
361bp SNPLex 4-61-27 
129 
222 rs3763840:C>T Normalized ESE 
scoring/ WD40 
0.559 - (-8) CCAAGGTGACAGATGAGACC
TCYGGCTGCTGTAAGTTGCC
TCATA 
12/70 PRPF19 NM_014502 CGACACCAACAAGATCCTCA 
GTAAAGTGAAGAATCTCCGTCCAT 
AAGTTCTGAACAAATCCTGGCTAC 
ATCTTGATCTGAGAGTCCATGGTT 
375bp SNPLex 39-9-43 
223 rs974144:C>T Normalized ESE 
scoring/ WD40 
0.479 - (-16) ATCCAAATCTTCTCYTGTCA
GTAAGTAAAGGTAAGTGAAG
CAAAT 
5/82 EED NM_152991 CATGGACCTATGATAGCAATACGA 
AACCTCATGTACCAAATGTCACAC 
CTGTAGCTGGATCTAGAGGCATAA 
ATCGCCCAAGAATAGTCACATTAG 
576bp SNPLex 12-35-45 
- S : Absolute difference between the two allelic splice scores as calculated for each SNP using Alex‘s online splice score tool; ESE: absolute normalized ESE score differences as calculated using ESEfinder; : absolute 
signal difference as calculated from the signals emitted from the neural network. 
- *: The extracted sequence for ss SNPs represented here as 15 nt of intronic and 5 nt of exonic sequence for the canonical ss; extracted sequence for ESE-SNPs is represented as 30 nt exonic and 15 nt at nearby ss. 
- SNP ambiguity codes, reference AG or GT dinucleotides and the overlapped SNPs ID in both rounds of investigation are represented in bold. 
- **: To prove the skipping of exon 1 in the respective genotypes, another primer that spanned exon 2 (GGAAGCTGGAGAGTAAGAAGGAA) was used. The expected product size of using the later primer with the nested 
reverse primer (CGGTCCTGAGAATCTCTCAATAGT), in the round 2 RT-PCR, was 223 bp. 
- ¶: To check for the presence of exon 4, another F primer spanning this exon (GAAAGAAGTTAACAAGGCACTATCAA) was used with the nested-reverse primer (CAGTGAGTACGAATAAAGCGATCA) resulting in 
an expected amplicon size of 450 bp. 
- HUGO HGNC-approved gene symbols (http://www.genenames.org/) were used here in this Table; 
- The mutation and splice effect nomenclature appears here to follow the format indicated in the HGVS (see the website http://www.hgvs.org/mutnomen/ ). 
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8.2. Detection of minor splice forms by direct sequencing of RT-PCR products 
100 : 0
90 : 10
70 : 30
 
 
Figure ‎8.1 Evaluation of direct PCR-product sequencing as a qualitative detection method for alternative 
splicing: a control experiment. 
Here, the sensitivity for a qualitative detection of AS was previously tested in splice variants from the CARD15 
locus. Diluted PCR products from two splice variants at the CARD15 locus were mixed in different 
stoichiometric ratios, re-amplified by PCR and directly sequenced. It is evident here that the presence of a 
second, alternatively spliced transcript can be detected down to the 90:10% level. This means that minor splice 
forms with a frequency down to 10% of the total transcripts can be clearly detected. Thus, direct sequencing may 
be a robust screening tool even in the presence of NMD. The data was obtained from previous in-house 
experience (see also comment in additional data file in (Hiller et al., 2006b)). 
 
 
8.3. Extraction of SNPs at ESE sites within a 30-nucleotides window of exon ends 
 
 
Figure ‎8.2 Density of Predicted ESEs and SNPs along Human Exons. 
This figure illustrates that SNP density is approximately 20 –30% lower near both ss of human exons than in the 
interior of exons, and reaches a plateau at about 25-30 bases from the ss. The distribution of predicted ESE 
hexamers along exons had roughly an inverse relationship to the SNP density, with the highest density of ESEs 
observed near the ss junctions and a lower density in the interior of exons. Selective pressure is likely to be 
higher on ESEs located near splice junctions relative to ESEs in the interior of exons, which could explain the 
trend in ESE density shown in the above Figure. As a consequence of the increased density of ESEs near ss, 
SNPs/mutations that occur in exons near ss should have a higher likelihood of disrupting ESEs and therefore be 
more likely to be eliminated by purifying selection. Thus, SNPs located inside these 30-bp windows of the 
nearest exon-intron boundary from either ss might be more consistent to be considered for further analysis for 
allele-dependent splicing. This figure modified from (Fairbrother et al., 2004a). 
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8.4. Abbreviations and Lists of Figures and Tables 
Table ‎8.2 List of abbreviations, units, symbols, and acronyms used in thesis text 
 
Abbreviation Description 
 Forever 
°C degree Celsius 
μ micro; 10-6 
µl microlitre(s) 
μg microgram 
μM micromolar (μmol/l) 
aa amino acid 
AS alternative splicing 
BLAST Basic Local Alignment Search Tool 
bp base pairs 
cDNA complementary DNA 
cds coding sequence 
CE capillary electrophoresis 
CEPH Centre d‘Etude du Polymorphisme Humain (positive 
control cell lines) 
chr chromosome 
ChromFA Human genomic sequence files in FASTA format 
extracted from the UCSC home page. 
conc concentration 
cSNP coding SNP (located in coding regions) 
ddNTP dideoxynucleotide triphosphate 
DDW double distilled water 
DNA(s)  deoxyribonucleic acid(s) 
dNTP 2‘-deoxynucleoside-5‘-triphosphate 
dsDNA double stranded DNA 
e.g. exempli gratia 
EDTA ethylenediaminetetraacetic acid 
ESE exonic-splicing enhancers 
ESS Exonic Splicing Silencer 
EST expressed sequence tag 
Exo I exonuclease I 
F forward 
FACS Fluorescence-activated cell sorting 
g gram 
gDNA Genomic DNA 
GFP Green fluorescent protein 
h hour 
HeLa epithelial-like malignant cells derived from the cervix of 
Henrietta Lacks 
hnRNP heterogeneous nuclear ribonucleoproteins 
i.e. id est 
ICMB Institute of clinical molecular biology (Kiel, Germany) 
Ig immunoglobulin 
ISE Intronic Splicing Enhancers 
ISS Intronic Splicing Silencers 
IVS Intervening sequence 
kb kilobase 
kDa kiloDalton 
l liter 
LIMS laboratory information management system at ICMB, Kiel, 
Germany 
132 
LRR leucine-rich repeat 
m milli; 10
-3
 
M molar (mol/l) 
Mb mega base 
MCS Multiple cloning site 
MDA multiple displacement assay 
mg milligram 
MGB minor groove binder 
MgCl2 magnesium chloride 
min minute 
ml milliliter 
mM millimolar (mmol/l) 
mRNA messenger RNA 
MTP microtiter plate 
NCBI National Center for Biotechnology Information 
ng nanogram 
NMD nonsense mediated decay (of mRNA) 
nmol nanomole(s) 
NN neural network 
nt nucleotide(s) 
OLA oligonucleotide ligation reaction (in SNPlex
TM
 genotyping 
procedure) 
ORF open reading frame 
PAGE polyacrylamide gel electrophoresis 
PBS Phosphate-Buffered Salines 
PCR polymerase chain reaction 
PGM2L1 Phosphoglucomutase-2-like 1 
pH potentia hydrogenii 
pmol picomol 
Pol II Polymerase II 
Poly A poly-adenosine tail 
PPT polypyrimidine tract 
pre-mRNA precursor- mRNA 
PTB polypyrimidinetract-binding protein 
PTCs Premature stop codons 
pUC Produced at the University of California (bacterial origin 
of replication) 
R reverse 
RefSeq Reference sequence 
RFP Red fluorescent protein 
RNA ribonucleic acid 
RNABPs RNA-binding proteins 
rpm rotations per minute 
RS domain arginine/serine dipeptides domain 
RT room temperature (roughly 21-23°C) 
s second 
SAP shrimp alkaline phosphatase 
SNP(s) single nucleotide polymorphism(s) 
snRNAs/snRNPs small nuclear ribonucleoprotein particles 
SR proteins serine/arginine-rich proteins 
ss splice site(s) 
SV40 Ori Simian virus 40 (mammalian origin of replication) 
TAE tris acetate EDTA 
Taq Thermophilus aquaticus 
TaqMan
®
 commercial name for sequence variation detection assay 
(5‘→3‘ exonuclease activity) 
TBE tris borate EDTA 
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TE Tris-hydroxymethyl aminomethane buffer 
Te-MO Tecan multipipetting option 
Tm melting temperature (of primer) 
Tris tris-(hydroxymethyl)-aminomethane 
UCSC University of California at Santa Cruz (The Genome 
Browser homepage) 
UV ultraviolet 
WGA whole genome amplification 
WT wild type 
 
DNA bases 
A Adenine 
C Cytosine 
G Guanine 
T Thymine 
 
IUPAC- SNP ambiguity code 
A A 
B C/G/T 
C C 
D A/G/T 
G G 
H A/C/T 
K G/T 
M A/C 
N G/A/T/C 
R A/G 
S C/G 
T/U T 
V A/C/G 
W A/T 
Y C/T 
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